

APPROVED DRUG PRODUCTS


With Therapeutic Equivalence Evaluations



The "Orange Book"

FDA data supplied by [DrugPatentWatch.com](https://www.drugpatentwatch.com)

**CUMULATIVE
SUPPLEMENT 5
MAY 2015**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

35th EDITION

Department of Health and Human Services

**Food and Drug Administration
Center for Drug Evaluation and Research
Office of Medical Products and Tobacco
Office of Generic Drugs**

2015

Prepared By
Office of Generic Drugs
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Food and Drug Administration

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

35th EDITION

Cumulative Supplement 5

May 2015

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION.....	iii
1.1 How to use the Cumulative Supplement	iii
1.2 Cumulative Supplement Content	iv
1.3 Applicant Name Changes	v
1.4 Levothyroxine Sodium.....	v
1.5 Availability of the Edition.....	vi
1.6 Report of Counts for the Prescription Drug Product List.....	vii
1.7 Cumulative Supplement Legend	viii
 DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List.....	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
 PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

35th EDITION

**CUMULATIVE SUPPLEMENT 5
May 2015**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 34th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2.1, How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - o Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - o Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).
- New Drug Application (NDA) approvals appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at drugproducts@fda.hhs.gov. Send changes by FAX: 301-595-1446.

mail to: FDA/CDER Orange Book Staff
Office of Generic Drugs
7620 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
EXCELLIUM PHARMACEUTICAL INC (EXCELLIUM)	LEADING PHARMA LLC (LEADING PHARMA LLC)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) and Levo-T (Alara NDA 21342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets. Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 76187), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically

equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), Levothyroxine Sodium (Mylan ANDA 076187), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levotheroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	76187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	21301	001
SYNTHROID	ABBOTT	0.025MG	AB1	21402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	21342	001
SYNTHROID	ABBOTT	0.025MG	AB2	21402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	76187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	21342	001
UNITHROID	STEVENS J	0.025MG	AB2	21210	001
LEVOXYL	KUNG PHARMS	0.025MG	AB3	21301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	21342	001
UNITHROID	STEVENS J	0.025MG	AB3	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	76187	001
LEVOTHROID	LLOYD	0.025MG	AB4	21116	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	76187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic

Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2014</u>	<u>MAR 2015</u>	<u>JUN 2015</u>	<u>SEPT 2015</u>	<u>DEC 2015</u>
DRUG PRODUCTS LISTED	16150	16352			
SINGLE SOURCE	2572 (15.9%)	2608 (15.9%)			
MULTISOURCE	13578 (84.1%)	13744 (84.1%)			
THERAPEUTICALLY EQUIVALENT	13443 (83.2%)	13610 (83.2%)			
NOT THERAPEUTICALLY EQUIVALENT	135 (0.8%)	134 (0.8%)			
EXCEPTIONS ¹	77 (0.5%)	75 (0.5%)			
NEW MOLECULAR ENTITIES APPROVED	13	22			
NUMBER OF APPLICANTS	927	935			

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.

CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

TABLET;ORAL

FIORICET

@ ACTAVIS LABS UT INC 325MG;50MG;40MG A088616 001 Nov 09, 1984 Feb CAHN

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL

FIORICET W/ CODEINE

AB + ACTAVIS LABS UT INC 325MG;50MG;40MG;30MG N020232 001 Jul 30, 1992 Jan CAHN

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA SUN PHARM INDS LTD 300MG;30MG A085868 001 Apr CAHN

AA 300MG;60MG A087083 001 Apr CAHN

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA + MIKART 325MG;2.5MG A040846 001 Jun 09, 2010 Feb CTEC

@ SUN PHARM INDS LTD 325MG;10MG A040826 001 Aug 16, 2007 Apr CAHN

NORCO

AA ACTAVIS LABS FL INC 325MG;2.5MG A040148 004 Jul 07, 2014 Feb NEWA

AA 325MG;5MG A040148 005 Jul 07, 2014 Feb NEWA

ACETYLCYSTEINE

INJECTABLE;INTRAVENOUS

ACETYLCYSTEINE

AP AKORN INC 6GM/30ML (200MG/ML) A203173 001 Mar 24, 2015 Mar NEWA

ACITRETIN

CAPSULE;ORAL

ACITRETIN

>A> AB SIGMAPHARM LABS LLC 10MG A204633 001 May 22, 2015 May NEWA

>A> AB 17.5MG A204633 002 May 22, 2015 May NEWA

>A> AB 22.5MG A204633 003 May 22, 2015 May NEWA

>A> AB 25MG A204633 004 May 22, 2015 May NEWA

ACOLIDINIUM BROMIDE

POWDER, METERED;INHALATION

TUDORZA PRESSAIR

+ ASTRAZENECA PHARMS 0.375MG/INH N202450 001 Jul 23, 2012 Apr CAHN

ACYCLOVIR

TABLET;ORAL

ACYCLOVIR

AB SUN PHARM INDS LTD 400MG A074980 001 Sep 30, 1998 Apr CAHN

AB 800MG A074980 002 Sep 30, 1998 Apr CAHN

ADENOSINE

INJECTABLE;INJECTION

ADENOSINE

AP MYLAN PHARMS INC 3MG/ML A078686 001 May 13, 2009 Apr CAHN

>D> AP WOCKHARDT 3MG/ML A090220 001 Jul 20, 2009 May DISC

>A> @ 3MG/ML A090220 001 Jul 20, 2009 May DISC

ALBUTEROL SULFATE

POWDER, METERED;INHALATION

PROAIR RESPICLICK

+ TEVA BRANDED PHARM EQ 0.090MG BASE/INH N205636 001 Mar 31, 2015 Mar NEWA

SYRUP;ORAL

ALBUTEROL SULFATE

AA G AND W LABS INC EQ 2MG BASE/5ML A074454 001 Sep 25, 1995 Apr CAHN

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

AEROSOL, METERED; INHALATION

>D> COMBIVENT

>D>	+	BOEHRINGER INGELHEIM	EQ 0.09MG BASE/INH;0.018MG/INH	N020291	001	Oct 24, 1996	May DISC
>A>	@		EQ 0.09MG BASE/INH;0.018MG/INH	N020291	001	Oct 24, 1996	May DISC

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

ALFUZOSIN HYDROCHLORIDE

@	WOCKHARDT LTD	10MG	A090221	001	Aug 10, 2012	Feb DISC
---	---------------	------	---------	-----	--------------	----------

ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE

>D> TABLET; ORAL

>D> TEKAMLO

>D>		NOVARTIS	EQ 150MG BASE;EQ 5MG BASE	N022545	001	Aug 26, 2010	May DISC
>A>	@		EQ 150MG BASE;EQ 5MG BASE	N022545	001	Aug 26, 2010	May DISC
>D>			EQ 150MG BASE;EQ 10MG BASE	N022545	002	Aug 26, 2010	May DISC
>A>	@		EQ 150MG BASE;EQ 10MG BASE	N022545	002	Aug 26, 2010	May DISC
>D>			EQ 300MG BASE;EQ 5MG BASE	N022545	003	Aug 26, 2010	May DISC
>A>	@		EQ 300MG BASE;EQ 5MG BASE	N022545	003	Aug 26, 2010	May DISC
>D>	+		EQ 300MG BASE;EQ 10MG BASE	N022545	004	Aug 26, 2010	May DISC
>A>	@		EQ 300MG BASE;EQ 10MG BASE	N022545	004	Aug 26, 2010	May DISC

ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE

>D> TABLET; ORAL

>D> AMTURNIDE

>D>		NOVARTIS	EQ 150MG BASE;EQ 5MG BASE;12.5MG	N200045	001	Dec 21, 2010	May DISC
>A>	@		EQ 150MG BASE;EQ 5MG BASE;12.5MG	N200045	001	Dec 21, 2010	May DISC
>D>			EQ 300MG BASE;EQ 5MG BASE;12.5MG	N200045	002	Dec 21, 2010	May DISC
>A>	@		EQ 300MG BASE;EQ 5MG BASE;12.5MG	N200045	002	Dec 21, 2010	May DISC
>D>			EQ 300MG BASE;EQ 5MG BASE;25MG	N200045	003	Dec 21, 2010	May DISC
>A>	@		EQ 300MG BASE;EQ 5MG BASE;25MG	N200045	003	Dec 21, 2010	May DISC
>D>			EQ 300MG BASE;EQ 10MG BASE;12.5MG	N200045	004	Dec 21, 2010	May DISC
>A>	@		EQ 300MG BASE;EQ 10MG BASE;12.5MG	N200045	004	Dec 21, 2010	May DISC
>D>	+		EQ 300MG BASE;EQ 10MG BASE;25MG	N200045	005	Dec 21, 2010	May DISC
>A>	@		EQ 300MG BASE;EQ 10MG BASE;25MG	N200045	005	Dec 21, 2010	May DISC

ALOSETRON HYDROCHLORIDE

TABLET; ORAL

ALOSETRON HYDROCHLORIDE

AB		ROXANE	EQ 0.5MG BASE	A200652	001	May 04, 2015	Apr NEWA
AB			EQ 1MG BASE	A200652	002	May 04, 2015	Apr NEWA
		LOTRONEX					
AB		PROMETHEUS LABS	EQ 0.5MG BASE	N021107	002	Dec 23, 2003	Apr CFTG
AB	+		EQ 1MG BASE	N021107	001	Feb 09, 2000	Apr CFTG

ALPRAZOLAM

TABLET; ORAL

ALPRAZOLAM

AB		NATCO PHARMA LTD	0.25MG	A200739	001	Apr 15, 2015	Mar NEWA
AB			0.5MG	A200739	002	Apr 15, 2015	Mar NEWA
AB			1MG	A200739	003	Apr 15, 2015	Mar NEWA
AB			2MG	A200739	004	Apr 15, 2015	Mar NEWA

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL

AMANTADINE HYDROCHLORIDE

AB		BANNER LIFE SCIENCES	100MG	A078720	001	May 29, 2008	Jan CAHN
----	--	----------------------	-------	---------	-----	--------------	----------

SYRUP; ORAL

AMANTADINE HYDROCHLORIDE

>D>	@	ACTAVIS MID ATLANTIC	50MG/5ML	A072655	001	Oct 30, 1990	May CAHN
>A>	@	G AND W LABS INC	50MG/5ML	A072655	001	Oct 30, 1990	May CAHN

AMIKACIN SULFATE

INJECTABLE; INJECTION

AMIKACIN SULFATE

@	IGI LABS INC	EQ 50MG BASE/ML	A063167	001	Dec 14, 1995	Mar CAHN
@		EQ 250MG BASE/ML	A063169	001	Dec 14, 1995	Mar CAHN

AMINO ACIDS

INJECTABLE;INJECTION

BRANCHAMIN 4% IN PLASTIC CONTAINER

@ BAXTER HLTHCARE 4% (4GM/100ML)

N018684 001 Sep 28, 1984 Feb DISC

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

TRAVASOL 3.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER

@ BAXTER HLTHCARE 3.5%;51MG/100ML;131MG/100ML;218MG/100ML;35MG/100ML

N020177 001 Oct 23, 1995 Feb DISC

AMINOCAPROIC ACID

SYRUP;ORAL

AMINOCAPROIC ACID

>D> AA MIKART 1.25GM/5ML
 >A> AA VERSAPHARM INC 1.25GM/5ML

A074759 001 Sep 02, 1998 May CAHN

A074759 001 Sep 02, 1998 May CAHN

TABLET;ORAL

AMINOCAPROIC

>D> AB MIKART 500MG
 >A> AB VERSAPHARM INC 500MG

A075602 001 May 24, 2001 May CAHN

A075602 001 May 24, 2001 May CAHN

AMLODIPINE BESYLATE

TABLET;ORAL

AMLODIPINE BESYLATE

AB CHINA RESOURCES EQ 5MG BASE
 AB EQ 10MG BASE
 AB SUN PHARM INDS LTD EQ 2.5MG BASE
 AB EQ 5MG BASE
 AB EQ 10MG BASE

A090752 001 Apr 15, 2011 Mar CAHN

A090752 002 Apr 15, 2011 Mar CAHN

A077974 001 Jul 09, 2007 Apr CAHN

A077974 002 Jul 09, 2007 Apr CAHN

A077974 003 Jul 09, 2007 Apr CAHN

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET;ORAL

AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE

>A> AB	LUPIN LTD	5MG;12.5MG;160MG	A200797	001	Jun 03, 2015	May NEWA
>A> AB		5MG;25MG;160MG	A200797	002	Jun 03, 2015	May NEWA
>A> AB		10MG;12.5MG;160MG	A200797	003	Jun 03, 2015	May NEWA
>A> AB		10MG;25MG;160MG	A200797	004	Jun 03, 2015	May NEWA
>A> AB		10MG;25MG;320MG	A200797	005	Jun 03, 2015	May NEWA
>A> AB	PAR PHARM	5MG;12.5MG;160MG	A201087	001	Jun 01, 2015	May NEWA
>A> AB		5MG;25MG;160MG	A201087	002	Jun 01, 2015	May NEWA
>A> AB		10MG;12.5MG;160MG	A201087	003	Jun 01, 2015	May NEWA
>A> AB		10MG;25MG;160MG	A201087	004	Jun 01, 2015	May NEWA
>A> AB		10MG;25MG;320MG	A201087	005	Jun 01, 2015	May NEWA
>A> AB	TEVA PHARMS	5MG;12.5MG;160MG	A200435	001	Sep 25, 2012	May CAIN
>A> AB		5MG;25MG;160MG	A200435	002	Sep 25, 2012	May CAIN
>A> AB		10MG;12.5MG;160MG	A200435	005	Sep 25, 2012	May CAIN
>A> AB		10MG;25MG;160MG	A200435	003	Sep 25, 2012	May CAIN
>A> AB		10MG;25MG;320MG	A200435	004	Sep 25, 2012	May CAIN
>A> AB	TORRENT PHARMS LTD	5MG;12.5MG;160MG	A201593	001	Jun 04, 2015	May NEWA
>A> AB		5MG;25MG;160MG	A201593	002	Jun 04, 2015	May NEWA
>A> AB		10MG;12.5MG;160MG	A201593	003	Jun 04, 2015	May NEWA
>A> AB		10MG;25MG;160MG	A201593	004	Jun 04, 2015	May NEWA
>A> AB		10MG;25MG;320MG	A201593	005	Jun 04, 2015	May NEWA

AMLODIPINE BESYLATE; PERINDOPRIL ARGinine

TABLET;ORAL

PRESTALIA

SYMPLEMD PHARMS LLC EQ 2.5MG BASE;3.5MG
 EQ 5MG BASE;7MG
 + EQ 10MG BASE;14MG

N205003 001 Jan 21, 2015 Jan NEWA

N205003 002 Jan 21, 2015 Jan NEWA

N205003 003 Jan 21, 2015 Jan NEWA

AMLODIPINE BESYLATE; VALSARTAN

TABLET;ORAL

AMLODIPINE BESYLATE AND VALSARTAN

AB	ALEMBIC PHARMS LTD	EQ 5MG BASE;160MG	A202713	001	Apr 03, 2015	Mar NEWA
AB		EQ 5MG BASE;320MG	A202713	003	Apr 03, 2015	Mar NEWA
AB		EQ 10MG BASE;160MG	A202713	002	Apr 03, 2015	Mar NEWA
AB		EQ 10MG BASE;320MG	A202713	004	Apr 03, 2015	Mar NEWA
AB	LUPIN	EQ 5MG BASE;160MG	A090245	001	Mar 30, 2015	Mar NEWA
AB		EQ 5MG BASE;320MG	A090245	003	Mar 30, 2015	Mar NEWA
AB		EQ 10MG BASE;160MG	A090245	002	Mar 30, 2015	Mar NEWA
AB		EQ 10MG BASE;320MG	A090245	004	Mar 30, 2015	Mar NEWA

TABLET;ORAL

AMLODIPINE BESYLATE AND VALSARTAN

AB	MATRIX LABS LTD	EQ 5MG BASE;160MG	A090483	001	Mar 30, 2015	Mar	NEWA
AB		EQ 5MG BASE;320MG	A090483	003	Mar 30, 2015	Mar	NEWA
AB		EQ 10MG BASE;160MG	A090483	002	Mar 30, 2015	Mar	NEWA
AB		EQ 10MG BASE;320MG	A090483	004	Mar 30, 2015	Mar	NEWA
AB	MYLAN PHARMS INC	EQ 5MG BASE;160MG	A090483	001	Mar 30, 2015	Apr	CAHN
AB		EQ 5MG BASE;320MG	A090483	003	Mar 30, 2015	Apr	CAHN
AB		EQ 10MG BASE;160MG	A090483	002	Mar 30, 2015	Apr	CAHN
AB		EQ 10MG BASE;320MG	A090483	004	Mar 30, 2015	Apr	CAHN
AB	NOVEL LABS INC	EQ 5MG BASE;160MG	A202829	001	Mar 30, 2015	Mar	NEWA
AB		EQ 5MG BASE;320MG	A202829	003	Mar 30, 2015	Mar	NEWA
AB		EQ 10MG BASE;160MG	A202829	002	Mar 30, 2015	Mar	NEWA
AB		EQ 10MG BASE;320MG	A202829	004	Mar 30, 2015	Mar	NEWA
AB	TEVA PHARMS USA	EQ 5MG BASE;160MG	A091235	001	Mar 30, 2015	Mar	NEWA
AB		EQ 5MG BASE;320MG	A091235	003	Mar 30, 2015	Mar	NEWA
AB		EQ 10MG BASE;160MG	A091235	002	Mar 30, 2015	Mar	NEWA
AB		EQ 10MG BASE;320MG	A091235	004	Mar 30, 2015	Mar	NEWA
AB	TORRENT PHARMS LTD	EQ 5MG BASE;160MG	A202377	001	Mar 30, 2015	Mar	NEWA
AB		EQ 5MG BASE;320MG	A202377	002	Mar 30, 2015	Mar	NEWA
AB		EQ 10MG BASE;160MG	A202377	003	Mar 30, 2015	Mar	NEWA
AB		EQ 10MG BASE;320MG	A202377	004	Mar 30, 2015	Mar	NEWA

>D> AMLODIPINE; HYDROCHLOROTHIAZIDE; VALSARTAN

>D> TABLET;ORAL

>D> AMLODIPINE, VALSARTAN AND HYDROCHLOROTHIAZIDE

>D> AB	TEVA PHARMS	5MG;12.5MG;160MG	A200435	001	Sep 25, 2012	May	CAIN
>D> AB		5MG;25MG;160MG	A200435	002	Sep 25, 2012	May	CAIN
>D> AB		10MG;12.5MG;160MG	A200435	005	Sep 25, 2012	May	CAIN
>D> AB		10MG;25MG;160MG	A200435	003	Sep 25, 2012	May	CAIN
>D> AB		10MG;25MG;320MG	A200435	004	Sep 25, 2012	May	CAIN

AMMONIA N-13

INJECTABLE;INTRAVENOUS

AMMONIA N 13

AP	BIOMEDCL RES FDN	48.75mCi-487.5mCi/13ML (3.75-37.5mCi/ML)	A204352	001	May 01, 2015	Apr	NEWA
AP	IBA MOLECULAR N AM	18.8mCi-188mCi/5ML (3.75-37.5mCi/ML)	A204667	001	Apr 22, 2015	Apr	NEWA
	NCM USA BRONX LLC	3.75-260mCi/mL	A204515	001	Feb 04, 2015	Jan	NEWA
AP	SPECTRON MRC LLC	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A204455	001	Apr 23, 2015	Apr	NEWA

AMOXICILLIN

CAPSULE;ORAL

AMOXICILLIN

AB	SUN PHARM INDS LTD	250MG	A065016	001	Apr 08, 1999	Apr	CAHN
AB		500MG	A065016	002	Apr 08, 1999	Apr	CAHN

FOR SUSPENSION;ORAL

AMOXICILLIN

@ SUN PHARM INDS LTD

@

200MG/5ML

400MG/5ML

A065113 001 Nov 29, 2002 Apr CAHN

A065113 002 Nov 29, 2002 Apr CAHN

TABLET;ORAL

AMOXICILLIN

AB	SUN PHARM INDS LTD	500MG	A065059	001	Nov 24, 2000	Apr	CAHN
AB		875MG	A065059	002	Nov 24, 2000	Apr	CAHN

TABLET, CHEWABLE;ORAL

AMOXICILLIN

AB	SUN PHARM INDS LTD	125MG	A065021	001	Dec 23, 1999	Apr	CAHN
	@	200MG	A065060	001	Nov 29, 2000	Apr	CAHN
AB		250MG	A065021	002	Dec 23, 1999	Apr	CAHN
	@	400MG	A065060	002	Nov 29, 2000	Apr	CAHN

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	SUN PHARM INDS LTD	200MG/5ML;EQ 28.5MG BASE/5ML	A065132	001	Mar 19, 2003	Apr	CAHN
AB		400MG/5ML;EQ 57MG BASE/5ML	A065132	002	Mar 19, 2003	Apr	CAHN
AB		600MG/5ML;EQ 42.9MG BASE/5ML	A065207	002	Jan 30, 2007	Apr	CAHN

TABLET;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

@ SUN PHARM INDS LTD

500MG;EQ 125MG BASE

875MG;EQ 125MG BASE

A065109 001 Nov 04, 2002 Apr CAHN

A065102 001 Sep 17, 2002 Apr CAHN

TABLET, CHEWABLE;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	SUN PHARM INDS LTD	200MG;EQ 28.5MG BASE	A065161	001	Dec 03, 2003	Apr CAHN
AB		400MG;EQ 57MG BASE	A065161	002	Dec 03, 2003	Apr CAHN

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

>A>	AB	COREPHARMA	1.875MG;1.875MG;1.875MG;1.875MG	A040444	005	Nov 03, 2014	May NEWA
>A>	AB		3.125MG;3.125MG;3.125MG;3.125MG	A040444	006	Nov 03, 2014	May NEWA
>A>	AB		3.75MG;3.75MG;3.75MG;3.75MG	A040444	007	Nov 03, 2014	May NEWA

AMPHETAMINE SULFATE

TABLET;ORAL

EVEKEO

	ARBOR PHARMS LLC	5MG	A200166	001	Aug 09, 2012	Mar CTNA
+		10MG	A200166	002	Aug 09, 2012	Mar CTNA

AMPICILLIN/AMPICILLIN TRIHYDRATE; PROBENECID

FOR SUSPENSION;ORAL

PROBAMPACIN

	@ G AND W LABS INC	EQ 3.5GM BASE/BOT;1GM/BOT	A061741	001		Apr CAHN
--	--------------------	---------------------------	---------	-----	--	----------

ANASTROZOLE

TABLET;ORAL

ANASTROZOLE

	@ KREMERS URBAN PHARMS	1MG	A091331	001	Jan 05, 2011	Mar CAHN
--	------------------------	-----	---------	-----	--------------	----------

ARGATROBAN

INJECTABLE;INJECTION

ARGATROBAN

AP	FRESENIUS KABI USA	250MG/2.5ML (100MG/ML)	N201811	001	Mar 23, 2015	Apr CDFR
----	--------------------	------------------------	---------	-----	--------------	----------

INJECTABLE;IV (INFUSION)

ARGATROBAN

AP	FRESENIUS KABI USA	250MG/2.5ML (100MG/ML)	N201811	001	Mar 23, 2015	Mar NEWA
----	--------------------	------------------------	---------	-----	--------------	----------

ARIPIPIRAZOLE

SOLUTION;ORAL

ABILIFY

	@ OTSUKA	1MG/ML	N021713	001	Dec 10, 2004	Apr DISC
--	----------	--------	---------	-----	--------------	----------

TABLET;ORAL

ABILIFY

AB	OTSUKA	2MG	N021436	006	Nov 15, 2002	Apr CFTG
AB	+	5MG	N021436	005	Nov 15, 2002	Apr CFTG
AB	+	10MG	N021436	001	Nov 15, 2002	Apr CFTG
AB		15MG	N021436	002	Nov 15, 2002	Apr CFTG
AB		20MG	N021436	003	Nov 15, 2002	Apr CFTG
AB		30MG	N021436	004	Nov 15, 2002	Apr CFTG

ARIPIPIRAZOLE

AB	ALEMBIC PHARMS LTD	2MG	A202101	001	Apr 28, 2015	Apr NEWA
AB		5MG	A202101	002	Apr 28, 2015	Apr NEWA
AB		10MG	A202101	003	Apr 28, 2015	Apr NEWA
AB		15MG	A202101	004	Apr 28, 2015	Apr NEWA
AB		20MG	A202101	005	Apr 28, 2015	Apr NEWA
AB		30MG	A202101	006	Apr 28, 2015	Apr NEWA
AB	HETERO LABS LTD V	2MG	A205064	001	Apr 28, 2015	Apr NEWA
AB		5MG	A205064	002	Apr 28, 2015	Apr NEWA
AB		10MG	A205064	003	Apr 28, 2015	Apr NEWA
AB		15MG	A205064	004	Apr 28, 2015	Apr NEWA
AB		20MG	A205064	005	Apr 28, 2015	Apr NEWA
AB		30MG	A205064	006	Apr 28, 2015	Apr NEWA
AB	TEVA PHARMS USA	2MG	A078607	001	Apr 28, 2015	Apr NEWA
AB		5MG	A078607	002	Apr 28, 2015	Apr NEWA
AB		10MG	A078608	001	Apr 28, 2015	Apr NEWA
AB		15MG	A078708	001	Apr 28, 2015	Apr NEWA
AB		20MG	A078708	002	Apr 28, 2015	Apr NEWA
AB		30MG	A078708	003	Apr 28, 2015	Apr NEWA
AB	TORRENT PHARMS LTD	2MG	A201519	001	Apr 28, 2015	Apr NEWA
AB		10MG	A201519	003	Apr 28, 2015	Apr NEWA
AB		5MG	A201519	002	Apr 28, 2015	Apr NEWA
AB		15MG	A201519	004	Apr 28, 2015	Apr NEWA
AB		20MG	A201519	005	Apr 28, 2015	Apr NEWA

TABLET;ORAL							
ARIPIRAZOLE							
AB		30MG	A201519	006	Apr 28, 2015	Apr	NEWA
TABLET, ORALLY DISINTEGRATING;ORAL							
ABILIFY							
AB	+	OTSUKA	10MG	N021729	002	Jun 07, 2006	Apr CFTG
AB			15MG	N021729	003	Jun 07, 2006	Apr CFTG
ARIPIRAZOLE							
AB		ALEMBIC PHARMS LTD	10MG	A202102	001	Apr 28, 2015	Apr NEWA
AB			15MG	A202102	002	Apr 28, 2015	Apr NEWA
<u>ASPIRIN; BUTALBITAL; CAFFEINE</u>							
CAPSULE;ORAL							
FIORINAL							
AA	+	ACTAVIS LABS UT INC	325MG;50MG;40MG	N017534	005	Apr 16, 1986	Jan CAHN
TABLET;ORAL							
FIORINAL							
	@	ACTAVIS LABS UT INC	325MG;50MG;40MG	N017534	003	Apr 16, 1986	Jan CAHN
<u>ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE</u>							
CAPSULE;ORAL							
FIORINAL W/CODEINE							
AB	+	ACTAVIS LABS UT INC	325MG;50MG;40MG;30MG	N019429	003	Oct 26, 1990	Jan CAHN
<u>ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE</u>							
TABLET;ORAL							
NORGESIC							
	@	MEDICIS	385MG;30MG;25MG	N013416	003	Oct 27, 1982	Mar DISC
NORGESIC FORTE							
	@	MEDICIS	770MG;60MG;50MG	N013416	004	Oct 27, 1982	Mar DISC
ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE							
		SANDOZ	385MG;30MG;25MG	A074654	001	Dec 31, 1996	Mar CTEC
	+		770MG;60MG;50MG	A074654	002	Dec 31, 1996	Mar CTEC
<u>ASPIRIN; OXYCODONE HYDROCHLORIDE</u>							
TABLET;ORAL							
OXYCODONE AND ASPIRIN							
AA		ACTAVIS LABS FL INC	325MG;4.8355MG	A090084	001	Mar 22, 2011	Mar CAHN
<u>ATAZANAVIR SULFATE; COBICISTAT</u>							
TABLET;ORAL							
EVOTAZ							
	+	BRISTOL MYERS SQUIBB	EQ 300MG BASE;150MG	N206353	001	Jan 29, 2015	Jan NEWA
<u>ATENOLOL</u>							
TABLET;ORAL							
TENORMIN							
AB		ALVOGEN IPCO SARL	25MG	N018240	004	Apr 09, 1990	Feb CAHN
AB			50MG	N018240	001		Feb CAHN
AB	+		100MG	N018240	002		Feb CAHN
<u>ATENOLOL; CHLORTHALIDONE</u>							
TABLET;ORAL							
TENORETIC 100							
AB	+	ALVOGEN IPCO SARL	100MG;25MG	N018760	001	Jun 08, 1984	Feb CAHN
TENORETIC 50							
AB		ALVOGEN IPCO SARL	50MG;25MG	N018760	002	Jun 08, 1984	Feb CAHN
<u>ATORVASTATIN CALCIUM</u>							
TABLET;ORAL							
ATORVASTATIN CALCIUM							
AB		KREMERS URBAN PHARMS	EQ 10MG BASE	A091624	001	Apr 05, 2013	Mar CAHN
AB			EQ 20MG BASE	A091624	002	Apr 05, 2013	Mar CAHN
AB			EQ 40MG BASE	A091624	003	Apr 05, 2013	Mar CAHN
AB			EQ 80MG BASE	A091624	004	Apr 05, 2013	Mar CAHN
AB		SUN PHARM INDS LTD	EQ 10MG BASE	A076477	001	Nov 30, 2011	Apr CAHN
AB			EQ 20MG BASE	A076477	002	Nov 30, 2011	Apr CAHN
AB			EQ 40MG BASE	A076477	003	Nov 30, 2011	Apr CAHN
AB			EQ 80MG BASE	A076477	004	Nov 30, 2011	Apr CAHN

>D> ATORVASTATIN CALCIUM; EZETIMIBE

>D> TABLET; ORAL

>D> LIPTRUZET

>D>	MERCK SHARP DOHME	EQ 10MG BASE;10MG	N200153	001	May 03, 2013	May DISC
>A>	@	EQ 10MG BASE;10MG	N200153	001	May 03, 2013	May DISC
>D>		EQ 20MG BASE;10MG	N200153	002	May 03, 2013	May DISC
>A>	@	EQ 20MG BASE;10MG	N200153	002	May 03, 2013	May DISC
>D>		EQ 40MG BASE;10MG	N200153	003	May 03, 2013	May DISC
>A>	@	EQ 40MG BASE;10MG	N200153	003	May 03, 2013	May DISC
>D>	+	EQ 80MG BASE;10MG	N200153	004	May 03, 2013	May DISC
>A>	@	EQ 80MG BASE;10MG	N200153	004	May 03, 2013	May DISC

ATOVAQUONE; PROGUANIL HYDROCHLORIDE

TABLET; ORAL

ATOVAQUONE AND PROGUANIL HYDROCHLORIDE

AB	GLENMARK GENERICS	62.5MG;25MG	A091211	002	Apr 06, 2015	Mar NEWA
----	-------------------	-------------	---------	-----	--------------	----------

ATRACURIUM BESYLATE

INJECTABLE; INJECTION

ATRACURIUM BESYLATE

AP	AUROBINDO PHARMA LTD	10MG/ML	A206011	001	Apr 08, 2015	Mar NEWA
	ATRACURIUM BESYLATE PRESERVATIVE FREE					
AP	AUROBINDO PHARMA LTD	10MG/ML	A206010	001	Apr 08, 2015	Mar NEWA

ATROPINE SULFATE

SOLUTION/DROPS; OPHTHALMIC

ATROPINE SULFATE

>D>	AKORN	1%	N206289	001	Jul 18, 2014	May CRLD
>A>	+	1%	N206289	001	Jul 18, 2014	May CRLD

ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE

TABLET; ORAL

MOTOFEN

+	SEBELA IRELAND LTD	0.025MG;1MG	N017744	002		Feb CAHN
	MOTOFEN HALF-STRENGTH					
@	SEBELA IRELAND LTD	0.025MG;0.5MG	N017744	001		Feb CAHN

AVIBACTAM SODIUM; CEFTAZIDIME

POWDER; IV (INFUSION)

AVYCAZ

+	CEREXA INC	EQ 0.5GM BASE;2GM/VIAL	N206494	001	Feb 25, 2015	Feb NEWA
---	------------	------------------------	---------	-----	--------------	----------

AZITHROMYCIN

FOR SUSPENSION; ORAL

AZITHROMYCIN

>A> AB	LUPIN LTD	EQ 100MG BASE/5ML	A065488	001	May 15, 2015	May NEWA
>A> AB		EQ 200MG BASE/5ML	A065488	002	May 15, 2015	May NEWA

TABLET; ORAL

AZITHROMYCIN

>A> AB	LUPIN LTD	EQ 250MG BASE	A065398	001	May 15, 2015	May NEWA
>A> AB		EQ 500MG BASE	A065399	001	May 15, 2015	May NEWA
>A> AB		EQ 600MG BASE	A065400	001	May 15, 2015	May NEWA

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE

AB	AMNEAL PHARMS LLC	5MG	A076820	001	Feb 03, 2006	Jan CAHN
AB		10MG	A076820	002	Feb 03, 2006	Jan CAHN
AB		20MG	A076820	003	Feb 03, 2006	Jan CAHN
AB		40MG	A076820	004	Feb 03, 2006	Jan CAHN
AB	SUN PHARM INDS LTD	5MG	A076344	001	Feb 11, 2004	Apr CAHN
AB		10MG	A076344	002	Feb 11, 2004	Apr CAHN
AB		20MG	A076344	003	Feb 11, 2004	Apr CAHN
AB		40MG	A076344	004	Feb 11, 2004	Apr CAHN

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB	SUN PHARM INDS LTD	5MG;6.25MG	A077483	001	Sep 08, 2005	Apr CAHN
AB		10MG;12.5MG	A077483	002	Sep 08, 2005	Apr CAHN
AB		20MG;12.5MG	A077483	003	Sep 08, 2005	Apr CAHN

TABLET;ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE					
AB	20MG;25MG	A077483	004	Sep 08, 2005	Apr CAHN

BENZONATATE

CAPSULE;ORAL

BENZONATATE					
AA	APOTEX INC 100MG	A091310	001	Jan 16, 2015	Jan NEWA
AA	200MG	A091310	002	Jan 16, 2015	Jan NEWA
AA	BANNER LIFE SCIENCES 100MG	A081297	001	Jan 29, 1993	Jan CAHN
AA	200MG	A081297	002	Oct 30, 2007	Jan CAHN

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL;TOPICAL

ONEXTON					
+	DOW PHARM 3.75%;EQ 1.2% BASE	N050819	002	Nov 24, 2014	Jan CRLD

BENZTROPINE MESYLATE

TABLET;ORAL

BENZTROPINE MESYLATE					
AA	NUVO PHARM INC 0.5MG	A204713	001	Apr 14, 2015	Mar NEWA
AA	1MG	A204713	002	Apr 14, 2015	Mar NEWA
AA	2MG	A204713	003	Apr 14, 2015	Mar NEWA

BETAMETHASONE DIPROPIONATE

LOTION;TOPICAL

BETAMETHASONE DIPROPIONATE					
AB	G AND W LABS INC EQ 0.05% BASE	A071467	001	Aug 10, 1987	Apr CAHN
	@ EQ 0.05% BASE	A071882	001	Jun 06, 1988	Apr CAHN

BETAMETHASONE VALERATE

LOTION;TOPICAL

BETA-VAL					
AB	G AND W LABS INC EQ 0.1% BASE	A070072	001	Jun 27, 1985	Apr CAHN

BETHANECHOL CHLORIDE

TABLET;ORAL

BETHANECHOL CHLORIDE					
AA	HERITAGE PHARMA 5MG	A091256	001	May 04, 2010	Mar CAHN
AA	10MG	A091256	002	May 04, 2010	Mar CAHN
AA	25MG	A091256	003	May 04, 2010	Mar CAHN
AA	50MG	A091256	004	May 04, 2010	Mar CAHN
AA	LANNETT HOLDINGS INC 5MG	A040703	001	Mar 27, 2008	Feb CMFD
AA	50MG	A040677	001	Mar 27, 2008	Feb CMFD
DUVOID					
AA	WELLSPRING PHARM 10MG	A086262	001		Jan CMFD
>D>	@ 25MG	A086263	001		May CMFD
>A> AA	25MG	A086263	001		May CMFD
>D>	@ 50MG	A085882	003		May CMFD
>A> AA	50MG	A085882	003		May CMFD

BEXAROTENE

CAPSULE;ORAL

BEXAROTENE					
	@ BANNER LIFE SCIENCES 75MG	A203174	001	Aug 12, 2014	Jan CAHN

BICALUTAMIDE

TABLET;ORAL

BICALUTAMIDE					
>A> AB	APOTEX INC 50MG	A200274	001	May 21, 2015	May NEWA
>A> AB	STASON PHARMS 50MG	A091011	001	Jun 10, 2015	May NEWA

BIMATOPROST

SOLUTION/DROPS;OPHTHALMIC

BIMATOPROST					
AT	ALCON RES LTD 0.03%	A202565	001	May 05, 2015	Apr NEWA
AT	+ LUPIN LTD 0.03%	A203991	001	Feb 20, 2015	Apr CTEC
	+ 0.03%	A203991	001	Feb 20, 2015	Mar CTEC
AT	+ 0.03%	A203991	001	Feb 20, 2015	Feb NEWA

BROMFENAC SODIUMSOLUTION/DROPS;OPHTHALMIC
BROMDAY

>D>	AT	+	BAUSCH AND LOMB INC	EQ 0.09% ACID	N021664	002	Oct 16, 2010	May CTEC
>A>	AT2	+		EQ 0.09% ACID	N021664	002	Oct 16, 2010	May CTEC
BROMFENAC SODIUM								
>D>	AT		APOTEX INC	EQ 0.09% ACID	A202620	001	Jun 23, 2014	May CTEC
>A>	AT2			EQ 0.09% ACID	A202620	001	Jun 23, 2014	May CTEC
>D>	AT1		COASTAL PHARMS	EQ 0.09% ACID	A201211	001	May 11, 2011	May CRLD
>A>	AT1	+		EQ 0.09% ACID	A201211	001	May 11, 2011	May CRLD
>D>	AT		HI-TECH PHARMACAL	EQ 0.09% ACID	A203395	001	Jan 22, 2014	May CTEC
>A>	AT2			EQ 0.09% ACID	A203395	001	Jan 22, 2014	May CTEC
	AT1		PADDOCK LLC	EQ 0.09% ACID	A201941	001	Feb 10, 2015	Jan NEWA

BUDESONIDEAEROSOL, FOAM;RECTAL
UCERIS+ VALEANT PHARMS INTL 2MG/ACTUATION
SPRAY, METERED;NASAL
BUDESONIDE

N205613	001	Oct 07, 2014	Apr CAHN
A078949	001	May 12, 2014	Mar CTEC

APOTEX INC 0.032MG/INH

BUPRENORPHINE HYDROCHLORIDE

TABLET;SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE

AB			ACTAVIS ELIZABETH	EQ 2MG BASE	A090819	001	Feb 19, 2015	Feb NEWA
AB				EQ 8MG BASE	A090819	002	Feb 19, 2015	Feb NEWA
AB			MYLAN PHARMS INC	EQ 2MG BASE	A201066	001	Mar 06, 2015	Feb NEWA
AB				EQ 8MG BASE	A201066	002	Mar 06, 2015	Feb NEWA
>A>	AB		SANDOZ INC	EQ 2MG BASE	A090279	001	Jun 10, 2015	May NEWA
>A>	AB			EQ 8MG BASE	A090279	002	Jun 10, 2015	May NEWA

BUPROPION HYDROBROMIDE

TABLET, EXTENDED RELEASE;ORAL

APLENZIN

VALEANT PHARMS NORTH	174MG
	348MG
+	522MG

N022108	001	Apr 23, 2008	Feb CAHN
N022108	002	Apr 23, 2008	Feb CAHN
N022108	003	Apr 23, 2008	Feb CAHN

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

BUPROPION HYDROCHLORIDE

>A>	AB1		PRINSTON INC	100MG	A202304	001	May 26, 2015	May NEWA
>A>	AB1			150MG	A202304	002	May 26, 2015	May NEWA
>A>	AB1			200MG	A202304	003	May 26, 2015	May NEWA
	AB2		SANDOZ INC	150MG	A077475	001	Mar 12, 2008	Mar CAHN
>D>	AB1		WOCKHARDT LTD	100MG	A201331	001	Aug 30, 2012	May DISC
>A>		@		100MG	A201331	001	Aug 30, 2012	May DISC
>D>	AB1			150MG	A201331	002	Aug 30, 2012	May DISC
>A>		@		150MG	A201331	002	Aug 30, 2012	May DISC
>D>	AB1			200MG	A201331	003	Aug 30, 2012	May DISC
>A>		@		200MG	A201331	003	Aug 30, 2012	May DISC

BUTABARBITAL SODIUM

TABLET;ORAL

BUTISOL SODIUM

>D>		+	MEDA PHARMS	50MG	N000793	003		May DISC
>A>		@		50MG	N000793	003		May DISC

BUTOCONAZOLE NITRATE

CREAM;VAGINAL

BUTOCONAZOLE NITRATE

>A>		@	ELAN PHARMA INTL LTD	2%	N019881	001	Feb 07, 1997	May CTNA
>D>			GYNAZOLE-1					
>D>		@	ELAN PHARMA INTL LTD	2%	N019881	001	Feb 07, 1997	May CTNA

CALCIPOTRIENECREAM; TOPICAL
CALCIPOTRIENE

>A> AB	GLENMARK PHARMS LTD	0.005%	A205772	001	Jun 09, 2015	May NEWA
--------	---------------------	--------	---------	-----	--------------	----------

CALCITONIN SALMONINJECTABLE; INJECTION
CALCITONIN-SALMON

@ IGI LABS INC	200 IU/ML	A073690	001	Apr 14, 1995	Mar CAHN
----------------	-----------	---------	-----	--------------	----------

CALCITRIOLCAPSULE; ORAL
CALCITRIOL

AB	BANNER LIFE SCIENCES	0.25MCG	A091174	001	May 24, 2013	Jan CAHN
AB		0.5MCG	A091174	002	May 24, 2013	Jan CAHN
AB	STRIDES PHARMA	0.25MCG	A091356	001	Dec 12, 2014	Jan CAHN
AB		0.5MCG	A091356	002	Dec 12, 2014	Jan CAHN

CALCIUM ACETATETABLET; ORAL
CALCIUM ACETATE

AB	ZYDUS PHARMS USA INC	EQ 169MG CALCIUM	A202885	001	Jan 22, 2015	Jan NEWA
----	----------------------	------------------	---------	-----	--------------	----------

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER

+	GAMBRO RENAL PRODS	N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.157GM/1000ML; 2.21GM/1000ML; 7.07GM/1000ML (5000ML)	N021703	010	Oct 10, 2008	Jan CPOT
---	--------------------	---	---------	-----	--------------	----------

PRISMASOL B22GK 2/2.5 IN PLASTIC CONTAINER

@	GAMBRO RENAL PRODS	3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.157GM/1000ML; 2.21GM/1000ML; 7.07GM/1000ML (5000ML)	N021703	012	Oct 10, 2008	Jan CPOT
---	--------------------	--	---------	-----	--------------	----------

PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER

+	GAMBRO RENAL PRODS	N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 2.21GM/1000ML; 7.07GM/1000ML (5000ML)	N021703	011	Oct 10, 2008	Jan CPOT
---	--------------------	---	---------	-----	--------------	----------

PRISMASOL B22GK 4/2.5 IN PLASTIC CONTAINER

+	GAMBRO RENAL PRODS	3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 2.21GM/1000ML; 7.07GM/1000ML (5000ML)	N021703	013	Oct 10, 2008	Jan CPOT
---	--------------------	--	---------	-----	--------------	----------

PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER

+	GAMBRO RENAL PRODS	3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	006	Oct 25, 2006	Jan CPOT
---	--------------------	--	---------	-----	--------------	----------

PRISMASOL BGK 2/0 IN PLASTIC CONTAINER

+	GAMBRO RENAL PRODS	N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; 0.157GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	002	Oct 25, 2006	Jan CPOT
---	--------------------	---	---------	-----	--------------	----------

PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER

+	GAMBRO RENAL PRODS	5.15GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; 0.157GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	003	Oct 25, 2006	Jan CPOT
---	--------------------	--	---------	-----	--------------	----------

PRISMASOL BGK 4/0 IN PLASTIC CONTAINER

@	GAMBRO RENAL PRODS	N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	005	Oct 25, 2006	Jan CPOT
---	--------------------	---	---------	-----	--------------	----------

PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER

+	GAMBRO RENAL PRODS	N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.44GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	015	Oct 10, 2008	Jan CPOT
---	--------------------	---	---------	-----	--------------	----------

PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER

+	GAMBRO RENAL PRODS	3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	004	Oct 25, 2006	Jan CPOT
---	--------------------	--	---------	-----	--------------	----------

INJECTABLE;INJECTION

PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER		GM/1000ML (5000ML)				
PRISMASOL BGK 4/3.5 IN PLASTIC CONTAINER						
@	GAMBRO RENAL PRODS	5.15GM/1000ML;20GM/1000ML;5.4GM/1000ML;2.03GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	008	Oct 25, 2006	Jan CPOT
PRISMASOL BK 0/0 IN PLASTIC CONTAINER						
@	GAMBRO RENAL PRODS	N/A/1000ML;N/A/1000ML;5.4GM/1000ML;3.05GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	007	Oct 25, 2006	Jan CPOT
PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER						
+	GAMBRO RENAL PRODS	N/A/1000ML;N/A/1000ML;5.4GM/1000ML;2.44GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	014	Oct 10, 2008	Jan CPOT
PRISMASOL BK 0/3.5 IN PLASTIC CONTAINER						
+	GAMBRO RENAL PRODS	5.15GM/1000ML;N/A/1000ML;5.4GM/1000ML;2.03GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	001	Oct 25, 2006	Jan CPOT
PRISMASOL BK 4/2.5 IN PLASTIC CONTAINER						
@	GAMBRO RENAL PRODS	3.68GM/1000ML;N/A/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	009	Oct 25, 2006	Jan CPOT

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

INJECTABLE;INJECTION

PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER						
+	GAMBRO LUNDIA	N/A/1000ML;N/A/1000ML;N/A/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;6.95GM/1000ML;0.187GM/1000ML (5000ML)	N207026	002	Jan 13, 2015	Jan NEWA
PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER						
+	GAMBRO LUNDIA	3.68GM/1000ML;N/A/1000ML;N/A/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.34GM/1000ML;0.187GM/1000ML (5000ML)	N207026	001	Jan 13, 2015	Jan NEWA

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER						
@	BAXTER HLTHCARE	37MG/100ML;5GM/100ML;30MG/100ML;119MG/100ML;161MG/100ML;94MG/100ML;138MG/100ML	N017390	001		Mar DISC

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

PLASMA-LYTE R IN PLASTIC CONTAINER						
@	BAXTER HLTHCARE	36.8MG/100ML;30.5MG/100ML;74.6MG/100ML;640MG/100ML;496MG/100ML;89.6MG/100ML	N017438	001		Mar DISC

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

INJECTABLE;INJECTION

PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER						
+	GAMBRO LUNDIA	N/A/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;6.95GM/1000ML;0.187GM/1000ML (5000ML)	N207026	002	Jan 13, 2015	Feb CAIN
PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER						
+	GAMBRO LUNDIA	3.68GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.34GM/1000ML;0.187GM/1000ML	N207026	001	Jan 13, 2015	Feb CAIN

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

TABLET;ORAL

CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE						
AB	MACLEODS PHARMS LTD	16MG;12.5MG	A204100	001	Feb 27, 2015	Feb NEWA
AB		32MG;12.5MG	A204100	002	Feb 27, 2015	Feb NEWA
AB		32MG;25MG	A204100	003	Feb 27, 2015	Feb NEWA

CAPECITABINE

TABLET; ORAL

CAPECITABINE

AB	ACCORD HLTHCARE	150MG	A202593	001	Apr 23, 2015	Apr NEWA
AB		500MG	A202593	002	Apr 23, 2015	Apr NEWA

CAPTOPRIL

TABLET; ORAL

CAPOTEN

>D>						
>D>	AB	PAR PHARM	12.5MG	N018343	005	Jan 17, 1985 May DISC
>A>		@	12.5MG	N018343	005	Jan 17, 1985 May DISC
>D>	AB		25MG	N018343	002	May DISC
>A>		@	25MG	N018343	002	May DISC
>D>	AB		50MG	N018343	001	May DISC
>A>		@	50MG	N018343	001	May DISC
>D>	AB	+	100MG	N018343	003	May DISC
>A>		@	100MG	N018343	003	May DISC

CAPTOPRIL

		@ G AND W LABS INC	12.5MG	A074462	001	Feb 13, 1996 Apr CAHN
		@	12.5MG	A074590	004	Aug 30, 1996 Apr CAHN
		@	25MG	A074462	002	Feb 13, 1996 Apr CAHN
		@	25MG	A074590	002	Aug 30, 1996 Apr CAHN
		@	50MG	A074462	003	Feb 13, 1996 Apr CAHN
		@	50MG	A074590	001	Aug 30, 1996 Apr CAHN
		@	100MG	A074462	004	Feb 13, 1996 Apr CAHN
		@	100MG	A074590	003	Aug 30, 1996 Apr CAHN
>D>	AB	MYLAN	100MG	A074434	004	Feb 13, 1996 May CRLD
>A>	AB	+	100MG	A074434	004	Feb 13, 1996 May CRLD

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

CAPTOPRIL AND HYDROCHLOROTHIAZIDE

AB	G AND W LABS INC	25MG;15MG	A074827	001	Dec 29, 1997 Apr CAHN
AB		25MG;25MG	A074827	002	Dec 29, 1997 Apr CAHN
AB		50MG;15MG	A074827	004	Dec 29, 1997 Apr CAHN
AB		50MG;25MG	A074827	003	Dec 29, 1997 Apr CAHN

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE; ORAL

CARBAMAZEPINE

>A>	AB	MYLAN PHARMS INC	100MG	A076697	001	May 20, 2011 May CAHN
>A>	AB		200MG	A076697	002	May 20, 2011 May CAHN
>A>	AB		300MG	A076697	003	May 20, 2011 May CAHN
>D>	AB	NOSTRUM	100MG	A076697	001	May 20, 2011 May CAHN
>D>	AB		200MG	A076697	002	May 20, 2011 May CAHN
>D>	AB		300MG	A076697	003	May 20, 2011 May CAHN

CARBIDOPA; LEVODOPA

CAPSULE, EXTENDED RELEASE; ORAL

RYTARY

IMPAX LABS INC

36.25MG;145MG

48.75MG;195MG

61.25MG;245MG

SUSPENSION; ENTERAL

DUOPA

+ ABBVIE INC

4.63MG/ML; 20MG/ML

N203312	001	Jan 07, 2015	Jan NEWA
N203312	002	Jan 07, 2015	Jan NEWA
N203312	003	Jan 07, 2015	Jan NEWA
N203312	004	Jan 07, 2015	Jan NEWA

N203952	001	Jan 09, 2015	Jan NEWA
---------	-----	--------------	----------

CARBOPLATIN

INJECTABLE; IV (INFUSION)

CARBOPLATIN

>A>	+	MYLAN PHARMS INC	1GM/100ML (10MG/ML)	A091478	001	Nov 23, 2011 May CAHN
>A>	AP		50MG/5ML (10MG/ML)	A091063	001	Nov 09, 2011 May CAHN
>A>	AP		150MG/15ML (10MG/ML)	A091063	002	Nov 09, 2011 May CAHN
>A>	AP		450MG/45ML (10MG/ML)	A091063	003	Nov 09, 2011 May CAHN
>A>	AP		600MG/60ML (10MG/ML)	A091063	004	Nov 09, 2011 May CAHN
>D>	+	ONCO THERAPIES LTD	1GM/100ML (10MG/ML)	A091478	001	Nov 23, 2011 May CAHN
>D>	AP		50MG/5ML (10MG/ML)	A091063	001	Nov 09, 2011 May CAHN
>D>	AP		150MG/15ML (10MG/ML)	A091063	002	Nov 09, 2011 May CAHN
>D>	AP		450MG/45ML (10MG/ML)	A091063	003	Nov 09, 2011 May CAHN
>D>	AP		600MG/60ML (10MG/ML)	A091063	004	Nov 09, 2011 May CAHN

CARVEDILOLTABLET; ORAL
CARVEDILOL

AB	SUN PHARM INDS LTD	3.125MG	A076989	001	Sep 05, 2007	Apr CAHN
AB		6.25MG	A076989	002	Sep 05, 2007	Apr CAHN
AB		12.5MG	A076989	003	Sep 05, 2007	Apr CAHN
AB		25MG	A076989	004	Sep 05, 2007	Apr CAHN

CEFADROXIL/CEFADROXIL HEMIHYDRATEFOR SUSPENSION; ORAL
CEFADROXIL

	SUN PHARM INDS LTD	EQ 125MG BASE/5ML	A065115	001	Mar 26, 2003	Apr CAHN
AB		EQ 250MG BASE/5ML	A065115	002	Mar 26, 2003	Apr CAHN
AB		EQ 500MG BASE/5ML	A065115	003	Mar 26, 2003	Apr CAHN

CEFAZOLIN SODIUMINJECTABLE; INJECTION
CEFAZOLIN SODIUM

AP	FACTA FARMA	EQ 1GM BASE/VIAL	A063207	001	Dec 27, 1991	Jan CAHN
AP		EQ 10GM BASE/VIAL	A063209	001	Dec 27, 1991	Jan CAHN
AP	+	EQ 20GM BASE/VIAL	A063209	002	Apr 30, 1999	Jan CAHN
AP		EQ 500MG BASE/VIAL	A063214	001	Dec 27, 1991	Jan CAHN

CEFIXIMEFOR SUSPENSION; ORAL
CEFIXIME

AB	AUROBINDO PHARMA LTD	100MG/5ML	A204835	001	Apr 14, 2015	Apr NEWA
AB		200MG/5ML	A204835	002	Apr 14, 2015	Apr NEWA
	SUPRAX					
AB	LUPIN PHARMS	100MG/5ML	A065129	001	Feb 23, 2004	Apr CFTG
AB		200MG/5ML	A065355	001	Apr 10, 2007	Apr CFTG

CEFOTETAN DISODIUMINJECTABLE; INJECTION
CEFOTAN

>D>	@ ASTRAZENECA	EQ 1GM BASE/VIAL	A063293	001	Apr 29, 1993	May CAHN
>D>	@	EQ 2GM BASE/VIAL	A063293	002	Apr 29, 1993	May CAHN
>A>	@ IGI LABS INC	EQ 1GM BASE/VIAL	A063293	001	Apr 29, 1993	May CAHN
	@	EQ 1GM BASE/VIAL	N050588	001	Dec 27, 1985	Mar CAHN
>A>	@	EQ 2GM BASE/VIAL	A063293	002	Apr 29, 1993	May CAHN
	@	EQ 2GM BASE/VIAL	N050588	002	Dec 27, 1985	Mar CAHN
	@	EQ 10GM BASE/VIAL	N050588	003	Apr 25, 1988	Mar CAHN
	CEFOTAN IN PLASTIC CONTAINER					
	@ IGI LABS INC	EQ 20MG BASE/ML	N050694	002	Jul 30, 1993	Mar CAHN
	@	EQ 40MG BASE/ML	N050694	001	Jul 30, 1993	Mar CAHN

CEFPODOXIME PROXETILFOR SUSPENSION; ORAL
CEFPODOXIME PROXETIL

AB	SUN PHARM INDS LTD	EQ 50MG BASE/5ML	A065082	001	May 31, 2002	Apr CAHN
AB		EQ 100MG BASE/5ML	A065082	002	May 31, 2002	Apr CAHN

TABLET; ORAL

	CEFPODOXIME PROXETIL					
AB	SUN PHARM INDS LTD	EQ 100MG BASE	A065083	001	Aug 20, 2003	Apr CAHN
AB		EQ 200MG BASE	A065083	002	Aug 20, 2003	Apr CAHN

CEFTRIAZONE SODIUMINJECTABLE; INJECTION
CEFTRIAZONE

AP	FACTA FARMA	EQ 10GM BASE/VIAL	A065269	001	Feb 28, 2007	Jan CAHN
----	-------------	-------------------	---------	-----	--------------	----------

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS
CEFTRIAZONE

@	FACTA FARMA	EQ 1GM BASE/VIAL	A065268	001	Feb 28, 2007	Jan CAHN
@		EQ 2GM BASE/VIAL	A065268	002	Feb 28, 2007	Jan CAHN

CEFUROXIME AXETILFOR SUSPENSION; ORAL
CEFUROXIME AXETIL

AB	SUN PHARM INDS LTD	EQ 125MG BASE/5ML	A065323	001	Feb 05, 2008	Apr CAHN
AB		EQ 250MG BASE/5ML	A065323	002	Feb 05, 2008	Apr CAHN

TABLET;ORAL

CEFUROXIME AXETIL

AB	SUN PHARM INDS LTD	EQ 125MG BASE	A065118	001	Apr 25, 2003	Apr CAHN
AB		EQ 250MG BASE	A065118	002	Apr 25, 2003	Apr CAHN
AB		EQ 500MG BASE	A065118	003	Apr 25, 2003	Apr CAHN

CEFUROXIME SODIUM

INJECTABLE;INJECTION

CEFUROXIME SODIUM

AP	FACTA FARMA	EQ 1.5GM BASE/VIAL	A064125	002	May 30, 1997	Jan CAHN
AP		EQ 7.5GM BASE/VIAL	A064124	001	May 30, 1997	Jan CAHN

INJECTABLE;INTRAMUSCULAR, INTRAVENOUS

CEFUROXIME SODIUM

AB	FACTA FARMA	EQ 750MG BASE/VIAL	A064125	001	May 30, 1997	Jan CAHN
----	-------------	--------------------	---------	-----	--------------	----------

CELECOXIB

CAPSULE;ORAL

CELECOXIB

>A>	AB	APOTEX INC	50MG	A204197	001	Jun 02, 2015	May NEWA
>A>	AB		100MG	A204197	002	Jun 02, 2015	May NEWA
>A>	AB		200MG	A204197	003	Jun 02, 2015	May NEWA
>A>	AB	LUPIN LTD	100MG	A202240	002	Jun 09, 2015	May NEWA
>A>	AB		200MG	A202240	003	Jun 09, 2015	May NEWA
>A>	AB		400MG	A202240	004	Jun 09, 2015	May NEWA
	AB	MYLAN PHARMS INC	100MG	A078857	002	Feb 11, 2015	Jan NEWA
	AB		200MG	A078857	003	Feb 11, 2015	Jan NEWA
	AB		400MG	A078857	004	Feb 11, 2015	Jan NEWA
	AB	WATSON LABS INC	50MG	A200562	001	Feb 11, 2015	Jan NEWA
	AB		100MG	A200562	002	Feb 11, 2015	Jan NEWA
	AB		200MG	A200562	003	Feb 11, 2015	Jan NEWA
	AB		400MG	A200562	004	Feb 11, 2015	Jan NEWA

CEPHALEXIN

CAPSULE;ORAL

CEPHALEXIN

AB	SUN PHARM INDS LTD	EQ 250MG BASE	A065007	001	Sep 16, 1999	Apr CAHN
AB		EQ 500MG BASE	A065007	002	Sep 16, 1999	Apr CAHN

FOR SUSPENSION;ORAL

CEPHALEXIN

@ SUN PHARM INDS LTD

@

EQ 125MG BASE/5ML

EQ 250MG BASE/5ML

A065081 001 Jul 27, 2001 Apr CAHN

A065081 002 Jul 27, 2001 Apr CAHN

CHLOROTHIAZIDE SODIUM

INJECTABLE;INJECTION

CHLOROTHIAZIDE SODIUM

>A>	AP	SAGENT PHARMS	EQ 500MG BASE/VIAL	A202462	001	May 29, 2015	May NEWA
-----	----	---------------	--------------------	---------	-----	--------------	----------

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE

SOLUTION;ORAL

HYDROCODONE BITARTRATE AND CHLORPHENIRAMINE MALEATE

AA	TRIS PHARMA INC	4MG/5ML;5MG/5ML	A206438	001	Jan 27, 2015	Jan NEWA
----	-----------------	-----------------	---------	-----	--------------	----------

VITUZ

AA	+ CYPRESS PHARM	4MG/5ML;5MG/5ML	N204307	001	Feb 20, 2013	Jan CFTG
----	-----------------	-----------------	---------	-----	--------------	----------

CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX

SUSPENSION, EXTENDED RELEASE;ORAL

TUZISTRA XR

+	TRIS PHARMA INC	EQ 2.8MG BASE/5ML;EQ 14.7MG BASE/5ML	N207768	001	Apr 30, 2015	Apr NEWA
---	-----------------	--------------------------------------	---------	-----	--------------	----------

CHLORPROMAZINE HYDROCHLORIDE

INJECTABLE;INJECTION

CHLORPROMAZINE HYDROCHLORIDE

+	EUROHLTH INTL SARL	25MG/ML	A083329	001		Feb CAHN
---	--------------------	---------	---------	-----	--	----------

TABLET;ORAL

CHLORPROMAZINE HYDROCHLORIDE

>D>	BP	SANDOZ	10MG	A080439	001		May DISC
>A>		@	10MG	A080439	001		May DISC
>D>	BP		25MG	A080439	002		May DISC
>A>		@	25MG	A080439	002		May DISC
>D>	BP		50MG	A080439	003		May DISC
>A>		@	50MG	A080439	003		May DISC

TABLET;ORAL

CHLORPROMAZINE HYDROCHLORIDE

>D>	BP	+	100MG	A080439	004		May	DISC
>A>		@	100MG	A080439	004		May	DISC
>D>	BP		200MG	A080439	005		May	DISC
>A>		@	200MG	A080439	005		May	DISC

CHLORTHALIDONE

TABLET;ORAL

CHLORTHALIDONE

		@ G AND W LABS INC	50MG	A088651	001	May 30, 1985	Apr	CAHN
AB		MUTUAL PHARM	50MG	A089286	001	Jul 21, 1986	Mar	CMFD

CHOLIC ACID

CAPSULE;ORAL

CHOLBAM

		ASKLEPION PHARMS LLC	50MG	N205750	001	Mar 17, 2015	Mar	NEWA
+			250MG	N205750	002	Mar 17, 2015	Mar	NEWA
		RTRX	50MG	N205750	001	Mar 17, 2015	Apr	CAHN
+			250MG	N205750	002	Mar 17, 2015	Apr	CAHN

CIDOFOVIR

INJECTABLE;INJECTION

CIDOFOVIR

>D>	AP		MYLAN INSTITUTIONAL	EQ 75MG BASE/ML	A201276	001	Jun 27, 2012	May	CRLD
>A>	AP	+		EQ 75MG BASE/ML	A201276	001	Jun 27, 2012	May	CRLD
>D>			VISTIDE						
>D>	AP	+	GILEAD SCIENCES INC	EQ 75MG BASE/ML	N020638	001	Jun 26, 1996	May	DISC
>A>		@		EQ 75MG BASE/ML	N020638	001	Jun 26, 1996	May	DISC

CIMETIDINE HYDROCHLORIDE

SOLUTION;ORAL

CIMETIDINE HYDROCHLORIDE

		@ G AND W LABS INC	EQ 300MG BASE/5ML	A074176	001	Jun 01, 1994	Apr	CAHN
--	--	--------------------	-------------------	---------	-----	--------------	-----	------

CIPROFLOXACIN

INJECTABLE;INJECTION

CIPROFLOXACIN

AP		CLARIS PHARMASERVICE	200MG/20ML (10MG/ML)	A078062	001	Apr 29, 2008	Apr	CAHN
AP			400MG/40ML (10MG/ML)	A078062	002	Apr 29, 2008	Apr	CAHN
			CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER					
AP		CLARIS PHARMASERVICE	200MG/100ML	A078024	001	Mar 18, 2008	Apr	CAHN
AP			400MG/200ML	A078024	002	Mar 18, 2008	Apr	CAHN

CIPROFLOXACIN HYDROCHLORIDE

TABLET;ORAL

CIPROFLOXACIN HYDROCHLORIDE

AB		SUN PHARM INDS LTD	EQ 250MG BASE	A075747	001	Jun 09, 2004	Apr	CAHN
AB			EQ 500MG BASE	A075747	002	Jun 09, 2004	Apr	CAHN
AB			EQ 750MG BASE	A075747	003	Jun 09, 2004	Apr	CAHN

CISATRACURIUM BESYLATE

INJECTABLE;INJECTION

CISATRACURIUM BESYLATE

AP		FRESENIUS KABI USA	EQ 2MG BASE/ML	A203183	001	Feb 26, 2015	Feb	NEWA
			CISATRACURIUM BESYLATE PRESERVATIVE FREE					
AP		FRESENIUS KABI USA	EQ 2MG BASE/ML	A203182	001	Feb 26, 2015	Feb	NEWA
AP			EQ 10MG BASE/ML	A203182	002	Feb 26, 2015	Feb	NEWA

CITALOPRAM HYDROBROMIDE

TABLET;ORAL

CITALOPRAM HYDROBROMIDE

AB		G AND W LABS INC	EQ 10MG BASE	A077048	001	Nov 16, 2004	Apr	CAHN
AB			EQ 20MG BASE	A077048	002	Nov 16, 2004	Apr	CAHN
AB			EQ 40MG BASE	A077048	003	Nov 16, 2004	Apr	CAHN

CLADRIBINE

INJECTABLE;INJECTION
CLADRIBINE

>A>	AP	MYLAN PHARMS INC	1MG/ML	A200510	001	Oct 06, 2011	May CAHN
>D>	AP	ONCO THERAPIES LTD	1MG/ML	A200510	001	Oct 06, 2011	May CAHN

CLARITHROMYCIN

FOR SUSPENSION;ORAL
CLARITHROMYCIN

AB		SUN PHARM INDS LTD	125MG/5ML	A065382	001	Aug 30, 2007	Apr CAHN
AB			250MG/5ML	A065382	002	Aug 30, 2007	Apr CAHN

TABLET;ORAL

CLARITHROMYCIN

AB		SUN PHARM INDS LTD	250MG	A065174	001	Sep 24, 2004	Apr CAHN
AB			500MG	A065174	002	Sep 24, 2004	Apr CAHN

TABLET, EXTENDED RELEASE;ORAL

BIAXIN XL

@ ABBVIE

500MG

N050775 001 Mar 03, 2000 Jan DISC

CLARITHROMYCIN

AB	+	TEVA	500MG	A065154	001	May 18, 2005	Jan CRLD
----	---	------	-------	---------	-----	--------------	----------

CLAVULANATE POTASSIUM; TICARCILLIN DISODIUM

INJECTABLE;INJECTION
TIMENTIN

>D>	+	GLAXOSMITHKLINE	EQ 1GM BASE/VIAL;EQ 30GM BASE/VIAL	N050590	003	Aug 18, 1987	May DISC
>A>	@		EQ 1GM BASE/VIAL;EQ 30GM BASE/VIAL	N050590	003	Aug 18, 1987	May DISC
>D>			EQ 100MG BASE/VIAL;EQ 3GM	A062691	001	Dec 19, 1986	May DISC
			BASE/VIAL				
>A>	@		EQ 100MG BASE/VIAL;EQ 3GM	A062691	001	Dec 19, 1986	May DISC
			BASE/VIAL				
>D>	+		EQ 100MG BASE/VIAL;EQ 3GM	N050590	001	Apr 01, 1985	May DISC
			BASE/VIAL				
>A>	@		EQ 100MG BASE/VIAL;EQ 3GM	N050590	001	Apr 01, 1985	May DISC
			BASE/VIAL				
>D>	+		EQ 200MG BASE/VIAL;EQ 3GM	N050590	002	Apr 01, 1985	May DISC
			BASE/VIAL				
>A>	@		EQ 200MG BASE/VIAL;EQ 3GM	N050590	002	Apr 01, 1985	May DISC
			BASE/VIAL				
>D>		TIMENTIN IN PLASTIC CONTAINER					
>D>	+	GLAXOSMITHKLINE	EQ 100MG BASE/100ML;EQ 3GM	N050658	001	Dec 15, 1989	May DISC
			BASE/100ML				
>A>	@		EQ 100MG BASE/100ML;EQ 3GM	N050658	001	Dec 15, 1989	May DISC
			BASE/100ML				

CLINDAMYCIN HYDROCHLORIDE

CAPSULE;ORAL

CLINDAMYCIN HYDROCHLORIDE

AB		G AND W LABS INC	EQ 150MG BASE	A063029	001	Sep 20, 1989	Apr CAHN
AB			EQ 300MG BASE	A063029	002	Aug 05, 2005	Apr CAHN
AB		SUN PHARM INDS LTD	EQ 150MG BASE	A065061	001	Feb 02, 2001	Apr CAHN
AB			EQ 300MG BASE	A065061	002	Feb 02, 2001	Apr CAHN

CLINDAMYCIN PHOSPHATE

INJECTABLE;INJECTION
CLINDAMYCIN PHOSPHATE

@ IGI LABS INC

EQ 150MG BASE/ML

A062928 001 Feb 13, 1989 Mar CAHN

SOLUTION;TOPICAL

CLINDAMYCIN PHOSPHATE

@ BOCA PHARMA LLC

EQ 1% BASE

A062944 001 Jan 11, 1989 Jan CAHN

>A>	AT	VINTAGE PHARMS	EQ 1% BASE	A203343	001	May 29, 2015	May NEWA
-----	----	----------------	------------	---------	-----	--------------	----------

CLOBETASOL PROPIONATE

CREAM;TOPICAL

CLOBETASOL PROPIONATE (EMOLLIENT)

>D>	AB2	FOUGERA PHARMS	0.05%	A075430	001	May 26, 1999	May CRLD
>A>	AB2	+	0.05%	A075430	001	May 26, 1999	May CRLD
>D>		TEMOVATE E					
>D>	AB2	+	FOUGERA PHARMS	0.05%	N020340	001	Jun 17, 1994
>A>		@	0.05%	N020340	001	Jun 17, 1994	May DISC

GEL;TOPICAL

CLOBETASOL PROPIONATE

>D>	AB	FOUGERA PHARMS	0.05%	A075368	001	Feb 15, 2000	May CRLD
-----	----	----------------	-------	---------	-----	--------------	----------

		GEL;TOPICAL						
		CLOBETASOL PROPIONATE						
>A>	AB	+	0.05%	A075368	001	Feb 15, 2000	May CRLD	
>D>	TEMOVATE							
>D>	AB	+	FOUGERA PHARMS	0.05%	N020337	001	Apr 29, 1994	May DISC
>A>	@		0.05%	N020337	001	Apr 29, 1994	May DISC	
		OINTMENT;TOPICAL						
		CLOBETASOL PROPIONATE						
	AB	G AND W LABS INC		0.05%	A074089	001	Feb 16, 1994	Feb CAHN
		SOLUTION;TOPICAL						
		CLOBETASOL PROPIONATE						
	AT	G AND W LABS INC		0.05%	A074331	001	Dec 15, 1995	Mar CMFD
<u>CLONIDINE</u>								
		FILM, EXTENDED RELEASE;TRANSDERMAL						
		CLONIDINE						
	AB	ACTAVIS LABS UT INC		0.1MG/24HR	A090873	001	May 06, 2014	Mar CAHN
	AB			0.2MG/24HR	A090873	002	May 06, 2014	Mar CAHN
	AB			0.3MG/24HR	A090873	003	May 06, 2014	Mar CAHN
<u>CLONIDINE HYDROCHLORIDE</u>								
		TABLET;ORAL						
		CLONIDINE HYDROCHLORIDE						
>D>	AB	DAVA PHARMS INC		0.1MG	A071783	001	Apr 05, 1988	May DISC
>A>	@		0.1MG	A071783	001	Apr 05, 1988	May DISC	
>D>	AB			0.2MG	A071784	001	Apr 05, 1988	May DISC
>A>	@		0.2MG	A071784	001	Apr 05, 1988	May DISC	
>D>	AB			0.3MG	A071785	001	Apr 05, 1988	May DISC
>A>	@		0.3MG	A071785	001	Apr 05, 1988	May DISC	
		TABLET, EXTENDED RELEASE;ORAL						
		CLONIDINE HYDROCHLORIDE						
>A>	AB2	ACTAVIS ELIZABETH		0.1MG	A202792	001	May 15, 2015	May NEWA
>A>	AB1			0.1MG	A203320	001	May 15, 2015	May NEWA
>A>	AB2			0.2MG	A202792	002	May 15, 2015	May NEWA
>A>	AB1			0.2MG	A203320	002	May 15, 2015	May NEWA
>D>	AB	ANCHEN PHARMS		0.1MG	A202983	001	Apr 02, 2014	May CTEC
>A>	AB2			0.1MG	A202983	001	Apr 02, 2014	May CTEC
>D>	AB			0.2MG	A202983	002	Apr 02, 2014	May CTEC
>A>	AB2			0.2MG	A202983	002	Apr 02, 2014	May CTEC
		CLONIDINE HYDROCHLORIDE						
>D>	AB	ANCHEN PHARMS		0.1MG	A202984	001	Sep 30, 2013	May CTEC
>A>	AB1			0.1MG	A202984	001	Sep 30, 2013	May CTEC
>D>	AB			0.2MG	A202984	002	Sep 30, 2013	May CTEC
>A>	AB1			0.2MG	A202984	002	Sep 30, 2013	May CTEC
		KAPVAY						
>D>	AB	+	CONCORDIA PHARMS INC	0.1MG	N022331	003	Sep 28, 2010	May CTEC
>A>	AB1	+		0.1MG	N022331	003	Sep 28, 2010	May CTEC
>D>	AB			0.2MG	N022331	004	Sep 28, 2010	May CTEC
>A>	AB1			0.2MG	N022331	004	Sep 28, 2010	May CTEC
<u>CLORAZEPATE DIPOTASSIUM</u>								
		TABLET;ORAL						
		CLORAZEPATE DIPOTASSIUM						
	AB	SUN PHARM INDS LTD		3.75MG	A076911	001	Sep 29, 2004	Apr CAHN
	AB			7.5MG	A076911	002	Sep 29, 2004	Apr CAHN
	AB			15MG	A076911	003	Sep 29, 2004	Apr CAHN
<u>COBICISTAT; DARUNAVIR ETHANOLATE</u>								
		TABLET;ORAL						
		PREZCOBIX						
	+	JANSSEN PRODS		150MG;EQ 800MG BASE	N205395	001	Jan 29, 2015	Jan NEWA
<u>CODEINE SULFATE</u>								
		SOLUTION;ORAL						
		CODEINE SULFATE						
	@	ROXANE		30MG/5ML	N202245	001	Jun 30, 2011	Jan DISC

COLCHICINECAPSULE;ORAL
MITIGARE

HIKMA INTL PHARMS

0.6MG

N204820 001 Sep 26, 2014 Jan CAHN

COLISTIMETHATE SODIUMINJECTABLE;INJECTION
COLISTIMETHATE SODIUM

>A> AP

XELLIA PHARMS APS

EQ 150MG BASE/VIAL

A205356 001 May 29, 2015 May NEWA

CYANOCOBALAMININJECTABLE;INJECTION
CYANOCOBALAMIN

@ EUROHLTH INTL SARL

1MG/ML

A080515 002 Feb CAHN

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET;ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

AB

SUN PHARM INDS LTD

5MG

A078722 001 May 12, 2008 Apr CAHN

AB

7.5MG

A078722 002 May 12, 2008 Apr CAHN

AB

10MG

A078722 003 May 12, 2008 Apr CAHN

CYTARABINEINJECTABLE;INJECTION
CYTARABINE

>A> AP

MYLAN PHARMS INC

20MG/ML

A200915 001 Dec 13, 2011 May CAHN

>A> AP

20MG/ML

A200916 001 Dec 13, 2011 May CAHN

>D> AP

ONCO THERAPIES LTD

20MG/ML

A200915 001 Dec 13, 2011 May CAHN

>D> AP

20MG/ML

A200916 001 Dec 13, 2011 May CAHN

DABRAFENIB MESYLATECAPSULE;ORAL
TAFINLAR

NOVARTIS PHARMS CORP

EQ 50MG BASE

N202806 001 May 29, 2013 Mar CAHN

+

EQ 75MG BASE

N202806 002 May 29, 2013 Mar CAHN

DALTEPARIN SODIUMINJECTABLE;INJECTION
FRAGMIN

@ PHARMACIA AND UPJOHN

7,500 IU/0.75ML

N020287 008 Apr 04, 2002 Apr CAHN

INJECTABLE;SUBCUTANEOUS
FRAGMIN

PHARMACIA AND UPJOHN

2,500IU/0.2ML (12,500IU/ML)

N020287 001 Dec 22, 1994 Apr CAHN

5,000IU/0.2ML (25,000IU/ML)

N020287 003 Mar 18, 1996 Apr CAHN

7,500IU/0.3ML (25,000IU/ML)

N020287 005 Apr 04, 2002 Apr CAHN

@

10,000IU/0.4ML (25,000IU/ML)

N020287 002 May 01, 2007 Apr CAHN

10,000IU/ML (10,000IU/ML)

N020287 004 Jan 30, 1998 Apr CAHN

12,500IU/0.5ML (25,000IU/ML)

N020287 009 May 01, 2007 Apr CAHN

15,000IU/0.6ML (25,000IU/ML)

N020287 010 May 01, 2007 Apr CAHN

18,000IU/0.72ML (25,000IU/ML)

N020287 011 May 01, 2007 Apr CAHN

+

95,000IU/3.8ML (25,000IU/ML)

N020287 006 Apr 04, 2002 Apr CAHN

@

95,000IU/9.5ML (10,000IU/ML)

N020287 007 Apr 04, 2002 Apr CAHN

DANTROLENE SODIUM

CAPSULE;ORAL

DANTROLENE SODIUM

>A> AB

ELITE LABS INC

25MG

A076686 001 Oct 24, 2005 May CAHN

>A> AB

50MG

A076686 002 Oct 24, 2005 May CAHN

>A> AB

100MG

A076686 003 Oct 24, 2005 May CAHN

>D> AB

MIKAH PHARMA

25MG

A076686 001 Oct 24, 2005 May CAHN

>D> AB

50MG

A076686 002 Oct 24, 2005 May CAHN

>D> AB

100MG

A076686 003 Oct 24, 2005 May CAHN

DARIFENACIN HYDROBROMIDETABLET, EXTENDED RELEASE;ORAL
DARIFENACIN HYDROBROMIDE

AB

ANCHEN PHARMS

EQ 7.5MG BASE

A091190 001 Mar 13, 2015 Mar NEWA

AB

EQ 15MG BASE

A091190 002 Mar 13, 2015 Mar NEWA

ENABLEX

AB

WARNER CHILCOTT LLC

EQ 7.5MG BASE

N021513 001 Dec 22, 2004 Mar CFTG

AB

+

EQ 15MG BASE

N021513 002 Dec 22, 2004 Mar CFTG

DECITABINEINJECTABLE; INTRAVENOUS
DACOGEN

AP	+	OTSUKA PHARM CO LTD	50MG/VIAL	N021790	001	May 02, 2006	Jan CAHN
----	---	---------------------	-----------	---------	-----	--------------	----------

DEFERASIROXTABLET; ORAL
JADENU

		NOVARTIS PHARMS CORP	90MG	N206910	001	Mar 30, 2015	Mar NEWA
			180MG	N206910	002	Mar 30, 2015	Mar NEWA
	+		360MG	N206910	003	Mar 30, 2015	Mar NEWA

DEOXYCHOLIC ACIDSOLUTION; SUBCUTANEOUS
KYBELLA

	+	KYETHERA BIOPHARMS	20MG/2ML (10MG/ML)	N206333	001	Apr 29, 2015	Apr NEWA
--	---	--------------------	--------------------	---------	-----	--------------	----------

DESIRUDIN RECOMBINANTINJECTABLE; SUBCUTANEOUS
IPRIVASK

>D>	+	MARATHON PHARMS LLC	15MG/VIAL	N021271	001	Apr 04, 2003	May CAHN
>A>	+	VALEANT PHARMS NORTH	15MG/VIAL	N021271	001	Apr 04, 2003	May CAHN

DESMOPRESSIN ACETATETABLET; ORAL
DDAVP

AB		FERRING PHARMS INC	0.1MG	N019955	001	Sep 06, 1995	Jan CAHN
AB	+		0.2MG	N019955	002	Sep 06, 1995	Jan CAHN
		DESMOPRESSIN ACETATE					
>A>	AB	GLENMARK PHARMS LTD	0.1MG	A201831	001	May 28, 2015	May NEWA
>A>	AB		0.2MG	A201831	002	May 28, 2015	May NEWA

DESOGESTREL; ETHINYL ESTRADIOLTABLET; ORAL-28
DESOGESTREL AND ETHINYL ESTRADIOL

>A>	AB	FAMY CARE LTD	0.15MG; 0.03MG	A202085	001	May 20, 2015	May NEWA
		KARIVA					
AB	+	BARR	0.15MG, N/A; 0.02MG, 0.01MG	A075863	001	Apr 05, 2002	Apr CTEC
		KIMIDESS					
AB		VINTAGE PHARMS	0.15MG, N/A; 0.02MG, 0.01MG	A076681	001	Apr 30, 2015	Apr NEWA

DESONIDECREAM; TOPICAL
DESONIDE

>D>		@ TEVA PHARMS	0.05%	A074027	001	Sep 28, 1992	May CMFD
>A>	AB		0.05%	A074027	001	Sep 28, 1992	May CMFD

DESOXIMETASONEOINTMENT; TOPICAL
DESOXIMETASONE

AB		PERRIGO NEW YORK	0.25%	A077770	001	Apr 20, 2015	Apr NEWA
----	--	------------------	-------	---------	-----	--------------	----------

DEXAMETHASONE SODIUM PHOSPHATEINJECTABLE; INJECTION
DEXAMETHASONE SODIUM PHOSPHATE

		@ EUROHLTH INTL SARL	EQ 4MG PHOSPHATE/ML	A084282	001		Mar CAHN
AP	+		EQ 10MG PHOSPHATE/ML	A087702	001	Sep 07, 1982	Feb CAHN
AP		MYLAN PHARMS INC	EQ 4MG PHOSPHATE/ML	A040803	001	Aug 29, 2008	Apr CAHN
AP			EQ 10MG PHOSPHATE/ML	A040802	001	Aug 29, 2008	Apr CAHN

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATEOINTMENT; OPHTHALMIC
MAXITROL

AT	+	ALCON LABS INC	0.1%; EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N050065	002		Mar CAHN
----	---	----------------	---	---------	-----	--	----------

SUSPENSION/DROPS; OPHTHALMIC
MAXITROL

AT	+	ALCON LABS INC	0.1%; EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N050023	002		Mar CAHN
----	---	----------------	---	---------	-----	--	----------

DEXMEDETOMIDINE HYDROCHLORIDEINJECTABLE; INJECTION
PRECEDEX

HOSPIRA

EQ 80MCG BASE/20ML (EQ 4MCG
BASE/ML)

N021038 004 Nov 14, 2014 Jan NEWA

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETH W/ DEXTROMETHORPHAN

>D> @ ACTAVIS MID ATLANTIC 15MG/5ML; 6.25MG/5ML

A088762 001 Oct 31, 1984 May CAHN

>A> @ G AND W LABS INC 15MG/5ML; 6.25MG/5ML

A088762 001 Oct 31, 1984 May CAHN

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION

PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER

@ BAXTER HLTHCARE 5GM/100ML; 30MG/100ML; 37MG/100ML; 36
8MG/100ML; 526MG/100ML; 502MG/100ML

N017451 001 Mar DISC

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE; INJECTION

MD-76R

AP + LIEBEL-FLARSHEIM 66%; 10%

N019292 001 Sep 29, 1989 Feb CAHN

SOLUTION; ORAL, RECTAL

MD-GASTROVIEW

AA LIEBEL-FLARSHEIM 66%; 10%

A087388 001 Jan CAHN

DIETHYLPROPION HYDROCHLORIDE

TABLET; ORAL

TENUATE

AA + ACTAVIS LABS UT INC 25MG

N011722 002 Mar CAHN

TABLET, EXTENDED RELEASE; ORAL

TENUATE DOSPAN

AB + ACTAVIS LABS UT INC 75MG

N012546 001 Mar CAHN

DIFLUNISAL

TABLET; ORAL

DIFLUNISAL

AB HERITAGE PHARMA 500MG

A202845 001 Mar 08, 2012 Mar CAHN

DIGOXIN

INJECTABLE; INJECTION

DIGOXIN

AP EUROHLTH INTL SARL 0.25MG/ML

A083391 001 Feb CAHN

TABLET; ORAL

DIGOXIN

AB MYLAN PHARMS INC 0.125MG

A040282 001 Dec 23, 1999 Jan CTEC

AB 0.25MG

A040282 002 Dec 23, 1999 Jan CTEC

AB SUN PHARM INDS INC 0.125MG

A076363 001 Jan 31, 2003 Feb CMFD

AB 0.25MG

A076363 002 Jan 31, 2003 Feb CMFD

LANOXIN

AB CONCORDIA PHARMS INC 0.0625MG

N020405 001 Sep 30, 1997 Apr CAHN

AB 0.125MG

N020405 002 Sep 30, 1997 Apr CAHN

AB 0.1875MG

N020405 003 Sep 30, 1997 Apr CAHN

AB + 0.25MG

N020405 004 Sep 30, 1997 Apr CAHN

@ 0.375MG

N020405 005 Sep 30, 1997 Apr CAHN

@ 0.5MG

N020405 006 Sep 30, 1997 Apr CAHN

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

DILACOR XR

@ ACTAVIS LABS UT INC 120MG

N020092 001 May 29, 1992 Mar CAHN

@ 180MG

N020092 002 May 29, 1992 Mar CAHN

@ 240MG

N020092 003 May 29, 1992 Mar CAHN

@ WATSON LABS 120MG

N020092 001 May 29, 1992 Feb DISC

@ 180MG

N020092 002 May 29, 1992 Feb DISC

@ 240MG

N020092 003 May 29, 1992 Feb DISC

DILTIAZEM HYDROCHLORIDE

AB2 + MYLAN 240MG

A075124 001 Mar 18, 1998 Feb CRLD

TIAZAC

AB4 VALEANT PHARMS NORTH 120MG

N020401 001 Sep 11, 1995 Feb CAHN

CAPSULE, EXTENDED RELEASE;ORAL
TIAZAC

AB4		180MG	N020401	002	Sep 11, 1995	Feb CAHN
AB4		240MG	N020401	003	Sep 11, 1995	Feb CAHN
AB4		300MG	N020401	004	Sep 11, 1995	Feb CAHN
AB4		360MG	N020401	005	Sep 11, 1995	Feb CAHN
AB4	+	420MG	N020401	006	Oct 16, 1998	Feb CAHN

INJECTABLE;INJECTION
DILTIAZEM HYDROCHLORIDE
@ MYLAN PHARMS INC

5MG/ML

A075375 001 Sep 30, 1999 Apr CAHN

DIPYRIDAMOLEINJECTABLE;INJECTION
DIPYRIDAMOLE

@ MYLAN PHARMS INC

5MG/ML

A075769 001 Nov 27, 2002 Apr CAHN

DISULFIRAMTABLET;ORAL
DISULFIRAM

AB MYLAN PHARMS INC

250MG

A203916 001 Mar 04, 2015 Feb NEWA

AB

500MG

A203916 002 Mar 04, 2015 Feb NEWA

DIVALPROEX SODIUMTABLET, EXTENDED RELEASE;ORAL
DIVALPROEX SODIUM

>A>	AB	AMNEAL PHARMS	EQ 250MG VALPROIC ACID	A203730	001	May 29, 2015	May NEWA
>A>	AB		EQ 500MG VALPROIC ACID	A203730	002	May 29, 2015	May NEWA

DOBUTAMINE HYDROCHLORIDEINJECTABLE;INJECTION
DOBUTAMINE HYDROCHLORIDE

@ IGI LABS INC EQ 12.5MG BASE/ML

A074098 001 Feb 21, 1995 Mar CAHN

DONEPEZIL HYDROCHLORIDETABLET;ORAL
DONEPEZIL HYDROCHLORIDE

AB HETERO LABS LTD V

5MG

A203034 001 Jan 30, 2015 Jan NEWA

AB

10MG

A203034 002 Jan 30, 2015 Jan NEWA

AB SUN PHARM INDS LTD

5MG

A076786 001 Nov 26, 2010 Apr CAHN

AB

10MG

A076786 002 Nov 26, 2010 Apr CAHN

>A> AB

23MG

A204293 001 Jun 05, 2015 May NEWA

DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDECAPSULE, EXTENDED RELEASE;ORAL
NAMZARIC

FOREST LABS LLC 10MG;14MG

N206439 001 Dec 23, 2014 Mar CAHN

+ 10MG;28MG

N206439 002 Dec 23, 2014 Mar CAHN

DOPAMINE HYDROCHLORIDEINJECTABLE;INJECTION
DOPAMINE HYDROCHLORIDE

@ IGI LABS INC 40MG/ML

A070087 001 Oct 23, 1985 Mar CAHN

@ 40MG/ML

N018656 001 Jun 28, 1983 Mar CAHN

@ 80MG/ML

A070089 001 Oct 23, 1985 Mar CAHN

@ 80MG/ML

A070090 001 Oct 23, 1985 Mar CAHN

@ 80MG/ML

A070091 001 Oct 23, 1985 Mar CAHN

@ 160MG/ML

A070092 001 Oct 23, 1985 Mar CAHN

@ 160MG/ML

A070093 001 Oct 23, 1985 Mar CAHN

@ 160MG/ML

A070094 001 Oct 23, 1985 Mar CAHN

DOXEPIIN HYDROCHLORIDECAPSULE;ORAL
DOXEPIIN HYDROCHLORIDE

AB	+	MYLAN PHARMS INC	EQ 100MG BASE	A070791	005	May 13, 1986	Jan CRLD
	+	PAR PHARM	EQ 150MG BASE	A071669	001	Nov 09, 1987	Jan CRLD

CREAM;TOPICAL
ZONALON

+ DELCOR ASSET CORP 5%

N020126 001 Apr 01, 1994 Mar CAHN

DOXERCALCIFEROLINJECTABLE; INJECTION
DOXERCALCIFEROL

AP	AKORN INC	4MCG/2ML (2MCG/ML)	A203929	001	May 07, 2015	Apr NEWA
----	-----------	--------------------	---------	-----	--------------	----------

DOXORUBICIN HYDROCHLORIDEINJECTABLE; INJECTION
DOXORUBICIN HYDROCHLORIDE

>A>	AP	MYLAN PHARMS INC	2MG/ML	A200901	001	Feb 14, 2012	May CAHN
>A>	AP		10MG/VIAL	A200170	001	Oct 28, 2011	May CAHN
>A>	AP		50MG/VIAL	A200170	002	Oct 28, 2011	May CAHN
>D>	AP	ONCO THERAPIES LTD	2MG/ML	A200901	001	Feb 14, 2012	May CAHN
>D>	AP		10MG/VIAL	A200170	001	Oct 28, 2011	May CAHN
>D>	AP		50MG/VIAL	A200170	002	Oct 28, 2011	May CAHN

DOXYCYCLINECAPSULE; ORAL
DOXYCYCLINE

>A>	AB	NOVEL LABS INC	EQ 50MG BASE	A204446	001	May 28, 2015	May NEWA
>A>	AB		EQ 75MG BASE	A204446	002	May 28, 2015	May NEWA
>A>	AB		EQ 100MG BASE	A204446	003	May 28, 2015	May NEWA
	AB	SUN PHARM INDS LTD	EQ 50MG BASE	A065053	001	Nov 22, 2000	Apr CAHN
	AB		EQ 75MG BASE	A065053	003	Sep 10, 2003	Apr CAHN
	AB		EQ 100MG BASE	A065053	002	Nov 22, 2000	Apr CAHN

TABLET; ORAL
DOXYCYCLINE

AB	SUN PHARM INDS LTD	EQ 50MG BASE	A065356	001	May 31, 2006	Apr CAHN
AB		EQ 75MG BASE	A065356	002	May 31, 2006	Apr CAHN
AB		EQ 100MG BASE	A065356	003	May 31, 2006	Apr CAHN

DROPERIDOLINJECTABLE; INJECTION
DROPERIDOL

@	IGI LABS INC	2.5MG/ML	A072019	001	Oct 19, 1988	Mar CAHN
@		2.5MG/ML	A072020	001	Oct 19, 1988	Mar CAHN
@		2.5MG/ML	A072021	001	Oct 19, 1988	Mar CAHN

DROSPIRENONE; ETHINYL ESTRADIOLTABLET; ORAL-28
DROSPIRENONE AND ETHINYL ESTRADIOL

AB	FAMY CARE LTD	3MG;0.03MG	A202131	001	May 04, 2015	Apr NEWA
----	---------------	------------	---------	-----	--------------	----------

ECONAZOLE NITRATECREAM; TOPICAL
ECONAZOLE NITRATE

AB	FOUGERA PHARMS	1%	A076075	001	Nov 26, 2002	Mar CRLD
AB	+ PERRIGO NEW YORK	1%	A076479	001	Jun 23, 2004	Mar CRLD

EDOXABAN TOSYLATETABLET; ORAL
SAVAYSA
DAIICHI SANKYO

		EQ 15MG BASE	N206316	001	Jan 08, 2015	Jan NEWA
		EQ 30MG BASE	N206316	002	Jan 08, 2015	Jan NEWA
+		EQ 60MG BASE	N206316	003	Jan 08, 2015	Jan NEWA

EDROPHONIUM CHLORIDEINJECTABLE; INJECTION
ENLON

+	MYLAN INSTITUTIONAL	10MG/ML	A088873	001	Aug 06, 1985	Mar CRLD
	TENSILON					
@	IGI LABS INC	10MG/ML	N007959	001		Apr CAHN
@	VALEANT PHARMS	10MG/ML	N007959	001		Mar DISC
	TENSILON PRESERVATIVE FREE					
@	IGI LABS INC	10MG/ML	N007959	002		Apr CAHN
@	VALEANT PHARMS	10MG/ML	N007959	002		Mar DISC

ELTROMBOPAG OLAMINETABLET; ORAL
PROMACTA

		NOVARTIS PHARMS CORP	EQ 12.5MG ACID	N022291	004	Oct 20, 2011	Mar CAHN
			EQ 25MG ACID	N022291	001	Nov 20, 2008	Mar CAHN
>D>	+		EQ 50MG ACID	N022291	002	Nov 20, 2008	May CRLD
>A>			EQ 50MG ACID	N022291	002	Nov 20, 2008	May CRLD
	+		EQ 50MG ACID	N022291	002	Nov 20, 2008	Mar CAHN
>D>			EQ 75MG ACID	N022291	003	Sep 08, 2009	May CRLD
>A>	+		EQ 75MG ACID	N022291	003	Sep 08, 2009	May CRLD
			EQ 75MG ACID	N022291	003	Sep 08, 2009	Mar CAHN
>D>			EQ 100MG ACID	N022291	005	Nov 16, 2012	May CRLD
>A>	+		EQ 100MG ACID	N022291	005	Nov 16, 2012	May CRLD
			EQ 100MG ACID	N022291	005	Nov 16, 2012	Mar CAHN

ELUXADOLINETABLET; ORAL
VIBERZI

>A>		FURIEX PHARMS	75MG	N206940	001	May 27, 2015	May NEWA
>A>	+		100MG	N206940	002	May 27, 2015	May NEWA

EMPAGLIFLOZIN; LINAGLIPTINTABLET; ORAL
GLYXAMBI

		BOEHRINGER INGELHEIM	10MG; 5MG	N206073	001	Jan 30, 2015	Jan NEWA
	+		25MG; 5MG	N206073	002	Jan 30, 2015	Jan NEWA

ENALAPRIL MALEATETABLET; ORAL
ENALAPRIL MALEATE

AB		SANDOZ INC	2.5MG	A075496	001	Aug 22, 2000	Mar CMFD
AB			5MG	A075496	002	Aug 22, 2000	Mar CMFD
AB			10MG	A075459	001	Aug 22, 2000	Mar CMFD
AB			20MG	A075459	002	Aug 22, 2000	Mar CMFD
	@	SUN PHARM INDS LTD	2.5MG	A075556	001	Aug 22, 2000	Apr CAHN
	@		5MG	A075556	002	Aug 22, 2000	Apr CAHN
	@		10MG	A075556	003	Aug 22, 2000	Apr CAHN
	@		20MG	A075556	004	Aug 22, 2000	Apr CAHN
		VASOTEC					
AB		VALEANT PHARMS NORTH	2.5MG	N018998	005	Jul 26, 1988	Apr CAHN
AB			5MG	N018998	001	Dec 24, 1985	Apr CAHN
AB			10MG	N018998	002	Dec 24, 1985	Apr CAHN
AB	+		20MG	N018998	003	Dec 24, 1985	Apr CAHN

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDETABLET; ORAL
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

AB		G AND W LABS INC	5MG; 12.5MG	A075727	001	Sep 18, 2001	Apr CAHN
AB			10MG; 25MG	A075727	002	Sep 18, 2001	Apr CAHN

EPIRUBICIN HYDROCHLORIDEINJECTABLE; INJECTION
EPIRUBICIN HYDROCHLORIDE

>A>	AP	MYLAN PHARMS INC	50MG/25ML (2MG/ML)	A091599	001	Mar 12, 2012	May CAHN
>A>	AP		200MG/100ML (2MG/ML)	A091599	002	Mar 12, 2012	May CAHN
>D>	AP	ONCO THERAPIES LTD	50MG/25ML (2MG/ML)	A091599	001	Mar 12, 2012	May CAHN
>D>	AP		200MG/100ML (2MG/ML)	A091599	002	Mar 12, 2012	May CAHN

EPTIFIBATIDEINJECTABLE; INJECTION
EPTIFIBATIDE

>A>	AP	TEVA PHARMS USA	75MG/100ML	A091555	001	Jun 05, 2015	May NEWA
		INTEGRILIN					
>D>	+	SCHERING	75MG/100ML	N020718	002	May 18, 1998	May CFTG
>A>	AP	+	75MG/100ML	N020718	002	May 18, 1998	May CFTG

ERGOCALCIFEROLCAPSULE;ORAL
VITAMIN D

AA	BANNER LIFE SCIENCES	50,000 IU	A080704	001		Jan	CAHN
----	----------------------	-----------	---------	-----	--	-----	------

ERYTHROMYCIN ESTOLATESUSPENSION;ORAL
ERYTHROMYCIN ESTOLATE

	@ G AND W LABS INC	EQ 125MG BASE/5ML	A062169	001	Oct 17, 1990	Apr	CAHN
	@	EQ 250MG BASE/5ML	A062169	002	Oct 17, 1990	Apr	CAHN

ESCITALOPRAM OXALATESOLUTION;ORAL
ESCITALOPRAM OXALATE

>A>	AA	ANTRIM PHARMS LLC	EQ 5MG BASE/5ML	A203967	001	May 26, 2015	May	NEWA
-----	----	-------------------	-----------------	---------	-----	--------------	-----	------

TABLET;ORAL
ESCITALOPRAM OXALATE

AB	MYLAN PHARMS INC	EQ 5MG BASE	A077550	001	May 14, 2015	Apr	NEWA
AB		EQ 10MG BASE	A077550	002	May 14, 2015	Apr	NEWA
AB		EQ 20MG BASE	A077550	003	May 14, 2015	Apr	NEWA

ESMOLOL HYDROCHLORIDEINJECTABLE;INJECTION
ESMOLOL HYDROCHLORIDE

AP	LUITPOLD	10MG/ML	A201126	001	Feb 20, 2015	Feb	NEWA
----	----------	---------	---------	-----	--------------	-----	------

ESOMEPRAZOLE MAGNESIUMCAPSULE, DELAYED REL PELLETS;ORAL
ESOMEPRAZOLE MAGNESIUM

AB	IVAX SUB TEVA PHARMS	EQ 20MG BASE	A078003	001	Jan 26, 2015	Jan	NEWA
AB		EQ 40MG BASE	A078003	002	Jan 26, 2015	Jan	NEWA

NEXIUM

AB	ASTRAZENECA PHARMS	EQ 20MG BASE	N021153	001	Feb 20, 2001	Jan	CFTG
AB	+	EQ 40MG BASE	N021153	002	Feb 20, 2001	Jan	CFTG

ESTRADIOLFILM, EXTENDED RELEASE;TRANSDERMAL
ALORA

BX	ACTAVIS LABS UT INC	0.025MG/24HR	N020655	004	Apr 05, 2002	Mar	CAHN
BX		0.05MG/24HR	N020655	001	Dec 20, 1996	Mar	CAHN
BX		0.075MG/24HR	N020655	002	Dec 20, 1996	Mar	CAHN
BX		0.1MG/24HR	N020655	003	Dec 20, 1996	Mar	CAHN

MINIVELLE

NOVEN 0.025MG/24HR

N203752	005	Sep 23, 2014	Jan	NEWA
---------	-----	--------------	-----	------

TABLET;VAGINAL

ESTRADIOL

>A>	@ AMNEAL PHARMS	10MCG	A205256	001	May 29, 2015	May	DISC
-----	-----------------	-------	---------	-----	--------------	-----	------

ESZOPICLONETABLET;ORAL
ESZOPICLONE

AB	MACLEODS PHARMS LTD	1MG	A202929	001	Jan 30, 2015	Jan	NEWA
AB		2MG	A202929	002	Jan 30, 2015	Jan	NEWA
AB		3MG	A202929	003	Jan 30, 2015	Jan	NEWA

ETHAMBUTOL HYDROCHLORIDETABLET;ORAL
ETHAMBUTOL HYDROCHLORIDE

AB	VERSAPHARM INC	100MG	A075095	001	Nov 30, 1999	Jan	CMFD
AB		400MG	A075095	002	Nov 30, 1999	Jan	CMFD

ETHINYL ESTRADIOL; LEVONORGESTRELTABLET;ORAL
ASHLYNA

AB	GLENMARK GENERICS	0.03MG;0.01MG;0.15MG,N/A	A203163	001	Feb 23, 2015	Feb	NEWA
	LEVONORGESTREL AND ETHINYL ESTRADIOL						

AB	FAMY CARE LTD	0.03MG;0.15MG	A200490	001	Apr 21, 2015	Apr	NEWA	
AB	GLENMARK GENERICS	0.02MG;0.09MG	A202791	001	Apr 09, 2015	Mar	NEWA	
AB	+	WATSON LABS	0.02MG;0.09MG	A079218	001	Jun 06, 2011	Mar	CTEC

TABLET;ORAL

LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL

>A> AB	FAMY CARE LTD	0.03MG,0.01MG;0.15MG,N/A	A200492	001	May 27, 2015	May NEWA
--------	---------------	--------------------------	---------	-----	--------------	----------

TABLET;ORAL-28

VIENVA

>A> AB1	SANDOZ INC	0.02MG;0.1MG	A201088	001	May 21, 2015	May NEWA
---------	------------	--------------	---------	-----	--------------	----------

ETHINYL ESTRADIOL; NORELGESTROMIN

FILM, EXTENDED RELEASE;TRANSDERMAL

ORTHO EVRA

@ JANSSEN PHARMS

0.035MG/24HR;0.15MG/24HR

N021180 001 Nov 20, 2001 Feb DISC

XULANE

AB + MYLAN TECHNOLOGIES

0.035MG/24HR;0.15MG/24HR

A200910 001 Apr 16, 2014 Feb CRLD

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET;ORAL-21

BREVICON 21-DAY

@ ACTAVIS LABS UT INC

0.035MG;0.5MG

N017566 001

Mar CAHN

NORINYL 1+35 21-DAY

AB ACTAVIS LABS UT INC

0.035MG;1MG

N017565 001

Feb CAHN

TRI-NORINYL 21-DAY

@ ACTAVIS LABS UT INC

0.035MG,0.035MG,0.035MG;0.5MG,1MG,
0.5MG

N018977 001 Apr 13, 1984

Feb CAHN

TABLET;ORAL-28

BREVICON 28-DAY

AB ACTAVIS LABS UT INC

0.035MG;0.5MG

N017743 001

Mar CAHN

NORETHINDRONE AND ETHINYL ESTRADIOL

AB FAMY CARE LTD

0.035MG;0.4MG

A200897 001 May 11, 2015

Apr NEWA

NORINYL 1+35 28-DAY

AB ACTAVIS LABS UT INC

0.035MG;1MG

N017565 002

Feb CAHN

TRI-NORINYL 28-DAY

AB + ACTAVIS LABS UT INC

0.035MG,0.035MG,0.035MG;0.5MG,1MG,
0.5MG

N018977 002 Apr 13, 1984

Feb CAHN

TABLET, CHEWABLE;ORAL

NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

AB FAMY CARE LTD

0.035MG;0.4MG

A202086 001 Apr 01, 2015

Mar NEWA

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL

FEMHRT

AB WARNER CHILCOTT LLC

0.0025MG;0.5MG

N021065 001 Jan 14, 2005

Mar CTEC

LARIN 24 FE

AB NOVAST LABS LTD

0.02MG;1MG

A202994 001 Feb 18, 2015

Feb NEWA

LOESTRIN 24 FE

@ WARNER CHILCOTT

0.02MG;1MG

N021871 001 Feb 17, 2006

Jan DISC

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

AB + BARR LABS INC

0.005MG;1MG

A076221 001 Nov 06, 2009

Mar CTEC

AB GLENMARK GENERICS

0.0025MG;0.5MG

A203038 001 Apr 02, 2015

Mar NEWA

AB

0.005MG;1MG

A203038 002 Apr 02, 2015

Mar NEWA

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

AB + AMNEAL PHARMS

0.02MG;1MG

A078267 001 Sep 01, 2009

Jan CRLD

TABLET;ORAL-21

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

AB FAMY CARE LTD

0.03MG;1.5MG

A202770 001 Feb 19, 2015

Feb NEWA

TABLET;ORAL-28

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

AB FAMY CARE LTD

0.03MG;1.5MG

A202741 001 Feb 20, 2015

Feb NEWA

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET;ORAL-28

NORGESTIMATE AND ETHINYL ESTRADIOL

AB OC PHARMA

0.035MG;0.035MG;0.035MG;0.18MG;0.2
15MG;0.25MG

A200383 001 Apr 07, 2015

Mar NEWA

AB

0.035MG;0.25MG

A200384 001 Apr 07, 2015

Mar NEWA

ETHINYL ESTRADIOL; NORGESTREL

TABLET;ORAL-28

LOW-OGESTREL-28

AB WATSON LABS

0.03MG;0.3MG

A075288 002 Jul 28, 1999

Feb CMFD

ETHOSUXIMIDECAPSULE;ORAL
ETHOSUXIMIDE

AB	BANNER LIFE SCIENCES	250MG	A040430	001	Oct 28, 2002	Jan CAHN
----	----------------------	-------	---------	-----	--------------	----------

ETOMIDATEINJECTABLE;INJECTION
ETOMIDATE

AP	MYLAN PHARMS INC	2MG/ML	A078289	001	Jan 02, 2009	Apr CAHN
----	------------------	--------	---------	-----	--------------	----------

FAMOTIDINETABLET;ORAL
PEPCID

AB	VALEANT PHARMS NORTH	20MG	N019462	001	Oct 15, 1986	Feb CAHN
AB	+	40MG	N019462	002	Oct 15, 1986	Feb CAHN

FELODIPINETABLET, EXTENDED RELEASE;ORAL
FELODIPINE

>A>	AB	ORCHID HLTHCARE	2.5MG	A203032	001	May 21, 2015	May NEWA
>A>	AB		5MG	A203032	002	May 21, 2015	May NEWA
>A>	AB		10MG	A203032	003	May 21, 2015	May NEWA
	AB	SUN PHARM INDS LTD	2.5MG	A091200	001	Dec 13, 2013	Apr CAHN
	AB		5MG	A091200	002	Dec 13, 2013	Apr CAHN
	AB		10MG	A091200	003	Dec 13, 2013	Apr CAHN

FENOFIBRATECAPSULE;ORAL
FENOFIBRATE

AB	SUN PHARM INDS LTD	43MG	A201748	001	Oct 31, 2014	Apr CAHN
AB		130MG	A201748	002	Oct 31, 2014	Apr CAHN

TABLET;ORAL
FENOFIBRATE

AB	SUN PHARM INDS LTD	54MG	A076635	001	Oct 31, 2005	Apr CAHN
		107MG	A076635	002	Oct 31, 2005	Apr CAHN
AB		160MG	A076635	003	Oct 31, 2005	Apr CAHN

FENTANYLFILM, EXTENDED RELEASE;TRANSDERMAL
FENTANYL-100

AB	ACTAVIS LABS UT INC	100MCG/HR	A076709	004	Aug 20, 2007	Mar CAHN
----	---------------------	-----------	---------	-----	--------------	----------

FENTANYL-25

AB	ACTAVIS LABS UT INC	25MCG/HR	A076709	001	Aug 20, 2007	Mar CAHN
----	---------------------	----------	---------	-----	--------------	----------

FENTANYL-50

AB	ACTAVIS LABS UT INC	50MCG/HR	A076709	002	Aug 20, 2007	Mar CAHN
----	---------------------	----------	---------	-----	--------------	----------

FENTANYL-75

AB	ACTAVIS LABS UT INC	75MCG/HR	A076709	003	Aug 20, 2007	Mar CAHN
----	---------------------	----------	---------	-----	--------------	----------

FENTANYL CITRATEFILM;BUCCAL
ONSOLIS

@	BIODELIVERY SCI INTL	EQ 0.2MG BASE	N022266	001	Jul 16, 2009	Mar CAHN
@		EQ 0.4MG BASE	N022266	002	Jul 16, 2009	Mar CAHN
@		EQ 0.6MG BASE	N022266	003	Jul 16, 2009	Mar CAHN
@		EQ 0.8MG BASE	N022266	004	Jul 16, 2009	Mar CAHN
@		EQ 1.2MG BASE	N022266	005	Jul 16, 2009	Mar CAHN

INJECTABLE;INJECTION

FENTANYL CITRATE PRESERVATIVE FREE

AP	+	EUROHLTH INTL SARL	EQ 0.05MG BASE/ML	N019101	001	Jul 11, 1984	Feb CAHN
----	---	--------------------	-------------------	---------	-----	--------------	----------

FENTANYL HYDROCHLORIDESYSTEM;IONTOPHORESIS, TRANSDERMAL
IONSYS

@ THE MEDICINES CO 10.8MCG

N021338	001	May 22, 2006	Apr CAHN
---------	-----	--------------	----------

FERRIC CITRATETABLET;ORAL
AURYXIA

+ KERYX BIOPHARMS EQ 210MG IRON N205874 001 Sep 05, 2014 Jan CTNA

FERRIC PYROPHOSPHATE CITRATESOLUTION;IV (INFUSION)
TRIFERIC

+ ROCKWELL MEDICAL INC 27.2MG IRON/5ML (5.44MG IRON/ML) N206317 001 Jan 23, 2015 Jan NEWA

FLECAINIDE ACETATE

TABLET;ORAL

FLECAINIDE ACETATE

AB	ANI PHARMS INC	50MG	A075882	001	Oct 28, 2002	Apr	CAHN
AB		100MG	A075882	002	Oct 28, 2002	Apr	CAHN
AB		150MG	A075882	003	Oct 28, 2002	Apr	CAHN
AB	SUN PHARM INDS LTD	50MG	A076421	001	Mar 28, 2003	Apr	CAHN
AB		100MG	A076421	002	Mar 28, 2003	Apr	CAHN
AB		150MG	A076421	003	Mar 28, 2003	Apr	CAHN

FLUCONAZOLEFOR SUSPENSION;ORAL
FLUCONAZOLE

AB	SUN PHARM INDS LTD	50MG/5ML	A076332	001	Jul 29, 2004	Apr	CAHN
AB		200MG/5ML	A076332	002	Jul 29, 2004	Apr	CAHN

INJECTABLE;INJECTION

FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	CLARIS PHARMASERVICE	200MG/100ML (2MG/ML)	A077988	001	May 26, 2010	Apr	CAHN
AP		400MG/200ML (2MG/ML)	A077988	002	May 26, 2010	Apr	CAHN
	@ MYLAN PHARMS INC	200MG/100ML (2MG/ML)	A076888	001	Mar 25, 2005	Apr	CAHN
	@	400MG/200ML (2MG/ML)	A076888	002	Mar 25, 2005	Apr	CAHN

FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

AP	CLARIS PHARMASERVICE	200MG/100ML (2MG/ML)	A077947	001	May 26, 2010	Apr	CAHN
AP		400MG/200ML (2MG/ML)	A077947	002	May 26, 2010	Apr	CAHN

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	CLARIS PHARMASERVICE	100MG/50ML (2MG/ML)	A077909	003	Apr 20, 2015	Apr	NEWA
		100MG/50ML (2MG/ML)	A077909	003	Apr 20, 2015	Apr	CAHN
AP		200MG/100ML (2MG/ML)	A077909	001	May 26, 2010	Apr	CAHN
AP		400MG/200ML (2MG/ML)	A077909	002	May 26, 2010	Apr	CAHN
	@ MYLAN PHARMS INC	200MG/100ML (2MG/ML)	A076889	001	Mar 25, 2005	Apr	CAHN
	@	400MG/200ML (2MG/ML)	A076889	002	Mar 25, 2005	Apr	CAHN

TABLET;ORAL

FLUCONAZOLE

>D>	@ HARRIS PHARM	50MG	A078423	001	Mar 07, 2011	May	CMFD
>A> AB		50MG	A078423	001	Mar 07, 2011	May	CMFD
>D>	@	100MG	A078423	002	Mar 07, 2011	May	CMFD
>A> AB		100MG	A078423	002	Mar 07, 2011	May	CMFD
>D>	@	150MG	A078423	003	Mar 07, 2011	May	CMFD
>A> AB		150MG	A078423	003	Mar 07, 2011	May	CMFD
>D>	@	200MG	A078423	004	Mar 07, 2011	May	CMFD
>A> AB		200MG	A078423	004	Mar 07, 2011	May	CMFD

FLUDARABINE PHOSPHATE

INJECTABLE;INJECTION

FLUDARABINE PHOSPHATE

>A> AP	MYLAN PHARMS INC	50MG/2ML (25MG/ML)	A200647	001	Dec 21, 2011	May	CAHN
>D> AP	ONCO THERAPIES LTD	50MG/2ML (25MG/ML)	A200647	001	Dec 21, 2011	May	CAHN

FLUDEOXYGLUCOSE F-18

INJECTABLE;INTRAVENOUS

FLUDEOXYGLUCOSE F 18

AP	BIOMEDCL RES FDN	20-300mCi/ML	A203710	001	May 01, 2015	Apr	NEWA
AP		20-300mCi/ML	A203837	001	May 01, 2015	Apr	NEWA
	UNIV NORTH DAKOTA	4-500mCi/ML	A203994	001	Feb 04, 2015	Jan	NEWA
	FLUDEOXYGLUCOSE F18						
AP	METHODIST HOSP RES	20-300mCi/ML	A203904	001	Apr 23, 2015	Apr	NEWA
	PRECISION NUCLEAR	20-500mCi/ML	A204546	001	Apr 07, 2015	Mar	NEWA
	SPECTRON MRC LLC	4-500mCi/ML	A203911	001	Apr 22, 2015	Apr	NEWA

FLUMAZENIL

INJECTABLE; INJECTION							
FLUMAZENIL							
	@ CLARIS PHARMASERVICE	0.5MG/5ML (0.1MG/ML)	A076755	002	Oct 12, 2004	Apr	CAHN
	@	1MG/10ML (0.1MG/ML)	A076755	001	Oct 12, 2004	Apr	CAHN
AP	MYLAN PHARMS INC	0.5MG/5ML (0.1MG/ML)	A078595	001	May 13, 2008	Apr	CAHN
AP	+	1MG/10ML (0.1MG/ML)	A078595	002	May 13, 2008	Apr	CAHN

FLUOCINONIDE

GEL; TOPICAL							
FLUOCINONIDE							
AB	G AND W LABS INC	0.05%	A072537	001	Feb 07, 1989	Apr	CAHN

FLUOROURACIL

CREAM; TOPICAL							
CARAC							
AB	+ VALEANT PHARMS NORTH	0.5%	N020985	001	Oct 27, 2000	Apr	CFTG
	+	0.5%	N020985	001	Oct 27, 2000	Feb	CAHN
FLUOROURACIL							
AB	SPEAR PHARMS INC	0.5%	A203122	001	Apr 20, 2015	Apr	NEWA
INJECTABLE; INJECTION							
FLUOROURACIL							
AP	MYLAN PHARMS INC	1GM/20ML (50MG/ML)	A202668	002	Jul 17, 2012	Apr	CAHN
AP		500MG/10ML (50MG/ML)	A202668	001	Jul 17, 2012	Apr	CAHN

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL							
FLUOXETINE HYDROCHLORIDE							
	@ ANI PHARMS INC	EQ 10MG BASE	A076287	001	May 20, 2008	Mar	DISC
	@	EQ 20MG BASE	A076287	002	May 20, 2008	Mar	DISC
	+ MYLAN	EQ 20MG BASE	A078045	002	Nov 17, 2008	Mar	CRLD
		EQ 20MG BASE	A078045	002	Nov 17, 2008	Mar	CTEC
	@ SANDOZ	EQ 10MG BASE	A077469	001	Nov 17, 2008	Mar	DISC
	@	EQ 20MG BASE	A077469	002	Nov 17, 2008	Mar	DISC
AB1	SCIEGEN PHARMS INC	EQ 10MG BASE	A204597	001	Mar 16, 2015	Mar	NEWA
AB1		EQ 20MG BASE	A204597	002	Mar 16, 2015	Mar	NEWA
AB		EQ 40MG BASE	A204597	003	Mar 16, 2015	Mar	NEWA
AB	SUN PHARM INDS LTD	EQ 40MG BASE	A076990	001	Dec 13, 2004	Apr	CAHN
SARAFEM							
	@ ELI LILLY AND CO	EQ 10MG BASE	N018936	007	Jul 06, 2000	Mar	DISC
	@	EQ 20MG BASE	N018936	008	Jul 06, 2000	Mar	DISC

FLUPHENAZINE DECANOATE

INJECTABLE; INJECTION							
FLUPHENAZINE DECANOATE							
	@ MYLAN PHARMS INC	25MG/ML	A075918	001	Aug 17, 2001	Apr	CAHN

FLURANDRENOLIDE

OINTMENT; TOPICAL							
CORDRAN							
>D>	@ AQUA PHARMS	0.05%	N012806	001		May	CMFD
>A>		0.05%	N012806	001		May	CMFD
TAPE; TOPICAL							
CORDRAN							
	+ ACTAVIS LABS UT INC	0.004MG/SQ CM	N016455	001		Mar	CAHN

FLUTICASONE FUROATE; VILANTEROL TRIFENATATE

POWDER; INHALATION							
BREO ELLIPTA							
	GLAXO GRP LTD	0.2MG/INH; EQ 0.025MG BASE/INH	N204275	002	Apr 30, 2015	Apr	NEWA

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET; ORAL							
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE							
AB	SUN PHARM INDS LTD	10MG; 12.5MG	A076739	001	Dec 17, 2004	Apr	CAHN
AB		20MG; 12.5MG	A076739	002	Dec 17, 2004	Apr	CAHN

FUROSEMIDEINJECTABLE; INJECTION
FUROSEMIDE

@ IGI LABS INC	10MG/ML	A070095	001	Sep 09, 1985	Mar CAHN
@	10MG/ML	A070096	001	Sep 09, 1985	Mar CAHN

GABAPENTINCAPSULE; ORAL
GABAPENTIN

AB	SUN PHARM INDS LTD	100MG	A076606	001	Oct 07, 2005	Apr CAHN
AB		300MG	A076606	002	Oct 07, 2005	Apr CAHN
AB		400MG	A076606	003	Oct 07, 2005	Apr CAHN

GADOVERSETAMIDEINJECTABLE; INJECTION
OPTIMARK

+	LIEBEL-FLARSHEIM	16.545GM/50ML (330.9MG/ML)	N020975	001	Dec 08, 1999	Feb CAHN
+		1654.5MG/5ML (330.9MG/ML)	N020937	001	Dec 08, 1999	Feb CAHN
+		3309MG/10ML (330.9MG/ML)	N020937	002	Dec 08, 1999	Feb CAHN
+		4963.5MG/15ML (330.9MG/ML)	N020937	003	Dec 08, 1999	Feb CAHN
+		6618MG/20ML (330.9MG/ML)	N020937	004	Dec 08, 1999	Feb CAHN
OPTIMARK IN PLASTIC CONTAINER						
+	LIEBEL-FLARSHEIM	3309MG/10ML (330.9MG/ML)	N020976	002	Dec 08, 1999	Feb CAHN
+		4963.5MG/15ML (330.9MG/ML)	N020976	003	Dec 08, 1999	Feb CAHN
+		6618MG/20ML (330.9MG/ML)	N020976	004	Dec 08, 1999	Feb CAHN
+		9927MG/30ML (330.9MG/ML)	N020976	001	Dec 08, 1999	Feb CAHN

GEMCITABINE HYDROCHLORIDEINJECTABLE; INJECTION
GEMCITABINE HYDROCHLORIDE

>A>	AP	MYLAN PHARMS INC	EQ 1GM BASE/VIAL	A200145	002	Jul 25, 2011	May CAHN
>A>	AP		EQ 2GM BASE/VIAL	A200145	003	Jul 25, 2011	May CAHN
>A>	AP		EQ 200MG BASE/VIAL	A200145	001	Jul 25, 2011	May CAHN
>D>	AP	ONCO THERAPIES LTD	EQ 1GM BASE/VIAL	A200145	002	Jul 25, 2011	May CAHN
>D>	AP		EQ 2GM BASE/VIAL	A200145	003	Jul 25, 2011	May CAHN
>D>	AP		EQ 200MG BASE/VIAL	A200145	001	Jul 25, 2011	May CAHN

GLATIRAMER ACETATEINJECTABLE; SUBCUTANEOUS
COPAXONE

AP	+	TEVA PHARMS USA	20MG/ML	N020622	002	Feb 12, 2002	Mar CFTG
AP		GLATOPIA					
AP		SANDOZ INC	20MG/ML	A090218	001	Apr 16, 2015	Mar NEWA

GLIMEPIRIDETABLET; ORAL
GLIMEPIRIDE

@	HIKMA PHARMS	1MG	A078952	001	Aug 01, 2013	Apr DISC
@		2MG	A078952	002	Aug 01, 2013	Apr DISC
@		4MG	A078952	003	Aug 01, 2013	Apr DISC

GLIPIZIDETABLET, EXTENDED RELEASE; ORAL
GLIPIZIDE

>A>	AB	MYLAN PHARMS INC	2.5MG	A202298	001	May 19, 2015	May NEWA
>A>	AB		5MG	A202298	002	May 19, 2015	May NEWA
>A>	AB		10MG	A202298	003	May 19, 2015	May NEWA

GLUCAGON HYDROCHLORIDE

>A>		POWDER; INTRAMUSCULAR, INTRAVENOUS					
>A>		GLUCAGON					
>A>	+	FRESENIUS KABI USA	EQ 1MG BASE/VIAL	N201849	001	May 08, 2015	May NEWA

GLYCEROL PHENYLBUTYRATELIQUID; ORAL
RAVICTI

>A>	+	HORIZON THERAPS INC	1.1GM/ML	N203284	001	Feb 01, 2013	May CAHN
>D>	+	HYPERION THERAP INC	1.1GM/ML	N203284	001	Feb 01, 2013	May CAHN

GLYCOPYRROLATE

TABLET; ORAL

GLYCOPYRROLATE

AA	SUN PHARM INDS LTD	1MG	A040844	001	Aug 18, 2009	Apr CAHN
AA		2MG	A040844	002	Aug 18, 2009	Apr CAHN

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

AP	BANNER LIFE SCIENCES	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078863	001	Jun 30, 2008	Jan CAHN
AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078880	001	Jun 30, 2008	Jan CAHN
	@ CLARIS PHARMASERVICE	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078198	001	Jun 30, 2008	Apr CAHN
	@	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078198	002	Jun 30, 2008	Apr CAHN
	GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE					
AP	BANNER LIFE SCIENCES	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078863	002	Jun 30, 2008	Jan CAHN

GUAIFENESIN; HYDROCODONE BITARTRATE

SOLUTION; ORAL

FLOWTUSS

>A>	MIKART INC	200MG/5ML; 2.5MG/5ML	N022424	001	May 14, 2015	May NEWA
-----	------------	----------------------	---------	-----	--------------	----------

GUAIFENESIN; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL

HYCOFENIX

>A>	+ MIKART INC	200MG/5ML; 2.5MG/5ML; 30MG/5ML	N022279	001	May 14, 2015	May NEWA
-----	--------------	--------------------------------	---------	-----	--------------	----------

GUANFACINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

GUANFACINE HYDROCHLORIDE

>A> AB	MYLAN PHARMS INC	EQ 1MG BASE	A202578	001	Jun 02, 2015	May NEWA
>A> AB		EQ 2MG BASE	A202578	002	Jun 02, 2015	May NEWA
>A> AB		EQ 3MG BASE	A202578	003	Jun 02, 2015	May NEWA
>A> AB		EQ 4MG BASE	A202578	004	Jun 02, 2015	May NEWA
>A> AB	SANDOZ INC	EQ 1MG BASE	A202568	001	Jun 03, 2015	May NEWA
>A> AB		EQ 2MG BASE	A202568	002	Jun 03, 2015	May NEWA
>A> AB		EQ 3MG BASE	A202568	003	Jun 03, 2015	May NEWA
>A> AB		EQ 4MG BASE	A202568	004	Jun 03, 2015	May NEWA
>A> AB	TEVA PHARMS USA	EQ 1MG BASE	A201382	001	Jun 02, 2015	May NEWA
>A> AB		EQ 2MG BASE	A201382	002	Jun 02, 2015	May NEWA
>A> AB		EQ 3MG BASE	A201382	003	Jun 02, 2015	May NEWA
>A> AB		EQ 4MG BASE	A201382	004	Jun 02, 2015	May NEWA
>A> AB	TWI PHARMS INC	EQ 1MG BASE	A201408	001	Jun 02, 2015	May NEWA
>A> AB		EQ 2MG BASE	A201408	002	Jun 02, 2015	May NEWA
>A> AB		EQ 3MG BASE	A201408	003	Jun 02, 2015	May NEWA
>A> AB		EQ 4MG BASE	A201408	004	Jun 02, 2015	May NEWA

HALOPERIDOL

TABLET; ORAL

HALOPERIDOL

>A>	@ CYCLE PHARMS LTD	0.5MG	A071128	001	Feb 17, 1987	May CAHN
>A>	@	20MG	A071133	001	May 12, 1987	May CAHN
>D>	@ ROXANE	0.5MG	A071128	001	Feb 17, 1987	May CAHN
>D>	@	20MG	A071133	001	May 12, 1987	May CAHN

HALOPERIDOL LACTATE

CONCENTRATE; ORAL

HALOPERIDOL INTENSOL

>A>	@ CYCLE PHARMS LTD	EQ 2MG BASE/ML	A072045	001	Apr 12, 1988	May CAHN
>D>	@ ROXANE	EQ 2MG BASE/ML	A072045	001	Apr 12, 1988	May CAHN

INJECTABLE; INJECTION

HALOPERIDOL

>D>	@ APOTEX INC	EQ 5MG BASE/ML	A076828	001	Aug 25, 2004	May CAHN
	@ CLARIS PHARMASERVICE	EQ 5MG BASE/ML	A076791	001	Aug 25, 2004	Apr CAHN
>A>	@	EQ 5MG BASE/ML	A076828	001	Aug 25, 2004	May CAHN
AP	MYLAN PHARMS INC	EQ 5MG BASE/ML	A078347	001	Sep 14, 2009	Apr CAHN

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
HYDRALAZINE HYDROCHLORIDE

AP	+	AKORN	20MG/ML	A040730	001	Apr 21, 2009	Feb CRLD
AP		LUITPOLD	20MG/ML	A040136	001	Jun 30, 1997	Feb CRLD

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL
MICROZIDE

AB	+	ACTAVIS LABS UT INC	12.5MG	N020504	001	Dec 27, 1996	Feb CAHN
----	---	---------------------	--------	---------	-----	--------------	----------

HYDROCHLOROTHIAZIDE; LISINAPRIL

TABLET; ORAL
LISINAPRIL AND HYDROCHLOROTHIAZIDE

AB		SUN PHARM INDS LTD	12.5MG; 10MG	A076007	001	Jul 01, 2002	Apr CAHN
AB			12.5MG; 20MG	A076007	002	Jul 01, 2002	Apr CAHN
AB			25MG; 20MG	A076007	003	Jul 01, 2002	Apr CAHN
		ZESTORETIC					
AB		ALVOGEN IPCO SARL	12.5MG; 10MG	N019888	003	Nov 18, 1993	Feb CAHN
AB	+		12.5MG; 20MG	N019888	001	Sep 20, 1990	Feb CAHN
AB	+		25MG; 20MG	N019888	002	Jul 20, 1989	Feb CAHN

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB		SUN PHARM INDS LTD	12.5MG; EQ 10MG BASE	A078211	001	Mar 04, 2009	Apr CAHN
AB			12.5MG; EQ 20MG BASE	A078211	002	Mar 04, 2009	Apr CAHN
AB			25MG; EQ 20MG BASE	A078211	003	Mar 04, 2009	Apr CAHN

HYDROCODONE BITARTRATE

CAPSULE, EXTENDED RELEASE; ORAL
ZOHYDRO ER

+	FERRIMILL LTD	10MG	N202880	001	Oct 25, 2013	Apr CAHN
		15MG	N202880	002	Oct 25, 2013	Apr CAHN
		20MG	N202880	003	Oct 25, 2013	Apr CAHN
		30MG	N202880	004	Oct 25, 2013	Apr CAHN
		40MG	N202880	005	Oct 25, 2013	Apr CAHN
		50MG	N202880	006	Oct 25, 2013	Apr CAHN

TABLET, EXTENDED RELEASE; ORAL
HYSINGLA

+	PURDUE PHARMA LP	20MG	N206627	001	Nov 20, 2014	Mar CRLD
---	------------------	------	---------	-----	--------------	----------

HYDROCORTISONE

CREAM; TOPICAL
HYDROCORTISONE

AT		RISING PHARMS INC	2.5%	A040879	001	Aug 20, 2010	Mar CAHN
----	--	-------------------	------	---------	-----	--------------	----------

POWDER; FOR RX COMPOUNDING
HYDRO-RX

@	X GEN PHARMS	100%	A085982	001		Apr DISC
---	--------------	------	---------	-----	--	----------

TABLET; ORAL
HYDROCORTISONE

AB		HIKMA INTL PHARMS	5MG	A083365	002	Feb 23, 2015	Feb NEWA
AB			10MG	A083365	003	Feb 23, 2015	Feb NEWA
AB			20MG	A083365	001		Feb CMFD

HYDROCORTISONE ACETATE

POWDER; FOR RX COMPOUNDING
HYDROCORTISONE ACETATE

@	X GEN PHARMS	100%	A085981	001		Apr DISC
---	--------------	------	---------	-----	--	----------

HYDROCORTISONE VALERATE

CREAM; TOPICAL
HYDROCORTISONE VALERATE

@	G AND W LABS INC	0.2%	A074489	001	Aug 12, 1998	Apr CAHN
---	------------------	------	---------	-----	--------------	----------

HYDROMORPHONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
HYDROMORPHONE HYDROCHLORIDE

AB	PADDOCK LLC	8MG	A204278	001	Apr 06, 2015	Mar	NEWA
AB		12MG	A204278	002	Apr 06, 2015	Mar	NEWA
AB		16MG	A204278	003	Apr 06, 2015	Mar	NEWA

HYDROXOCOBALAMIN

INJECTABLE;INJECTION
CYANOKIT

@ SERB SAS 2.5GM/VIAL (5GM/KIT)
+ 5GM/VIAL (5GM/KIT)

N022041	002	Dec 15, 2006	Apr	CAHN
N022041	001	Apr 08, 2011	Apr	CAHN

HYDROXYPROGESTERONE CAPROATE

INJECTABLE;INJECTION
HYDROXYPROGESTERONE CAPROATE

@ ACTAVIS LABS UT INC 125MG/ML
@ 250MG/ML

N017439	001		Mar	CAHN
N017439	002		Mar	CAHN

HYDROXYZINE HYDROCHLORIDE

TABLET;ORAL
HYDROXYZINE HYDROCHLORIDE

AB	HERITAGE PHARMA	10MG	A204279	001	Aug 20, 2014	Mar	CAHN
AB		25MG	A204279	002	Aug 20, 2014	Mar	CAHN
AB		50MG	A204279	003	Aug 20, 2014	Mar	CAHN
AB	MIKAH PHARMA	10MG	A040600	001	Dec 28, 2004	Mar	CMFD
AB		25MG	A040602	001	Dec 28, 2004	Mar	CMFD
AB		50MG	A040604	001	Dec 28, 2004	Mar	CMFD

HYDROXYZINE PAMOATE

CAPSULE;ORAL
HYDROXYZINE PAMOATE

AB	HERITAGE PHARMA	EQ 25MG HYDROCHLORIDE	A201507	001	Jun 03, 2013	Mar	CAHN
AB		EQ 50MG HYDROCHLORIDE	A201507	002	Jun 03, 2013	Mar	CAHN

IFOSFAMIDE

INJECTABLE;INJECTION
IFOSFAMIDE

>A>	AP	MYLAN PHARMS INC	1GM/20ML (50MG/ML)	A201689	001	Nov 26, 2012	May	CAHN
>A>	AP		3GM/60ML (50MG/ML)	A201689	002	Nov 26, 2012	May	CAHN
>D>	AP	ONCO THERAPIES LTD	1GM/20ML (50MG/ML)	A201689	001	Nov 26, 2012	May	CAHN
>D>	AP		3GM/60ML (50MG/ML)	A201689	002	Nov 26, 2012	May	CAHN

LOPERIDONE

TABLET;ORAL
FANAPT

+ VANDA PHARMS INC

1MG
2MG
4MG
6MG
8MG
10MG
12MG

N022192	001	May 06, 2009	Jan	CAHN
N022192	002	May 06, 2009	Jan	CAHN
N022192	003	May 06, 2009	Jan	CAHN
N022192	004	May 06, 2009	Jan	CAHN
N022192	005	May 06, 2009	Jan	CAHN
N022192	006	May 06, 2009	Jan	CAHN
N022192	007	May 06, 2009	Jan	CAHN

IMIQUIMOD

CREAM;TOPICAL
IMIQUIMOD

AB	G AND W LABS INC	5%	A200481	001	Apr 18, 2011	Apr	CAHN
----	------------------	----	---------	-----	--------------	-----	------

INGENOL MEBUTATE

GEL;TOPICAL
PICATO

>D>		LEO PHARMA AS	0.015%	N202833	001	Jan 23, 2012	May	CRLD
>A>	+		0.015%	N202833	001	Jan 23, 2012	May	CRLD

INSULIN GLARGINE

SOLUTION;SUBCUTANEOUS
TOUJEO SOLOSTAR

+ SANOFI US SERVICES 300UNITS/ML (300UNITS/ML)

N206538	001	Feb 25, 2015	Feb	NEWA
---------	-----	--------------	-----	------

INSULIN GLARGINE RECOMBINANTSOLUTION;SUBCUTANEOUS
TOUJEO SOLOSTAR

+	SANOFI US SERVICES	300UNITS/ML (300UNITS/ML)	N206538	001	Feb 25, 2015	Feb NEWA
---	--------------------	---------------------------	---------	-----	--------------	----------

INSULIN LISPRO RECOMBINANTSOLUTION;SUBCUTANEOUS
HUMALOG KWIKPEN

>A>

>A>

+	ELI LILLY AND CO	200 UNITS/ML	N205747	001	May 26, 2015	May NEWA
---	------------------	--------------	---------	-----	--------------	----------

INSULIN RECOMBINANT HUMANPOWDER;INHALATION
AFREZZA

	SANOFI AVENTIS	12 UNITS/INH	N022472	003	Apr 17, 2015	Apr NEWA
--	----------------	--------------	---------	-----	--------------	----------

IOHEXOLFOR SOLUTION;ORAL
ORALTAG

	INTERPHARMA PRAHA AS	9.7GM/BOT	N205383	001	Mar 26, 2015	Mar NEWA
--	----------------------	-----------	---------	-----	--------------	----------

IOPAMIDOLINJECTABLE;INJECTION
IOPAMIDOL-250

@	FRESENIUS KABI USA	51%	A074679	001	Apr 02, 1997	Jan DISC
---	--------------------	-----	---------	-----	--------------	----------

IOPAMIDOL-300

@	FRESENIUS KABI USA	61%	A074679	002	Apr 02, 1997	Jan DISC
---	--------------------	-----	---------	-----	--------------	----------

IOPAMIDOL-370

@	FRESENIUS KABI USA	76%	A074679	003	Apr 02, 1997	Jan DISC
---	--------------------	-----	---------	-----	--------------	----------

ISOVUE-200

+	BRACCO	41%	N018735	006	Jul 07, 1987	Feb CTEC
---	--------	-----	---------	-----	--------------	----------

ISOVUE-250

+	BRACCO	51%	N018735	007	Jul 06, 1992	Feb CTEC
---	--------	-----	---------	-----	--------------	----------

+		51%	N020327	002	Oct 12, 1994	Feb CTEC
---	--	-----	---------	-----	--------------	----------

ISOVUE-300

+	BRACCO	61%	N020327	003	Oct 12, 1994	Feb CTEC
---	--------	-----	---------	-----	--------------	----------

ISOVUE-370

+	BRACCO	76%	N020327	004	Oct 12, 1994	Feb CTEC
---	--------	-----	---------	-----	--------------	----------

IOTHALAMATE MEGLUMINEINJECTABLE;INJECTION
CONRAY

+	LIEBEL-FLARSHEIM	60%	N013295	001		Feb CAHN
---	------------------	-----	---------	-----	--	----------

CONRAY 30

+	LIEBEL-FLARSHEIM	30%	N016983	001		Feb CAHN
---	------------------	-----	---------	-----	--	----------

CONRAY 43

+	LIEBEL-FLARSHEIM	43%	N013295	002		Feb CAHN
---	------------------	-----	---------	-----	--	----------

SOLUTION;INTRAVESICAL
CYSTO-CONRAY II

	LIEBEL-FLARSHEIM	17.2%	N017057	002		Feb CAHN
--	------------------	-------	---------	-----	--	----------

IOVERSOLINJECTABLE;INJECTION
OPTIRAY 160

@	LIEBEL-FLARSHEIM	34%	N019710	003	Dec 30, 1988	Feb CAHN
---	------------------	-----	---------	-----	--------------	----------

OPTIRAY 240

+	LIEBEL-FLARSHEIM	51%	N019710	002	Dec 30, 1988	Feb CAHN
---	------------------	-----	---------	-----	--------------	----------

@

		51%	N020923	001	May 28, 1998	Feb CAHN
--	--	-----	---------	-----	--------------	----------

OPTIRAY 300

+	LIEBEL-FLARSHEIM	64%	N019710	004	Jan 22, 1992	Feb CAHN
---	------------------	-----	---------	-----	--------------	----------

+		64%	N020923	004	May 13, 1999	Feb CAHN
---	--	-----	---------	-----	--------------	----------

OPTIRAY 320

+	LIEBEL-FLARSHEIM	68%	N019710	001	Dec 30, 1988	Feb CAHN
---	------------------	-----	---------	-----	--------------	----------

@

		68%	N020923	002	May 29, 1998	Feb CAHN
--	--	-----	---------	-----	--------------	----------

OPTIRAY 350

+	LIEBEL-FLARSHEIM	74%	N019710	005	Jan 22, 1992	Feb CAHN
---	------------------	-----	---------	-----	--------------	----------

+		74%	N020923	003	May 28, 1998	Feb CAHN
---	--	-----	---------	-----	--------------	----------

>D> IOXAGLATE MEGLUMINE; IOXAGLATE SODIUM

>D> INJECTABLE; INJECTION

>D> HEXABRIX

>D> + GUERBET 39.3%;19.6%

N018905 002 Jul 26, 1985 May DISC

>A> @ 39.3%;19.6%

N018905 002 Jul 26, 1985 May DISC

IRBESARTAN

TABLET; ORAL

IRBESARTAN

AB JUBILANT GENERICS 75MG

A203534 001 Feb 23, 2015 Feb NEWA

AB 150MG

A203534 002 Feb 23, 2015 Feb NEWA

AB 300MG

A203534 003 Feb 23, 2015 Feb NEWA

IRON DEXTRAN

INJECTABLE; INJECTION

INFED

BP + ACTAVIS LABS UT INC EQ 50MG IRON/ML

N017441 001

Mar CAHN

ISAVUCONAZONIUM SULFATE

CAPSULE; ORAL

CRESEMBA

+ ASTELLAS 186MG

N207500 001 Mar 06, 2015 Mar NEWA

POWDER; IV (INFUSION)

CRESEMBA

+ ASTELLAS 372MG

N207501 001 Mar 06, 2015 Mar NEWA

ISOSORBIDE DINITRATE

TABLET; ORAL

ISORDIL

AB VALEANT PHARMS NORTH 5MG

N012093 007 Jul 29, 1988 Feb CAHN

@ 10MG

N012093 002 Jul 29, 1988 Feb CAHN

@ 20MG

N012093 006 Jul 29, 1988 Feb CAHN

@ 30MG

N012093 005 Jul 29, 1988 Feb CAHN

+ 40MG

N012093 001 Jul 29, 1988 Feb CAHN

ISOTRETINOIN

CAPSULE; ORAL

ABSORICA

RANBAXY 25MG

N021951 005 Aug 15, 2014 Feb NEWA

35MG

N021951 006 Aug 15, 2014 Feb NEWA

SOTRET

AB SUN PHARM INDS LTD 10MG

A076041 001 Dec 24, 2002 Apr CAHN

AB 20MG

A076041 002 Dec 24, 2002 Apr CAHN

AB 30MG

A076503 001 Jun 20, 2003 Apr CAHN

AB 40MG

A076041 003 Dec 24, 2002 Apr CAHN

ZENATANE

AB DR REDDYS LABS LTD 30MG

A202099 004 Feb 23, 2015 Feb NEWA

ISRADIPINE

CAPSULE; ORAL

ISRADIPINE

AB ELITE LABS INC 2.5MG

A077169 001 Apr 24, 2006 Mar CAHN

AB 5MG

A077169 002 Apr 24, 2006 Mar CAHN

IVABRADINE HYDROCHLORIDE

TABLET; ORAL

CORLANOR

AMGEN INC EQ 5MG BASE

N206143 001 Apr 15, 2015 Apr NEWA

+ EQ 7.5MG BASE

N206143 002 Apr 15, 2015 Apr NEWA

IVACAFTOR

GRANULE; ORAL

KALYDECO

VERTEX PHARMS INC 50MG/PACKET

N207925 001 Mar 17, 2015 Mar NEWA

+ 75MG/PACKET

N207925 002 Mar 17, 2015 Mar NEWA

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION							
KETOROLAC TROMETHAMINE							
	@ CLARIS PHARMASERVICE	15MG/ML	A075631	002	Jun 29, 2001	Apr	CAHN
	@	30MG/ML	A075631	001	Jun 29, 2001	Apr	CAHN
AP	MYLAN PHARMS INC	15MG/ML	A078299	001	Jul 16, 2007	Apr	CAHN
AP		30MG/ML	A078299	002	Jul 16, 2007	Apr	CAHN
SPRAY, METERED; NASAL							
SPRIX							
+	EGALET US INC	15.75MG/SPRAY	N022382	001	May 14, 2010	Jan	CAHN

KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE

SOLUTION; IRRIGATION							
OMIDRIA							
+	OMEROS	EQ 4.24MG BASE/ML; EQ 12.4MG BASE/ML	N205388	001	May 30, 2014	Feb	CPOT

LABETALOL HYDROCHLORIDE

INJECTABLE; INJECTION							
LABETALOL HYDROCHLORIDE							
	@ CLARIS PHARMASERVICE	5MG/ML	A076051	001	Jul 05, 2002	Apr	CAHN
TABLET; ORAL							
LABETALOL HYDROCHLORIDE							
AB	MUTUAL PHARM	100MG	A075215	001	Jul 29, 1999	Jan	CMFD
AB		200MG	A075215	002	Jul 29, 1999	Jan	CMFD
AB		300MG	A075215	003	Jul 29, 1999	Jan	CMFD

LACTULOSE

SOLUTION; ORAL, RECTAL							
LACTULOSE							
AA	BIO-PHARM INC	10GM/15ML	A203762	001	Mar 27, 2015	Mar	NEWA

LAMIVUDINE; RALTEGRAVIR POTASSIUM

TABLET; ORAL							
DUTREBIS							
+	MERCK SHARP DOHME	150MG; EQ 300MG BASE	N206510	001	Feb 06, 2015	Feb	NEWA

LAMIVUDINE; ZIDOVUDINE

TABLET; ORAL							
LAMIVUDINE AND ZIDOVUDINE							
AB	STRIDES ARCOLAB LTD	150MG; 300MG	A079128	001	May 13, 2015	Apr	NEWA

LAMOTRIGINE

TABLET; ORAL							
LAMOTRIGINE							
>D> AB	HIKMA PHARMS	25MG	A078134	001	Apr 19, 2011	May	DISC
>A>	@	25MG	A078134	001	Apr 19, 2011	May	DISC
>D> AB		100MG	A078134	002	Apr 19, 2011	May	DISC
>A>	@	100MG	A078134	002	Apr 19, 2011	May	DISC
>D> AB		150MG	A078134	003	Apr 19, 2011	May	DISC
>A>	@	150MG	A078134	003	Apr 19, 2011	May	DISC
>D> AB		200MG	A078134	004	Apr 19, 2011	May	DISC
>A>	@	200MG	A078134	004	Apr 19, 2011	May	DISC

LAPATINIB DITOSYLATE

TABLET; ORAL							
TYKERB							
+	NOVARTIS PHARMS CORP	EQ 250MG BASE	N022059	001	Mar 13, 2007	Mar	CAHN

LENVATINIB MESYLATE

CAPSULE; ORAL							
LENVIMA							
	EISAI INC	EQ 4MG BASE	N206947	001	Feb 13, 2015	Feb	NEWA
+		EQ 10MG BASE	N206947	002	Feb 13, 2015	Feb	NEWA

LEVETIRACETAM

SOLUTION; ORAL							
LEVETIRACETAM							
>A> AA	PHARM ASSOC	100MG/ML	A201157	001	Jun 04, 2015	May	NEWA

TABLET, EXTENDED RELEASE;ORAL

ELEPSIA XR

SPARC

1GM

N204417 001 Mar 02, 2015 Mar NEWA

1.5GM

N204417 002 Mar 02, 2015 Mar NEWA

LEVETIRACETAM

APOTEX INC

1GM

A202958 001 Feb 25, 2015 Feb NEWA

>A> AB

PRINSTON INC

500MG

A203468 001 May 21, 2015 May NEWA

>A> AB

750MG

A203468 002 May 21, 2015 May NEWA

LEVOCARNITINE

INJECTABLE;INJECTION

LEVOCARNITINE

@ TEVA PHARMS USA

200MG/ML

A075881 001 Mar 29, 2001 Apr DISC

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET;ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

AB

APOTEX INC

5MG

A203027 001 Feb 13, 2015 Feb NEWA

LEVOFLOXACIN

INJECTABLE;INJECTION

LEVOFLOXACIN

AP

CLARIS PHARMASERVICE EQ 500MG/20ML (EQ 25MG/ML)

A091436 001 Jun 05, 2013 Apr CAHN

LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

AP

CLARIS PHARMASERVICE

EQ 250MG/50ML (EQ 5MG/ML)

A091397 001 Aug 08, 2013 Apr CAHN

AP

EQ 500MG/100ML (EQ 5MG/ML)

A091397 002 Aug 08, 2013 Apr CAHN

AP

EQ 750MG/150ML (EQ 5MG/ML)

A091397 003 Aug 08, 2013 Apr CAHN

LEVOLEUCOVORIN CALCIUM

SOLUTION;IV (INFUSION)

LEVOLEUCOVORIN CALCIUM

SANDOZ

EQ 250MG BASE/25ML (EQ 10MG
BASE/ML)

A203563 002 Mar 09, 2015 Feb NEWA

SANDOZ INC

EQ 175MG BASE/17.5ML (EQ 10MG
BASE/ML)

A203563 001 Mar 09, 2015 Feb NEWA

+

EQ 250MG BASE/25ML (EQ 10MG
BASE/ML)

A203563 002 Mar 09, 2015 Mar CRLD

LEVONORGESTREL

INTRAUTERINE DEVICE;INTRAUTERINE

LILETTA

MEDICINES360

52MG

N206229 001 Feb 26, 2015 Feb NEWA

LEVORPHANOL TARTRATE

TABLET;ORAL

LEVORPHANOL TARTRATE

+

SENTYNL THERAPS INC

2MG

A074278 001 Mar 31, 2000 Apr CAHN

LIDOCAINE

PATCH;TOPICAL

LIDOCAINE

AB

ACTAVIS LABS UT INC

5%

A200675 001 Aug 23, 2012 Mar CAHN

LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

LIDOCAINE HYDROCHLORIDE

>D> AP

AGILA SPECLTS

0.5%

A091056 001 Dec 08, 2010 May CAHN

>D> AP

0.5%

A091058 001 Sep 30, 2010 May CAHN

>D> AP

1%

A091056 002 Dec 08, 2010 May CAHN

>D> AP

1%

A091058 002 Sep 30, 2010 May CAHN

@ EUROHLTH INTL SARL

1%

A080407 001 Mar CAHN

@

2%

A080407 002 Mar CAHN

>A> AP

MYLAN PHARMS INC

0.5%

A091056 001 Dec 08, 2010 May CAHN

>A> AP

0.5%

A091058 001 Sep 30, 2010 May CAHN

>A> AP

1%

A091056 002 Dec 08, 2010 May CAHN

>A> AP

1%

A091058 002 Sep 30, 2010 May CAHN

LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE

>D> AP

AGILA SPECLTS

2%

A090665 001 Sep 27, 2010 May CAHN

@ EUROHLTH INTL SARL

1%

A084625 001 Feb CAHN

@

2%

A084625 002 Feb CAHN

>A> AP

MYLAN PHARMS INC

2%

A090665 001 Sep 27, 2010 May CAHN

JELLY; TOPICAL

ANESTACON

@ BANNER LIFE SCIENCES 2%

A080429 001

Jan CAHN

LIDOCAINE HYDROCHLORIDE

@ G AND W LABS INC 2%

A081318 001 Apr 29, 1993 Apr CAHN

LIDOCAINE; PRILOCAINE

CREAM; TOPICAL

EMLA

AB + ACTAVIS LABS UT INC 2.5%; 2.5%

N019941 001 Dec 30, 1992 Feb CAHN

LINACLOTIDE

CAPSULE; ORAL

LINZESS

FOREST LABS LLC 145MCG

N202811 001 Aug 30, 2012 Mar CAHN

+ 290MCG

N202811 002 Aug 30, 2012 Mar CAHN

LINCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

LINCOCIN

>D> + PHARMACIA AND UPJOHN EQ 300MG BASE/ML

N050317 001

May CFTG

>A> AP + EQ 300MG BASE/ML

N050317 001

May CFTG

>A> LINCOMYCIN

>A> AP X-GEN PHARMS INC EQ 300MG BASE/ML

A201746 001 Jun 04, 2015 May NEWA

LINEZOLID

FOR SUSPENSION; ORAL

LINEZOLID

>A> AB ROXANE 100MG/5ML

A200068 001 Jun 03, 2015 May NEWA

ZYVOX

>D> + PHARMACIA AND UPJOHN 100MG/5ML

N021132 001

Apr 18, 2000 May CFTG

>A> AB + 100MG/5ML

N021132 001

Apr 18, 2000 May CFTG

>D> INJECTABLE; INJECTION

>D> LINEZOLID

>D> AP TEVA PHARMS 200MG/100ML

A200222 001

Jun 27, 2012 May CDFR

>D> ZYVOX

>D> AP + PHARMACIA AND UPJOHN 200MG/100ML

N021131 001

Apr 18, 2000 May CDFR

>A> SOLUTION; IV (INFUSION)

>A> LINEZOLID

>A> AP TEVA PHARMS 600MG/300ML (2MG/ML)

A200222 001

Jun 27, 2012 May CDFR

>A> ZYVOX

>A> PHARMACIA AND UPJOHN 200MG/100ML (2MG/ML)

N021131 001

Apr 18, 2000 May CDFR

>A> 400MG/200ML (2MG/ML)

N021131 002

Apr 18, 2000 May NEWA

>A> AP + 600MG/300ML (2MG/ML)

N021131 003

Apr 18, 2000 May NEWA

TABLET; ORAL

LINEZOLID

>A> AB TEVA PHARMS USA 600MG

A078061 001

May 18, 2015 May NEWA

ZYVOX

>D> + PHARMACIA AND UPJOHN 600MG

N021130 002

Apr 18, 2000 May CFTG

>A> AB + 600MG

N021130 002

Apr 18, 2000 May CFTG

LISINAPRIL

TABLET; ORAL

LISINAPRIL

AB SUN PHARM INDS LTD 2.5MG

A075944 001

Jul 01, 2002 Apr CAHN

AB 5MG

A075944 002

Jul 01, 2002 Apr CAHN

AB 10MG

A075944 003

Jul 01, 2002 Apr CAHN

AB 20MG

A075944 004

Jul 01, 2002 Apr CAHN

AB 30MG

A075944 006

Feb 11, 2003 Apr CAHN

AB 40MG

A075944 005

Jul 01, 2002 Apr CAHN

ZESTRIL

AB ALVOGEN IPCO SARL 2.5MG

N019777 005

Apr 29, 1993 Feb CAHN

AB 5MG

N019777 001

May 19, 1988 Feb CAHN

AB 10MG

N019777 002

May 19, 1988 Feb CAHN

AB 20MG

N019777 003

May 19, 1988 Feb CAHN

AB 30MG

N019777 006

Jan 20, 1999 Feb CAHN

AB + 40MG

N019777 004

May 19, 1988 Feb CAHN

LITHIUM CARBONATE

TABLET, EXTENDED RELEASE;ORAL
LITHIUM CARBONATE

>A>	AB	ALEMBIC PHARMS LTD	300MG	A204445	001	Jun 10, 2015	May NEWA
		@ HIKMA INTL PHARMS	450MG	A076490	001	Jun 17, 2003	Feb DISC

LOMITAPIDE MESYLATE

CAPSULE;ORAL
JUXTAPID

		AEGERION	EQ 30MG BASE	N203858	004	Apr 23, 2015	Apr NEWA
			EQ 40MG BASE	N203858	005	Apr 23, 2015	Apr NEWA
			EQ 60MG BASE	N203858	006	Apr 23, 2015	Apr NEWA

LOMUSTINE

CAPSULE;ORAL
GLEOSTINE

		CORDEN PHARMA	5MG	N017588	004	Dec 19, 2014	Jan NEWA
--	--	---------------	-----	---------	-----	--------------	----------

LORAZEPAM

TABLET;ORAL
LORAZEPAM

AB		SUN PHARM INDS LTD	0.5MG	A076045	001	Aug 29, 2001	Apr CAHN
AB			1MG	A076045	002	Aug 29, 2001	Apr CAHN
AB			2MG	A076045	003	Aug 29, 2001	Apr CAHN

LOSARTAN POTASSIUM

TABLET;ORAL

LOSARTAN POTASSIUM

AB		WATSON LABS	25MG	A091129	001	Oct 06, 2010	Feb CMFD
AB			50MG	A091129	002	Oct 06, 2010	Feb CMFD
AB			100MG	A091129	003	Oct 06, 2010	Feb CMFD

LOVASTATIN

TABLET, EXTENDED RELEASE;ORAL

ALTOPREV

>D>		@ ANDRX LABS LLC	10MG	N021316	001	Jun 26, 2002	May CAHN
>D>			20MG	N021316	002	Jun 26, 2002	May CAHN
>D>			40MG	N021316	003	Jun 26, 2002	May CAHN
>D>	+		60MG	N021316	004	Jun 26, 2002	May CAHN
>A>		@ COVIS PHARMA SARL	10MG	N021316	001	Jun 26, 2002	May CAHN
>A>			20MG	N021316	002	Jun 26, 2002	May CAHN
>A>			40MG	N021316	003	Jun 26, 2002	May CAHN
>A>	+		60MG	N021316	004	Jun 26, 2002	May CAHN

LOXAPINE HYDROCHLORIDE

CONCENTRATE;ORAL

LOXITANE C

		@ ACTAVIS LABS UT INC	EQ 25MG BASE/ML	N017658	001		Mar CAHN
--	--	-----------------------	-----------------	---------	-----	--	----------

INJECTABLE;INJECTION

LOXITANE IM

		@ ACTAVIS LABS UT INC	EQ 50MG BASE/ML	N018039	001		Mar CAHN
--	--	-----------------------	-----------------	---------	-----	--	----------

LOXAPINE SUCCINATE

CAPSULE;ORAL

LOXAPINE SUCCINATE

>A>	AB	ELITE LABS INC	EQ 5MG BASE	A076868	001	Aug 04, 2005	May CAHN
>A>	AB		EQ 10MG BASE	A076868	002	Aug 04, 2005	May CAHN
>A>	AB		EQ 25MG BASE	A076868	003	Aug 04, 2005	May CAHN
>A>	AB		EQ 50MG BASE	A076868	004	Aug 04, 2005	May CAHN
>D>	AB	MIKAH PHARMA	EQ 5MG BASE	A076868	001	Aug 04, 2005	May CAHN
>D>	AB		EQ 10MG BASE	A076868	002	Aug 04, 2005	May CAHN
>D>	AB		EQ 25MG BASE	A076868	003	Aug 04, 2005	May CAHN
>D>	AB		EQ 50MG BASE	A076868	004	Aug 04, 2005	May CAHN

LOXITANE

		@ ACTAVIS LABS UT INC	EQ 5MG BASE	N017525	001		Mar CAHN
--	--	-----------------------	-------------	---------	-----	--	----------

		@	EQ 10MG BASE	N017525	002		Mar CAHN
--	--	---	--------------	---------	-----	--	----------

		@	EQ 25MG BASE	N017525	003		Mar CAHN
--	--	---	--------------	---------	-----	--	----------

		@	EQ 50MG BASE	N017525	004		Mar CAHN
--	--	---	--------------	---------	-----	--	----------

TABLET;ORAL

LOXITANE

		@ ACTAVIS LABS UT INC	EQ 10MG BASE	N017525	006		Mar CAHN
--	--	-----------------------	--------------	---------	-----	--	----------

TABLET;ORAL
LOXITANE

@	EQ 25MG BASE	N017525	007			Mar CAHN
@	EQ 50MG BASE	N017525	008			Mar CAHN

>D> LUCINACTANT

>D> SUSPENSION;INTRATRACHEAL
>D> SURFAXIN

>D>	+	DISCOVERY LABS	8.5ML	N021746	001	Mar 06, 2012	May DISC
>A>	@		8.5ML	N021746	001	Mar 06, 2012	May DISC

MAGNESIUM ACETATE TETRAHYDRATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

PLASMA-LYTE 56 IN PLASTIC CONTAINER

@	BAXTER HLTHCARE	32MG/100ML;128MG/100ML;234MG/100ML	N019047	001	Jun 15, 1984	Mar DISC
---	-----------------	------------------------------------	---------	-----	--------------	----------

MAGNESIUM SULFATE

SOLUTION;INTRAMUSCULAR, INTRAVENOUS
MAGNESIUM SULFATE

AP		EXELA PHARMA SCS LLC	5GM/10ML (500MG/ML)	A206039	001	Dec 18, 2014	Apr CDFR
AP	+	FRESENIUS KABI USA	5GM/10ML (500MG/ML)	N019316	001	Sep 08, 1986	Apr CPOT
AP	+	HOSPIRA	5GM/10ML (500MG/ML)	A075151	001	Apr 25, 2000	Apr CDFR
		HOSPIRA INC	10GM/20ML (500MG/ML)	A202411	001	May 14, 2015	Apr NEWA

MAGNESIUM SULFATE

SOLUTION;INTRAMUSCULAR, INTRAVENOUS
MAGNESIUM SULFATE

+	FRESENIUS KABI USA	1GM/2ML (500MG/ML)	N019316	002	Sep 08, 1986	Apr NEWA
---	--------------------	--------------------	---------	-----	--------------	----------

MANNITOL

INJECTABLE;INJECTION
MANNITOL 25%

@	IGI LABS INC	12.5GM/50ML	A089239	001	May 06, 1987	Mar CAHN
@		12.5GM/50ML	A089240	001	May 06, 1987	Mar CAHN

MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
NAMENDA XR

	FOREST LABS LLC	7MG	N022525	001	Jun 21, 2010	Mar CAHN
		14MG	N022525	002	Jun 21, 2010	Mar CAHN
		21MG	N022525	003	Jun 21, 2010	Mar CAHN
+		28MG	N022525	004	Jun 21, 2010	Mar CAHN

SOLUTION;ORAL

NAMENDA

+	FOREST LABS LLC	2MG/ML	N021627	001	Apr 18, 2005	Mar CAHN
---	-----------------	--------	---------	-----	--------------	----------

TABLET;ORAL
MEMANTINE

AB		SUN PHARMA GLOBAL	5MG	A090058	001	May 05, 2010	Mar CMFD
AB			10MG	A090058	002	May 05, 2010	Mar CMFD

MEMANTINE HYDROCHLORIDE

AB		AMNEAL PHARMS	5MG	A090041	001	Apr 10, 2015	Mar NEWA
AB			10MG	A090041	002	Apr 10, 2015	Mar NEWA
AB		LUPIN LTD	5MG	A090051	001	Apr 10, 2015	Mar NEWA
AB			10MG	A090051	002	Apr 10, 2015	Mar NEWA
	@	MYLAN PHARMS INC	5MG	A079225	001	Jan 30, 2015	Mar DISC
AB			5MG	A079225	001	Jan 30, 2015	Jan NEWA
	@		10MG	A079225	002	Jan 30, 2015	Mar DISC
AB			10MG	A079225	002	Jan 30, 2015	Jan NEWA
>D>	@	TEVA PHARMS	5MG	A090052	001	Oct 25, 2011	May CMFD
>A>	AB		5MG	A090052	001	Oct 25, 2011	May CMFD
>D>	@		10MG	A090052	002	Oct 25, 2011	May CMFD
>A>	AB		10MG	A090052	002	Oct 25, 2011	May CMFD

NAMENDA

AB		FOREST LABS LLC	5MG	N021487	001	Oct 16, 2003	Mar CAHN
AB	+		10MG	N021487	002	Oct 16, 2003	Mar CAHN

MENOTROPINS (FSH;LH)

>D> INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS
>D> REPRONEX

>D>	+	FERRING	75 IU/VIAL	N021047	001	Aug 27, 1999	May DISC
>A>	@		75 IU/VIAL;75 IU/VIAL	N021047	001	Aug 27, 1999	May DISC

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
MEPERIDINE HYDROCHLORIDE

>D>	@	ASTRAZENECA	25MG/ML	A089781	001	Mar 31, 1989	May CAHN
AP		EUROHLTH INTL SARL	25MG/ML	A080445	001		Feb CAHN
AP			50MG/ML	A080445	002		Feb CAHN
AP			75MG/ML	A080445	003		Feb CAHN
AP			100MG/ML	A080445	004		Feb CAHN
>A>	@	IGI LABS INC	25MG/ML	A089781	001	Mar 31, 1989	May CAHN
	@		50MG/ML	A089782	001	Mar 31, 1989	Mar CAHN
	@		50MG/ML	A089783	001	Mar 31, 1989	Mar CAHN
	@		50MG/ML	A089784	001	Mar 31, 1989	Mar CAHN
	@		75MG/ML	A089785	001	Mar 31, 1989	Mar CAHN
	@		100MG/ML	A089786	001	Mar 31, 1989	Mar CAHN
	@		100MG/ML	A089787	001	Mar 31, 1989	Mar CAHN
	@		100MG/ML	A089788	001	Mar 31, 1989	Mar CAHN

MEROPENEM

POWDER; IV (INFUSION)
MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER
B BRAUN MEDICAL INC 1GM/VIAL
500MG/VIAL

N202106 002 Apr 30, 2015 Apr NEWA
N202106 001 Apr 30, 2015 Apr NEWA

MESTRANOL; NORETHINDRONE

TABLET; ORAL-20
NORINYL

@ ACTAVIS LABS UT INC 0.1MG; 2MG

N013625 004 Mar CAHN

TABLET; ORAL-21

NORINYL 1+50 21-DAY

@ ACTAVIS LABS UT INC 0.05MG; 1MG

N013625 002 Mar CAHN

TABLET; ORAL-28

NORINYL 1+50 28-DAY

+ ACTAVIS LABS UT INC 0.05MG; 1MG

N016659 001 Mar CAHN

METAPROTERENOL SULFATE

SOLUTION; INHALATION
METAPROTERENOL SULFATE

@ MYLAN SPECLT 0.4%

A071786 001 Aug 05, 1988 Apr DISC

@ 0.6%

A070804 001 Aug 17, 1987 Apr DISC

@ WOCKHARDT 0.4%

A075586 001 May 30, 2002 Apr DISC

@ 0.6%

A075586 002 May 30, 2002 Apr DISC

SYRUP; ORAL

METAPROTERENOL SULFATE

@ G AND W LABS INC 10MG/5ML

A072761 001 Feb 27, 1992 Apr CAHN

@ 10MG/5ML

A073034 001 Aug 30, 1991 Apr CAHN

METAXALONE

TABLET; ORAL

METAXALONE

COREPHARMA 400MG

A040486 001 Feb 27, 2015 Feb NEWA

METFORMIN HYDROCHLORIDE

SOLUTION; ORAL

RIOMET

+ SUN PHARM INDS LTD 500MG/5ML

N021591 001 Sep 11, 2003 Apr CAHN

METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE

TABLET; ORAL

AVANDAMET

>D>							
>D>	AB	SB PHARMCO	1GM; EQ 2MG BASE	N021410	004	Aug 25, 2003	May DISC
>A>		@	1GM; EQ 2MG BASE	N021410	004	Aug 25, 2003	May DISC
>D>	AB	+	1GM; EQ 4MG BASE	N021410	005	Aug 25, 2003	May DISC
>A>		@	1GM; EQ 4MG BASE	N021410	005	Aug 25, 2003	May DISC
>D>	AB		500MG; EQ 2MG BASE	N021410	002	Oct 10, 2002	May DISC
>A>		@	500MG; EQ 2MG BASE	N021410	002	Oct 10, 2002	May DISC
>D>	AB		500MG; EQ 4MG BASE	N021410	003	Oct 10, 2002	May DISC
>A>		@	500MG; EQ 4MG BASE	N021410	003	Oct 10, 2002	May DISC
			ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE				
>D>	AB	TEVA	1GM; EQ 4MG BASE	A077337	004	May 07, 2014	May CRLD
>A>		+	1GM; EQ 4MG BASE	A077337	004	May 07, 2014	May CRLD
>D>	AB		1GM; EQ 2MG BASE	A077337	003	May 07, 2014	May CTEC

TABLET;ORAL

ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE

>A>		1GM;EQ 2MG BASE	A077337	003	May 07, 2014	May CTEC
>D>	AB	500MG;EQ 2MG BASE	A077337	001	May 07, 2014	May CTEC
>A>		500MG;EQ 2MG BASE	A077337	001	May 07, 2014	May CTEC
>D>	AB	500MG;EQ 4MG BASE	A077337	002	May 07, 2014	May CTEC
>A>		500MG;EQ 4MG BASE	A077337	002	May 07, 2014	May CTEC

METHIMAZOLE

TABLET;ORAL

METHIMAZOLE

AB	HERITAGE PHARMA	5MG	A040734	001	Dec 14, 2007	Mar CAHN
AB		10MG	A040734	002	Dec 14, 2007	Mar CAHN

METHOTREXATE SODIUM

INJECTABLE;INJECTION

METHOTREXATE PRESERVATIVE FREE

>D>	@ FRESenius KABI USA	EQ 25MG BASE/ML	A040265	001	Feb 26, 1999	May CMFD	
>A>	AP	EQ 25MG BASE/ML	A040265	001	Feb 26, 1999	May CMFD	
		METHOTREXATE SODIUM PRESERVATIVE FREE					
>A>	AP	MYLAN LABS INC	EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	A201530	001	Mar 29, 2012	May CAHN
>D>	AP	ONCO THERAPIES LTD	EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	A201530	001	Mar 29, 2012	May CAHN

TABLET;ORAL

METHOTREXATE SODIUM

>A>	AB	ORION CORP ORION	EQ 2.5MG BASE	A201749	001	May 21, 2015	May NEWA
-----	----	------------------	---------------	---------	-----	--------------	----------

METHOXSALLEN

CAPSULE;ORAL

METHOXSALLEN

>A>	AB	ACTAVIS INC	10MG	A202603	001	Jun 09, 2015	May NEWA
-----	----	-------------	------	---------	-----	--------------	----------

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

APTENSIO XR

		RHODES PHARMS	10MG	N205831	001	Apr 17, 2015	Apr NEWA
			15MG	N205831	002	Apr 17, 2015	Apr NEWA
			20MG	N205831	003	Apr 17, 2015	Apr NEWA
			30MG	N205831	004	Apr 17, 2015	Apr NEWA
			40MG	N205831	005	Apr 17, 2015	Apr NEWA
			50MG	N205831	006	Apr 17, 2015	Apr NEWA
			60MG	N205831	007	Apr 17, 2015	Apr NEWA
		+ RITALIN LA					
AB1		NOVARTIS	40MG	N021284	003	Jun 05, 2002	Feb CRLD
		+	60MG	N021284	005	Oct 27, 2014	Feb CRLD

TABLET, CHEWABLE;ORAL

METHYLIN

AB		MALLINCKRODT	2.5MG	N021475	001	Apr 15, 2003	Feb CFTG
AB			5MG	N021475	002	Apr 15, 2003	Feb CFTG
AB		+	10MG	N021475	003	Apr 15, 2003	Feb CFTG
		METHYLPHENIDATE HYDROCHLORIDE					
AB		NOVEL LABS INC	2.5MG	A204115	001	Feb 25, 2015	Feb NEWA
AB			5MG	A204115	002	Feb 25, 2015	Feb NEWA
AB			10MG	A204115	003	Feb 25, 2015	Feb NEWA

TABLET, EXTENDED RELEASE;ORAL

METHYLIN ER

>D>		MALLINCKRODT INC	10MG	A075629	001	May 09, 2000	May CTEC
>A>	AB		10MG	A075629	001	May 09, 2000	May CTEC
		METHYLPHENIDATE HYDROCHLORIDE					
>A>	AB	ABHAI	10MG	A207488	001	Jun 09, 2015	May NEWA
>A>	AB		20MG	A207488	002	Jun 09, 2015	May NEWA

METOPROLOL TARTRATE

INJECTABLE;INJECTION

METOPROLOL TARTRATE

AP		CLARIS PHARMASERVICE	1MG/ML	A078950	001	Apr 29, 2013	Apr CAHN
----	--	----------------------	--------	---------	-----	--------------	----------

TABLET;ORAL

METOPROLOL TARTRATE

		MYLAN	37.5MG	A076704	004	Mar 18, 2015	Mar NEWA
			75MG	A076704	005	Mar 18, 2015	Mar NEWA

METRONIDAZOLECREAM; TOPICAL
NORITATE

+ VALEANT PHARMS NORTH 1%

N020743 001 Sep 26, 1997 Feb CAHN

GEL; VAGINAL

METRONIDAZOLE

+ ACTAVIS LABS UT INC 1.3%

N205223 001 Mar 24, 2014 Feb CAHN

NUVESSA

+ ACTAVIS LABS UT INC 1.3%

N205223 001 Mar 24, 2014 Feb CTNA

INJECTABLE; INJECTION

METRONIDAZOLE IN PLASTIC CONTAINER

AP CLARIS PHARMASERVICE 500MG/100ML

A078084 001 Mar 31, 2008 Apr CAHN

TABLET; ORAL

METRONIDAZOLE

>A> AB AUROBINDO PHARMA LTD 250MG

A203974 001 May 29, 2015 May NEWA

>A> AB 500MG

A203974 002 May 29, 2015 May NEWA

MICONAZOLE

TABLET; BUCCAL

ORAVIG

+ DARA BIOSCIENCES 50MG

N022404 001 Apr 16, 2010 Apr CAHN

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HYDROCHLORIDE

@ CLARIS PHARMASERVICE EQ 1MG BASE/ML

A075637 001 Oct 31, 2000 Apr CAHN

@ EQ 5MG BASE/ML

A075637 002 Oct 31, 2000 Apr CAHN

@ IGI LABS INC EQ 5MG BASE/ML

A075263 001 Jun 26, 2000 Apr CAHN

@ WOCKHARDT EQ 1MG BASE/ML

A078141 001 May 30, 2008 Mar DISC

@ EQ 1MG BASE/ML

A078511 001 Nov 10, 2008 Mar DISC

@ EQ 5MG BASE/ML

A078141 002 May 30, 2008 Mar DISC

@ EQ 5MG BASE/ML

A078511 002 Nov 10, 2008 Mar DISC

SYRUP; ORAL

MIDAZOLAM HYDROCHLORIDE

AA SUN PHARM INDS LTD EQ 2MG BASE/ML

A076058 001 Mar 15, 2002 Apr CAHN

MIGLITOL

TABLET; ORAL

GLYSET

AB PHARMACIA AND UPJOHN 25MG

N020682 001 Dec 18, 1996 Mar CTEC

AA 25MG

N020682 001 Dec 18, 1996 Feb CFTG

AB 50MG

N020682 002 Dec 18, 1996 Mar CTEC

AA 50MG

N020682 002 Dec 18, 1996 Feb CFTG

AB + 100MG

N020682 003 Dec 18, 1996 Mar CTEC

AA + 100MG

N020682 003 Dec 18, 1996 Feb CFTG

MIGLITOL

AB ORIENT PHARMA CO LTD 25MG

A203965 001 Feb 24, 2015 Mar CTEC

AA 25MG

A203965 001 Feb 24, 2015 Feb NEWA

AB 50MG

A203965 002 Feb 24, 2015 Mar CTEC

AA 50MG

A203965 002 Feb 24, 2015 Feb NEWA

AB 100MG

A203965 003 Feb 24, 2015 Mar CTEC

AA 100MG

A203965 003 Feb 24, 2015 Feb NEWA

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE

AP BEDFORD EQ 1MG BASE/ML

A075660 001 May 28, 2002 Jan CRLD

AP + HIKMA FARMACEUTICA EQ 1MG BASE/ML

A077966 001 Dec 03, 2010 Jan CRLD

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL

MINOCYCLINE HYDROCHLORIDE

AB SUN PHARM INDS LTD EQ 50MG BASE

A065062 001 Nov 30, 2000 Apr CAHN

AB EQ 75MG BASE

A065062 002 Nov 30, 2000 Apr CAHN

AB EQ 100MG BASE

A065062 003 Nov 30, 2000 Apr CAHN

CAPSULE, EXTENDED RELEASE; ORAL

XIMINO

@ SUN PHARM INDS LTD EQ 45MG BASE

N201922 001 Jul 11, 2012 Apr CAHN

@ EQ 67.5MG BASE

N201922 002 Jul 11, 2012 Apr CAHN

@ EQ 90MG BASE

N201922 003 Jul 11, 2012 Apr CAHN

@ EQ 112.5MG BASE

N201922 004 Jul 11, 2012 Apr CAHN

CAPSULE, EXTENDED RELEASE;ORAL									
XIMINO									
	@	EQ 135MG BASE		N201922	005	Jul 11, 2012	Apr	CAHN	
TABLET;ORAL									
MINOCYCLINE HYDROCHLORIDE									
AB	SUN PHARM INDS LTD	EQ 50MG BASE		A065156	001	Jan 06, 2004	Apr	CAHN	
AB		EQ 75MG BASE		A065156	002	Jan 06, 2004	Apr	CAHN	
AB		EQ 100MG BASE		A065156	003	Jan 06, 2004	Apr	CAHN	
TABLET, EXTENDED RELEASE;ORAL									
MINOCYCLINE HYDROCHLORIDE									
AB	SUN PHARM INDS LTD	EQ 45MG BASE		A091118	001	Sep 25, 2014	Apr	CAHN	
AB		EQ 80MG BASE		A091118	004	Sep 25, 2014	Apr	CAHN	
AB		EQ 90MG BASE		A091118	005	Sep 25, 2014	Apr	CAHN	
AB		EQ 105MG BASE		A091118	006	Sep 25, 2014	Apr	CAHN	
AB		EQ 135MG BASE		A091118	008	Sep 25, 2014	Apr	CAHN	
<u>MIVACURIUM CHLORIDE</u>									
INJECTABLE;INJECTION									
MIVACURIUM CHLORIDE									
>D>	@ AGILA SPECLTS	EQ 2MG BASE/ML		A078562	001	Apr 30, 2009	May	CAHN	
>A>	@ MYLAN PHARMS INC	EQ 2MG BASE/ML		A078562	001	Apr 30, 2009	May	CAHN	
SOLUTION;INTRAVENOUS									
MIVACRON									
	ABBVIE	EQ 10MG BASE/5ML (EQ 2MG BASE/ML)		N020098	004	Jan 22, 1992	Jan	NEWA	
	+	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)		N020098	005	Jan 22, 1992	Jan	NEWA	
<u>MOLINDONE HYDROCHLORIDE</u>									
TABLET;ORAL									
MOLINDONE HYDROCHLORIDE									
	COREPHARMA	5MG		A090453	001	Mar 20, 2015	Mar	NEWA	
		10MG		A090453	002	Mar 20, 2015	Mar	NEWA	
	+	25MG		A090453	003	Mar 20, 2015	Mar	NEWA	
<u>MONTELUKAST SODIUM</u>									
TABLET;ORAL									
MONTELUKAST SODIUM									
AB	KREMERS URBAN PHARMS	EQ 10MG BASE		A201522	001	Aug 03, 2012	Mar	CAHN	
TABLET, CHEWABLE;ORAL									
MONTELUKAST SODIUM									
>A>	AB	HETERO LABS LTD V	EQ 4MG BASE	A204093	001	May 22, 2015	May	NEWA	
>A>	AB		EQ 5MG BASE	A204093	002	May 22, 2015	May	NEWA	
	AB	JUBILANT GENERICS	EQ 4MG BASE	A203795	001	Feb 27, 2015	Feb	NEWA	
	AB		EQ 5MG BASE	A203795	002	Feb 27, 2015	Feb	NEWA	
	AB	KREMERS URBAN PHARMS	EQ 4MG BASE	A200405	001	Aug 03, 2012	Mar	CAHN	
	AB		EQ 5MG BASE	A200405	002	Aug 03, 2012	Mar	CAHN	
	AB	MACLEODS PHARMS LTD	EQ 4MG BASE	A203582	001	Mar 12, 2015	Feb	NEWA	
	AB		EQ 5MG BASE	A203582	002	Mar 12, 2015	Feb	NEWA	
<u>MORPHINE SULFATE</u>									
CAPSULE, EXTENDED RELEASE;ORAL									
KADIAN									
	AB1	+	ACTAVIS LABS UT INC	10MG	N020616	008	Apr 20, 2007	Mar	CAHN
	AB1			20MG	N020616	001	Jul 03, 1996	Mar	CAHN
	AB1			30MG	N020616	004	Mar 09, 2001	Mar	CAHN
>D>				40MG	N020616	009	Jul 09, 2012	May	CTEC
>A>	AB1			40MG	N020616	009	Jul 09, 2012	May	CTEC
				40MG	N020616	009	Jul 09, 2012	Mar	CAHN
	AB1			50MG	N020616	002	Jul 03, 1996	Mar	CAHN
	AB1			60MG	N020616	005	Mar 09, 2001	Mar	CAHN
>D>				70MG	N020616	010	Jul 09, 2012	May	CTEC
>A>	AB1			70MG	N020616	010	Jul 09, 2012	May	CTEC
				70MG	N020616	010	Jul 09, 2012	Mar	CAHN
	AB1			80MG	N020616	006	Oct 27, 2006	Mar	CAHN
	AB1	+		100MG	N020616	003	Jul 03, 1996	Mar	CAHN
				130MG	N020616	011	Jul 09, 2012	Mar	CAHN
				150MG	N020616	012	Jul 09, 2012	Mar	CAHN
	AB1	+		200MG	N020616	007	Feb 27, 2007	Mar	CAHN
MORPHINE SULFATE									
>A>	AB1		TEVA PHARMS USA	40MG	A202718	007	Jun 03, 2015	May	NEWA
>A>	AB1			70MG	A202718	008	Jun 03, 2015	May	NEWA

INJECTABLE;INJECTION

MORPHINE SULFATE

>A>	AP	EUROHLTH INTL SARL	4MG/ML	A205758	001	May 21, 2015	May NEWA
>A>	AP		8MG/ML	A205758	002	May 21, 2015	May NEWA
>A>	AP		10MG/ML	A205758	003	May 21, 2015	May NEWA
>D>	+	HOSPIRA INC	4MG/ML	N202515	002	Nov 14, 2011	May CFTG
>A>	AP	+	4MG/ML	N202515	002	Nov 14, 2011	May CFTG
>D>	+		8MG/ML	N202515	003	Nov 14, 2011	May CFTG
>A>	AP	+	8MG/ML	N202515	003	Nov 14, 2011	May CFTG
>D>	+		10MG/ML	N202515	004	Nov 14, 2011	May CFTG
>A>	AP	+	10MG/ML	N202515	004	Nov 14, 2011	May CFTG

SOLUTION;ORAL

MORPHINE SULFATE

>A>	AA	TRIS PHARMA INC	10MG/5ML	A203518	001	May 12, 2015	May NEWA
>A>	AA		100MG/5ML	A203518	002	May 12, 2015	May NEWA

TABLET, EXTENDED RELEASE;ORAL

MORPHINE SULFATE

AB		ACTAVIS ELIZABETH	15MG	A203849	001	Apr 06, 2015	Mar NEWA
AB			30MG	A203849	002	Apr 06, 2015	Mar NEWA
AB			60MG	A203849	003	Apr 06, 2015	Mar NEWA
AB			100MG	A203849	004	Apr 06, 2015	Mar NEWA
AB			200MG	A203849	005	Apr 06, 2015	Mar NEWA
AB		SUN PHARM INDS LTD	15MG	A078761	001	May 11, 2012	Apr CAHN
AB			30MG	A078761	002	May 11, 2012	Apr CAHN
AB			60MG	A078761	003	May 11, 2012	Apr CAHN
AB			100MG	A078761	004	May 11, 2012	Apr CAHN
AB			200MG	A078761	005	May 11, 2012	Apr CAHN

MOXIFLOXACIN HYDROCHLORIDE

SOLUTION;IV (INFUSION)

MOXIFLOXACIN HYDROCHLORIDE

+		FRESENIUS KABI USA	EQ 400MG BASE/250ML (EQ 1.6MG BASE/ML)	N205572	001	Apr 03, 2015	Apr NEWA
---	--	--------------------	--	---------	-----	--------------	----------

SOLUTION/DROPS;OPHTHALMIC

MOXEZA

>D>	+	ALCON PHARMS LTD	EQ 0.5% BASE	N022428	001	Nov 19, 2010	May CFTG
>A>	AT2	+	EQ 0.5% BASE	N022428	001	Nov 19, 2010	May CFTG

MOXIFLOXACIN HYDROCHLORIDE

>D>	AT	LUPIN LTD	EQ 0.5% BASE	A202867	001	Sep 04, 2014	May CTEC
>A>	AT1		EQ 0.5% BASE	A202867	001	Sep 04, 2014	May CTEC
>A>	AT2		EQ 0.5% BASE	A204079	001	May 28, 2015	May NEWA
>D>	AT	WATSON LABS INC	EQ 0.5% BASE	A202525	001	Mar 06, 2015	May CTEC
>A>	AT1		EQ 0.5% BASE	A202525	001	Mar 06, 2015	May CTEC
	AT		EQ 0.5% BASE	A202525	001	Mar 06, 2015	Feb NEWA

VIGAMOX

>D>	AT	+	ALCON PHARMS LTD	EQ 0.5% BASE	N021598	001	Apr 15, 2003	May CTEC
>A>	AT1	+		EQ 0.5% BASE	N021598	001	Apr 15, 2003	May CTEC

NALBUPHINE HYDROCHLORIDE

INJECTABLE;INJECTION

NALBUPHINE HYDROCHLORIDE

@		IGI LABS INC	10MG/ML	A072070	001	Apr 10, 1989	Mar CAHN
@			10MG/ML	A072071	001	Apr 10, 1989	Mar CAHN
@			10MG/ML	A072072	001	Apr 10, 1989	Mar CAHN
@			20MG/ML	A072073	001	Apr 10, 1989	Mar CAHN
@			20MG/ML	A072074	001	Apr 10, 1989	Mar CAHN
@			20MG/ML	A072075	001	Apr 10, 1989	Mar CAHN

NALOXONE HYDROCHLORIDE

INJECTABLE;INJECTION

NALOXONE

@		EUROHLTH INTL SARL	0.4MG/ML	A070299	001	Sep 24, 1986	Mar CAHN
---	--	--------------------	----------	---------	-----	--------------	----------

NALOXONE HYDROCHLORIDE

@		IGI LABS INC	0.02MG/ML	A072082	001	Apr 11, 1989	Mar CAHN
@			0.02MG/ML	A072083	001	Apr 11, 1989	Mar CAHN
@			0.02MG/ML	A072084	001	Apr 11, 1989	Mar CAHN
@			0.02MG/ML	A072085	001	Apr 11, 1989	Mar CAHN
@			0.4MG/ML	A072086	001	Apr 11, 1989	Mar CAHN
@			0.4MG/ML	A072087	001	Apr 11, 1989	Mar CAHN
@			0.4MG/ML	A072088	001	Apr 11, 1989	Mar CAHN
@			0.4MG/ML	A072089	001	Apr 11, 1989	Mar CAHN
@			0.4MG/ML	A072090	001	Apr 11, 1989	Mar CAHN
@			1MG/ML	A072091	001	Apr 11, 1989	Mar CAHN

INJECTABLE; INJECTION
NALOXONE HYDROCHLORIDE

@	1MG/ML	A072092	001	Apr 11, 1989	Mar CAHN
@	1MG/ML	A072093	001	Apr 11, 1989	Mar CAHN

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE

AB	SUN PHARM INDS LTD	EQ 0.5MG BASE; EQ 50MG BASE	A075523	001	Mar 17, 2000	Apr CAHN
----	--------------------	-----------------------------	---------	-----	--------------	----------

NAPROXEN

SUSPENSION; ORAL

NAPROSYN

AB	+	PEDIAPHARM INC	25MG/ML	N018965	001	Mar 23, 1987	Apr CAHN
----	---	----------------	---------	---------	-----	--------------	----------

NEBIVOLOL HYDROCHLORIDE

TABLET; ORAL

BYSTOLIC

		FOREST LABS	EQ 2.5MG BASE	N021742	002	Dec 17, 2007	Apr CTEC
AB			EQ 2.5MG BASE	N021742	002	Dec 17, 2007	Mar CFTG
			EQ 5MG BASE	N021742	003	Dec 17, 2007	Apr CTEC
AB			EQ 5MG BASE	N021742	003	Dec 17, 2007	Mar CFTG
			EQ 10MG BASE	N021742	004	Dec 17, 2007	Apr CTEC
AB			EQ 10MG BASE	N021742	004	Dec 17, 2007	Mar CFTG
	+		EQ 20MG BASE	N021742	005	Oct 08, 2008	Apr CTEC
AB	+		EQ 20MG BASE	N021742	005	Oct 08, 2008	Mar CFTG

NEBIVOLOL HYDROCHLORIDE

	@	AMERIGEN PHARMS LTD	EQ 2.5MG BASE	A203659	001	Apr 16, 2015	Apr DISC
AB			EQ 2.5MG BASE	A203659	001	Apr 16, 2015	Mar NEWA
	@		EQ 5MG BASE	A203659	002	Apr 16, 2015	Apr DISC
AB			EQ 5MG BASE	A203659	002	Apr 16, 2015	Mar NEWA
	@		EQ 10MG BASE	A203659	003	Apr 16, 2015	Apr DISC
AB			EQ 10MG BASE	A203659	003	Apr 16, 2015	Mar NEWA
	@		EQ 20MG BASE	A203659	004	Apr 16, 2015	Apr DISC
AB			EQ 20MG BASE	A203659	004	Apr 16, 2015	Mar NEWA

NEFAZODONE HYDROCHLORIDE

TABLET; ORAL

NEFAZODONE HYDROCHLORIDE

	@	IDT AUSTRALIA LTD	50MG	A076072	001	Sep 16, 2003	Apr CAHN
	@		100MG	A076072	002	Sep 16, 2003	Apr CAHN
	@		150MG	A076072	003	Sep 16, 2003	Apr CAHN
	@		200MG	A076072	004	Sep 16, 2003	Apr CAHN
	@		250MG	A076072	005	Sep 16, 2003	Apr CAHN
AB		SUN PHARM INDS LTD	50MG	A076409	001	Sep 16, 2003	Apr CAHN
AB			100MG	A076409	002	Sep 16, 2003	Apr CAHN
AB			150MG	A076409	003	Sep 16, 2003	Apr CAHN
AB			200MG	A076409	004	Sep 16, 2003	Apr CAHN
AB			250MG	A076409	005	Sep 16, 2003	Apr CAHN

NELARABINE

INJECTABLE; IV (INFUSION)

ARRANON

+	NOVARTIS PHARMS CORP	250MG/50ML (5MG/ML)	N021877	001	Oct 28, 2005	Mar CAHN
---	----------------------	---------------------	---------	-----	--------------	----------

NEOSTIGMINE METHYLSULFATE

SOLUTION; INTRAVENOUS

NEOSTIGMINE METHYLSULFATE

	FRESENIUS KABI USA	5MG/10ML (0.5MG/ML)	N203629	001	Jan 08, 2015	Jan NEWA
		10MG/10ML (1MG/ML)	N203629	002	Jan 08, 2015	Jan NEWA

NIFEDIPINE

CAPSULE; ORAL

NIFEDIPINE

AB	HERITAGE PHARMA	10MG	A202644	001	Apr 25, 2013	Mar CAHN
AB		20MG	A202644	002	Apr 25, 2013	Mar CAHN

NILUTAMIDETABLET; ORAL
NILANDRON@ CONCORDIA PHARMS INC 50MG
+ 150MGN020169 001 Sep 19, 1996 Apr CAHN
N020169 002 Apr 30, 1999 Apr CAHNNIMODIPINECAPSULE; ORAL
NIMODIPINE

AB + BANNER LIFE SCIENCES 30MG

A076740 001 Jan 17, 2008 Jan CAHN

NINTEDANIB ESYLATECAPSULE; ORAL
OFEVBOEHRINGER INGELHEIM EQ 100MG BASE
+ EQ 150MG BASEN205832 001 Oct 15, 2014 Mar CAIN
N205832 002 Oct 15, 2014 Mar CAINNORETHINDRONETABLET; ORAL-28
NOR-QD

AB1 + ACTAVIS LABS UT INC 0.35MG

N017060 001 Mar CAHN

NYSTATINSUSPENSION; ORAL
NYSTATINAA G AND W LABS INC 100,000 UNITS/ML
@ 100,000 UNITS/MLA062349 001 Jul 14, 1982 Apr CAHN
A062776 001 Dec 17, 1987 Apr CAHNNYSTATIN; TRIAMCINOLONE ACETONIDECREAM; TOPICAL
MYKACET

AT G AND W LABS INC 100,000 UNITS/GM; 0.1%

A062367 001 May 28, 1985 Mar CMFD

OINTMENT; TOPICAL
MYKACET

AT G AND W LABS INC 100,000 UNITS/GM; 0.1%

A062733 001 Mar 09, 1987 Mar CMFD

OLANZAPINETABLET; ORAL
OLANZAPINE

AB IVAX PHARMS INC 20MG

A077301 001 Apr 29, 2015 Apr NEWA

TABLET, ORALLY DISINTEGRATING; ORAL
OLANZAPINEAB MACLEODS PHARMS LTD 5MG
AB 10MG
AB 15MG
AB 20MG
AB ORCHID HLTHCARE 5MG
AB 10MG
AB 15MG
AB 20MGA203044 001 Feb 20, 2015 Feb NEWA
A203044 002 Feb 20, 2015 Feb NEWA
A203044 003 Feb 20, 2015 Feb NEWA
A203044 004 Feb 20, 2015 Feb NEWA
A202937 001 Mar 02, 2015 Feb NEWA
A202937 002 Mar 02, 2015 Feb NEWA
A202937 003 Mar 02, 2015 Feb NEWA
A202937 004 Mar 02, 2015 Feb NEWAOLAPARIBCAPSULE; ORAL
LYNPARZA

ASTRAZENECA PHARMS 50MG

N206162 001 Dec 19, 2014 Jan CTNA

>A> OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE>A> SPRAY, METERED; INHALATION
>A> STIOLTO RESPIMAT>A> + BOEHRINGER INGELHEIM EQ 0.0025MG BASE/INH; EQ 0.0025MG
BASE/INH

N206756 001 May 21, 2015 May NEWA

OLOPATADINE HYDROCHLORIDESOLUTION/DROPS; OPHTHALMIC
PAZEO

+ ALCON RES LTD EQ 0.7% BASE

N206276 001 Jan 30, 2015 Jan NEWA

ONDANSETRON

TABLET, ORALLY DISINTEGRATING;ORAL
ONDANSETRON

AB	SUN PHARM INDS LTD	4MG	A078602	001	Feb 24, 2011	Apr CAHN
AB		8MG	A078602	002	Feb 24, 2011	Apr CAHN
	ZOFTRAN ODT					
AB	NOVARTIS PHARMS CORP	4MG	N020781	001	Jan 27, 1999	Mar CAHN
AB	+	8MG	N020781	002	Jan 27, 1999	Mar CAHN

ONDANSETRON HYDROCHLORIDE

INJECTABLE;INJECTION
ONDANSETRON HYDROCHLORIDE

>D>	AP	AGILA SPECLTS	EQ 2MG BASE/ML	A078257	001	Apr 23, 2008	May CAHN	
	AP	CLARIS PHARMASERVICE	EQ 2MG BASE/ML	A078288	001	Feb 22, 2013	Apr CAHN	
>A>	AP	MYLAN PHARMS INC	EQ 2MG BASE/ML	A078257	001	Apr 23, 2008	May CAHN	
		ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE						
	AP	CLARIS PHARMASERVICE	EQ 2MG BASE/ML	A078287	001	Feb 22, 2013	Apr CAHN	
	AP	MYLAN PHARMS INC	EQ 2MG BASE/ML	A078244	001	Apr 23, 2008	Apr CAHN	
		@ TARO PHARMS IRELAND	EQ 2MG BASE/ML	A078014	001	Mar 21, 2008	Jan DISC	
		ZOFTRAN						
	AP	+	NOVARTIS PHARMS CORP	EQ 2MG BASE/ML	N020007	001	Jan 04, 1991	Mar CAHN
		ZOFTRAN PRESERVATIVE FREE						
	AP	+	NOVARTIS PHARMS CORP	EQ 2MG BASE/ML	N020007	003	Dec 10, 1993	Mar CAHN
		SOLUTION;ORAL						
		ZOFTRAN						
	AA	+	NOVARTIS PHARMS CORP	EQ 4MG BASE/5ML	N020605	001	Jan 24, 1997	Mar CAHN
		TABLET;ORAL						
		ZOFTRAN						
	AB	NOVARTIS PHARMS CORP	EQ 4MG BASE	N020103	001	Dec 31, 1992	Mar CAHN	
	AB		EQ 8MG BASE	N020103	002	Dec 31, 1992	Mar CAHN	
	AB	+	EQ 24MG BASE	N020103	003	Aug 27, 1999	Mar CAHN	

ORPHENADRINE CITRATE

INJECTABLE;INJECTION
NORFLEX

		@ IGI LABS INC	30MG/ML	N013055	001		Apr CAHN
		@ MEDICIS	30MG/ML	N013055	001		Mar DISC
		ORPHENADRINE CITRATE					
AP	+	AKORN	30MG/ML	A040484	001	May 24, 2006	Mar CRLD

OXCARBAZEPINE

SUSPENSION;ORAL
OXCARBAZEPINE

AB	SUN PHARM INDS LTD	300MG/5ML	A078734	001	Jun 26, 2009	Apr CAHN
----	--------------------	-----------	---------	-----	--------------	----------

OXYBUTYNIN

FILM, EXTENDED RELEASE;TRANSDERMAL
OXYTROL

AB	+	ACTAVIS LABS UT INC	3.9MG/24HR	N021351	002	Feb 26, 2003	Mar CAHN
		GEL, METERED;TRANSDERMAL					
		GELNIQUE 3%					
	+	ACTAVIS LABS UT INC	3%	N202513	001	Dec 07, 2011	Mar CAHN

OXYBUTYNIN CHLORIDE

GEL;TRANSDERMAL
GELNIQUE

+	ACTAVIS LABS UT INC	10%(100MG/PACKET)	N022204	001	Jan 27, 2009	Mar CAHN
---	---------------------	-------------------	---------	-----	--------------	----------

OXYCODONE HYDROCHLORIDE

SOLUTION;ORAL
OXYCODONE HYDROCHLORIDE

>A>	AA	ANI PHARMS INC	5MG/5ML	A204979	001	Jun 01, 2015	May NEWA
	AA	NOVEL LABS INC	100MG/5ML	A204603	001	Apr 29, 2015	Apr NEWA
		TABLET;ORAL					
		OXAYDO					
>D>		ACURA PHARMS INC	5MG	N202080	001	Jun 17, 2011	May CAHN
			5MG	N202080	001	Jun 17, 2011	Mar CTNA
>D>			7.5MG	N202080	002	Jun 17, 2011	May CAHN
			7.5MG	N202080	002	Jun 17, 2011	Mar CTNA
>A>		EGALET LTD	5MG	N202080	001	Jun 17, 2011	May CAHN

TABLET; ORAL									
OXAYDO									
>A>		7.5MG		N202080	002	Jun 17, 2011	May	CAHN	
	OXYCODONE HYDROCHLORIDE								
AB	ACTAVIS ELIZABETH	5MG		A076636	003	Apr 07, 2015	Mar	NEWA	
AB	VINTAGE PHARMS	10MG		A077712	004	Apr 13, 2015	Mar	NEWA	
AB		20MG		A077712	005	Apr 13, 2015	Mar	NEWA	
<u>OXYMORPHONE HYDROCHLORIDE</u>									
TABLET, EXTENDED RELEASE; ORAL									
OXYMORPHONE HYDROCHLORIDE									
AB	SUN PHARM INDS LTD	5MG		A203506	001	Apr 24, 2015	Apr	NEWA	
AB		7.5MG		A203506	002	Apr 24, 2015	Apr	NEWA	
AB		10MG		A203506	003	Apr 24, 2015	Apr	NEWA	
AB		15MG		A203506	004	Apr 24, 2015	Apr	NEWA	
AB		20MG		A203506	005	Apr 24, 2015	Apr	NEWA	
AB		30MG		A203506	006	Apr 24, 2015	Apr	NEWA	
AB		40MG		A203506	007	Apr 24, 2015	Apr	NEWA	
<u>OXYTOCIN</u>									
INJECTABLE; INJECTION									
OXYTOCIN									
AP	+	EUROHLTH INTL SARL	10USP UNITS/ML (10USP UNITS/ML)	N018243	001		Feb	CAHN	
AP	+		100USP UNITS/10ML (10USP UNITS/ML)	N018243	002	Jan 10, 2007	Feb	CAHN	
<u>PACLITAXEL</u>									
INJECTABLE; INJECTION									
PACLITAXEL									
AP	MYLAN PHARMS INC	6MG/ML		A091540	001	Sep 29, 2011	Apr	CAHN	
<u>PALBOCICLIB</u>									
CAPSULE; ORAL									
IBRANCE									
	PFIZER INC	75MG		N207103	001	Feb 03, 2015	Feb	NEWA	
		100MG		N207103	002	Feb 03, 2015	Feb	NEWA	
	+	125MG		N207103	003	Feb 03, 2015	Feb	NEWA	
<u>PALIPERIDONE PALMITATE</u>									
SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR									
INVEGA TRINZA									
>A>	JANSSEN PHARMS	273MG/0.875ML (273MG/0.875ML)		N207946	001	May 18, 2015	May	NEWA	
>A>		410MG/1.315ML (311.79MG/ML)		N207946	002	May 18, 2015	May	NEWA	
>A>		546MG/1.75ML (312MG/ML)		N207946	003	May 18, 2015	May	NEWA	
>A>	+	819MG/2.625ML (312MG/ML)		N207946	004	May 18, 2015	May	NEWA	
<u>PAMIDRONATE DISODIUM</u>									
INJECTABLE; INJECTION									
PAMIDRONATE DISODIUM									
AP	MYLAN PHARMS INC	30MG/10ML (3MG/ML)		A078520	001	Oct 31, 2008	Apr	CAHN	
AP		90MG/10ML (9MG/ML)		A078520	002	Oct 31, 2008	Apr	CAHN	
<u>PANCURONIUM BROMIDE</u>									
INJECTABLE; INJECTION									
PANCURONIUM BROMIDE									
	@ IGI LABS INC	1MG/ML		A072210	001	Mar 31, 1988	Mar	CAHN	
	@	2MG/ML		A072211	001	Mar 31, 1988	Mar	CAHN	
	@	2MG/ML		A072212	001	Mar 31, 1988	Mar	CAHN	
	@	2MG/ML		A072213	001	Mar 31, 1988	Mar	CAHN	
<u>PANOBINOSTAT</u>									
CAPSULE; ORAL									
FARYDAK									
	NOVARTIS PHARMS CORP	10MG		N205353	001	Feb 23, 2015	Feb	NEWA	
		15MG		N205353	002	Feb 23, 2015	Feb	NEWA	
	+	20MG		N205353	003	Feb 23, 2015	Feb	NEWA	
<u>PANOBINOSTAT LACTATE</u>									
CAPSULE; ORAL									
FARYDAK									
	NOVARTIS PHARMS CORP	EQ 10MG BASE		N205353	001	Feb 23, 2015	Mar	CAIN	
		EQ 10MG BASE		N205353	001	Feb 23, 2015	Mar	CPOT	
		EQ 15MG BASE		N205353	002	Feb 23, 2015	Mar	CAIN	

CAPSULE;ORAL
FARYDAK

	EQ 15MG BASE	N205353	002	Feb 23, 2015	Mar CPOT
+	EQ 20MG BASE	N205353	003	Feb 23, 2015	Mar CAIN
+	EQ 20MG BASE	N205353	003	Feb 23, 2015	Mar CPOT

PANTOPRAZOLE SODIUMTABLET, DELAYED RELEASE;ORAL
PANTOPRAZOLE SODIUM

AB	KREMERS URBAN PHARMS	EQ 20MG BASE	A078281	001	Jan 20, 2011	Mar CAHN
AB		EQ 40MG BASE	A078281	002	Jan 20, 2011	Mar CAHN
AB	SUN PHARM INDS LTD	EQ 20MG BASE	A200794	001	May 02, 2012	Apr CAHN
AB		EQ 40MG BASE	A200794	002	May 02, 2012	Apr CAHN

PARICALCITOLCAPSULE;ORAL
PARICALCITOL

AB	BANNER LIFE SCIENCES	1MCG	A202539	001	Mar 27, 2014	Jan CAHN
AB		2MCG	A202539	002	Mar 27, 2014	Jan CAHN
AB		4MCG	A202539	003	Mar 27, 2014	Jan CAHN

PAZOPANIB HYDROCHLORIDETABLET;ORAL
VOTRIENT

+	NOVARTIS PHARMS CORP	EQ 200MG BASE	N022465	001	Oct 19, 2009	Mar CAHN
		EQ 400MG BASE	N022465	002	Oct 19, 2009	Mar CAHN

PENTOXIFYLLINETABLET, EXTENDED RELEASE;ORAL
PENTOXIFYLLINE

AB	VALEANT PHARMS	400MG	A075028	001	Jul 20, 1998	Feb CAHN
----	----------------	-------	---------	-----	--------------	----------

PHENDIMETRAZINE TARTRATECAPSULE, EXTENDED RELEASE;ORAL
BONTRIL

@	VALEANT	105MG	A088021	001	Sep 21, 1982	Jan DISC
+	SANDOZ	105MG	N018074	001		Jan CTEC

PHENYLEPHRINE HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC
PHENYLEPHRINE HYDROCHLORIDE

	AKORN INC	2.5%	N207926	001	Jan 15, 2015	Jan NEWA
		10%	N207926	002	Jan 15, 2015	Jan NEWA

PHENYTOIN SODIUMCAPSULE;ORAL
PHENYTOIN SODIUM

>A> AB	AUROBINDO PHARMA LTD	100MG EXTENDED	A204309	001	Jun 10, 2015	May NEWA
	INJECTABLE;INJECTION					
	PHENYTOIN SODIUM					

AP	+	EUROHLTH INTL SARL	50MG/ML	A084307	001	Feb CAHN
----	---	--------------------	---------	---------	-----	----------

PHYTONADIONEINJECTABLE;INJECTION
AQUAMEPHYTON

@	IGI LABS INC	1MG/0.5ML	N012223	002		Apr CAHN
@		10MG/ML	N012223	001		Apr CAHN

PILOCARPINE HYDROCHLORIDETABLET;ORAL
PILOCARPINE HYDROCHLORIDE

AB	ELAN PHARMA INTL LTD	5MG	A076746	001	Nov 16, 2004	Mar CAHN
----	----------------------	-----	---------	-----	--------------	----------

PINDOLOLTABLET;ORAL
PINDOLOL

@	G AND W LABS INC	5MG	A073661	001	Oct 31, 1993	Apr CAHN
@		5MG	A073687	001	Feb 26, 1993	Apr CAHN
@		5MG	A074123	001	Apr 17, 1997	Apr CAHN
@		10MG	A073661	002	Oct 31, 1993	Apr CAHN
@		10MG	A073687	002	Feb 26, 1993	Apr CAHN

TABLET;ORAL
PINDOLOL
@

10MG

A074123 002 Apr 17, 1997 Apr CAHN

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE;INJECTION
PIPERACILLIN AND TAZOBACTAM

AP AGILA SPECLTS EQ 3GM BASE/VIAL;EQ 375MG
BASE/VIAL

A065458 002 Aug 15, 2014 Mar CPOT

PIRBUTEROL ACETATE

AEROSOL, METERED;INHALATION
MAXAIR

@ MEDICIS EQ 0.2MG BASE/INH

N020014 001 Nov 30, 1992 Jan DISC

PIRFENIDONE

CAPSULE;ORAL
ESBRIET

+ GENENTECH INC 267MG

N022535 001 Oct 15, 2014 Feb CAHN

PIROXICAM

CAPSULE;ORAL
PIROXICAM

>A> AB MYLAN PHARMS INC 10MG
>A> AB 20MG
>D> AB NOSTRUM LABS 10MG
>D> AB 20MG

A074116 001 Jun 15, 1993 May CAHN
A074118 001 Jun 15, 1993 May CAHN
A074116 001 Jun 15, 1993 May CAHN
A074118 001 Jun 15, 1993 May CAHN

PODOFILOX

GEL;TOPICAL
CONDYLOX

+ ACTAVIS LABS UT INC 0.5%

N020529 001 Mar 13, 1997 Feb CAHN

SOLUTION;TOPICAL
CONDYLOX

AT + ACTAVIS LABS UT INC 0.5%
PODOFILOX

N019795 001 Dec 13, 1990 Jan CAHN

>A> AT BAUSCH AND LOMB INC 0.5%
>D> AT PRECISION DERMAT 0.5%

A090184 001 Jul 21, 2010 May CAHN
A090184 001 Jul 21, 2010 May CAHN

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION;ORAL
PEG-3350;POTASSIUM CHLORIDE;SODIUM BICARBONATE;SODIUM CHLORIDE

AA STRIDES ARCOLAB LTD 420GM/BOT;1.48GM/BOT;5.72GM/BOT;11
.2GM/BOT

A204559 001 Apr 13, 2015 Mar NEWA

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS;OPHTHALMIC
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE

AT ALCON RES LTD 10,000 UNITS/ML;EQ 1MG BASE/ML

A064211 001 Apr 13, 1998 Jan CAHN

PONATINIB HYDROCHLORIDE

TABLET;ORAL
ICLUSIG

ARIAD EQ 30MG BASE

N203469 003 Apr 23, 2015 Apr NEWA

POTASSIUM CHLORIDE

TABLET, EXTENDED RELEASE;ORAL
POTASSIUM CHLORIDE

AB2 MYLAN PHARMS INC 8MEQ
AB2 10MEQ

A204662 001 Aug 21, 2014 Feb CPOT
A204662 002 Aug 21, 2014 Feb CPOT

PREDNICARBATE

OINTMENT;TOPICAL
DERMATOP

AB + VALEANT PHARMS NORTH 0.1%

N019568 001 Sep 23, 1991 Apr CAHN

PREGABALIN

CAPSULE;ORAL

LYRICA

PF PRISM CV

25MG

N021446 001 Dec 30, 2004 Apr CTEC

50MG

N021446 002 Dec 30, 2004 Apr CTEC

75MG

N021446 003 Dec 30, 2004 Apr CTEC

100MG

N021446 004 Dec 30, 2004 Apr CTEC

150MG

N021446 005 Dec 30, 2004 Apr CTEC

200MG

N021446 006 Dec 30, 2004 Apr CTEC

225MG

N021446 007 Dec 30, 2004 Apr CTEC

+

300MG

N021446 008 Dec 30, 2004 Apr CTEC

PROCHLORPERAZINE EDISYLATE

INJECTABLE;INJECTION

PROCHLORPERAZINE EDISYLATE

AP + EUROHLTH INTL SARL EQ 5MG BASE/ML

A089903 001 Aug 29, 1989 Feb CAHN

PROGESTERONE

CAPSULE;ORAL

PROGESTERONE

AB BANNER LIFE SCIENCES

100MG

A200900 001 Aug 16, 2013 Jan CAHN

AB

200MG

A200900 002 Aug 16, 2013 Jan CAHN

GEL;VAGINAL

CRINONE

ACTAVIS LABS UT INC

4%

N020701 001 Jul 31, 1997 Feb CAHN

+

8%

N020701 002 Jul 31, 1997 Feb CAHN

INJECTABLE;INJECTION

PROGESTERONE

AO + ACTAVIS LABS UT INC 50MG/ML

N017362 002 Mar CAHN

PROMETHAZINE HYDROCHLORIDE

SUPPOSITORY;RECTAL

PHENERGAN

@ DELCOR ASSET CORP

12.5MG

N010926 002 Apr CAHN

@

25MG

N010926 001 Apr CAHN

TABLET;ORAL

PROMETHAZINE HYDROCHLORIDE

AB HERITAGE PHARMA

12.5MG

A040673 001 Mar 05, 2008 Mar CAHN

AB

25MG

A040673 002 Mar 05, 2008 Mar CAHN

AB

50MG

A040673 003 Mar 05, 2008 Mar CAHN

QUETIAPINE FUMARATE

TABLET;ORAL

SEROQUEL

>D> AB + ASTRAZENECA

EQ 25MG BASE

N020639 001 Sep 26, 1997 May CAHN

>D> AB

EQ 50MG BASE

N020639 007 Oct 04, 2005 May CAHN

>D> AB

EQ 100MG BASE

N020639 002 Sep 26, 1997 May CAHN

>D>

@

EQ 150MG BASE

N020639 004 Dec 20, 1998 May CAHN

>D> AB

EQ 200MG BASE

N020639 003 Sep 26, 1997 May CAHN

>D> AB

+

EQ 300MG BASE

N020639 005 Jul 26, 2000 May CAHN

>D> AB

EQ 400MG BASE

N020639 006 Oct 04, 2005 May CAHN

>A> AB

+

ASTRAZENECA PHARMS

EQ 25MG BASE

N020639 001 Sep 26, 1997 May CAHN

>A> AB

EQ 50MG BASE

N020639 007 Oct 04, 2005 May CAHN

>A> AB

EQ 100MG BASE

N020639 002 Sep 26, 1997 May CAHN

>A>

@

EQ 150MG BASE

N020639 004 Dec 20, 1998 May CAHN

>A> AB

EQ 200MG BASE

N020639 003 Sep 26, 1997 May CAHN

>A> AB

+

EQ 300MG BASE

N020639 005 Jul 26, 2000 May CAHN

>A> AB

EQ 400MG BASE

N020639 006 Oct 04, 2005 May CAHN

QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

QUINAPRIL HYDROCHLORIDE

AB SUN PHARM INDS LTD

EQ 5MG BASE

A076607 001 Dec 15, 2004 Apr CAHN

AB

EQ 10MG BASE

A076607 002 Dec 15, 2004 Apr CAHN

AB

EQ 20MG BASE

A076607 003 Dec 15, 2004 Apr CAHN

AB

EQ 40MG BASE

A076607 004 Dec 15, 2004 Apr CAHN

QUINIDINE SULFATE

TABLET, EXTENDED RELEASE;ORAL
QUINIDINE SULFATE

+ G AND W LABS INC 300MG A040045 001 Jun 30, 1994 Apr CAHN

QUININE SULFATE

CAPSULE;ORAL
QUININE SULFATE

AB LUPIN LTD 324MG A203112 001 Apr 24, 2015 Apr NEWA

RALOXIFENE HYDROCHLORIDE

TABLET;ORAL
RALOXIFENE HYDROCHLORIDE

AB WATSON LABS INC 60MG A200825 001 Jan 21, 2015 Jan NEWA

RANITIDINE HYDROCHLORIDE

TABLET;ORAL
RANITIDINE HYDROCHLORIDE

@ SUN PHARM INDS LTD EQ 150MG BASE A075439 001 Apr 19, 2000 Apr CAHN

@ EQ 300MG BASE A075439 002 Apr 19, 2000 Apr CAHN

REPAGLINIDE

TABLET;ORAL
REPAGLINIDE

AB STANDARD CHEM PHARM 0.5MG A091517 001 Apr 24, 2015 Apr NEWA

AB 1MG A091517 002 Apr 24, 2015 Apr NEWA

AB 2MG A091517 003 Apr 24, 2015 Apr NEWA

RIFAMPIN

INJECTABLE;INJECTION
RIFAMPIN

AP MYLAN PHARMS INC 600MG/VIAL A065421 001 May 22, 2008 Apr CAHN

RISEDRONATE SODIUM

TABLET, DELAYED RELEASE;ORAL
ATELVIA

>D> + WARNER CHILCOTT LLC 35MG N022560 001 Oct 08, 2010 May CFTG

>A> AB + 35MG N022560 001 Oct 08, 2010 May CFTG

>A> RISEDRONATE SODIUM

>A> AB TEVA PHARMS USA 35MG A203217 001 May 18, 2015 May NEWA

RISPERIDONE

TABLET, ORALLY DISINTEGRATING;ORAL
RISPERIDONE

AB SUN PHARM INDS LTD 0.5MG A077542 001 Aug 06, 2010 Apr CAHN

AB 1MG A077542 002 Aug 06, 2010 Apr CAHN

AB 2MG A077542 003 Aug 06, 2010 Apr CAHN

AB 3MG A078474 001 Aug 06, 2010 Apr CAHN

AB 4MG A078474 002 Aug 06, 2010 Apr CAHN

RIVAROXABAN

TABLET;ORAL
XARELTO

JANSSEN PHARMS 10MG N022406 001 Jul 01, 2011 Apr CRLD

RIVASTIGMINE TARTRATE

CAPSULE;ORAL
RIVASTIGMINE TARTRATE

>A> AB ORCHID HLTHCARE EQ 1.5MG BASE A090879 001 Jun 10, 2015 May NEWA

>A> AB EQ 3MG BASE A090879 002 Jun 10, 2015 May NEWA

>A> AB EQ 4.5MG BASE A090879 003 Jun 10, 2015 May NEWA

>A> AB EQ 6MG BASE A090879 004 Jun 10, 2015 May NEWA

ROFLUMILAST

TABLET;ORAL
DALIRESP

+ ASTRAZENECA PHARMS 500MCG N022522 001 Feb 28, 2011 Mar CAHN

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL

ROPINIROLE HYDROCHLORIDE

AB	G AND W LABS INC	EQ 0.25MG BASE	A077460	001	May 05, 2008	Apr CAHN
AB		EQ 0.5MG BASE	A077460	002	May 05, 2008	Apr CAHN
AB		EQ 1MG BASE	A077460	003	May 05, 2008	Apr CAHN
AB		EQ 2MG BASE	A077460	004	May 05, 2008	Apr CAHN
AB		EQ 3MG BASE	A077460	005	May 05, 2008	Apr CAHN
AB		EQ 4MG BASE	A077460	006	May 05, 2008	Apr CAHN
AB		EQ 5MG BASE	A077460	007	May 19, 2008	Apr CAHN

SCOPOLAMINE

FILM, EXTENDED RELEASE; TRANSDERMAL

SCOPOLAMINE

AB	PERRIGO PHARMS CO	1MG/72HR	A078830	001	Jan 30, 2015	Mar CAHN
AB	PERRIGO R AND D	1MG/72HR	A078830	001	Jan 30, 2015	Jan NEWA
AB	TRANSDERM SCOP					
AB	+ NOVARTIS	1MG/72HR	N017874	001		Jan CFTG

SELEGILINE HYDROCHLORIDE

TABLET; ORAL

SELEGILINE HYDROCHLORIDE

@ G AND W LABS INC 5MG
 @ 5MG
 @ 5MG

A074537 001 Aug 02, 1996 Apr CAHN
 A074744 001 Jan 27, 1997 Apr CAHN
 A074756 001 Nov 25, 1998 Apr CAHN

SERTRALINE HYDROCHLORIDE

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

>D> AB	HIKMA PHARMS	EQ 25MG BASE	A077864	001	Aug 10, 2009	May DISC
>A>	@	EQ 25MG BASE	A077864	001	Aug 10, 2009	May DISC
>D> AB		EQ 50MG BASE	A077864	002	Aug 10, 2009	May DISC
>A>	@	EQ 50MG BASE	A077864	002	Aug 10, 2009	May DISC
>D> AB		EQ 100MG BASE	A077864	003	Aug 10, 2009	May DISC
>A>	@	EQ 100MG BASE	A077864	003	Aug 10, 2009	May DISC
AB	SUN PHARM INDS LTD	EQ 25MG BASE	A077977	001	Feb 06, 2007	Apr CAHN
AB		EQ 50MG BASE	A077977	002	Feb 06, 2007	Apr CAHN
AB		EQ 100MG BASE	A077977	003	Feb 06, 2007	Apr CAHN
		EQ 150MG BASE	A077977	004	Feb 06, 2007	Apr CAHN
		EQ 200MG BASE	A077977	005	Feb 06, 2007	Apr CAHN

SILDENAFIL CITRATE

SOLUTION; INTRAVENOUS

REVATIO

AP	+ PFIZER	EQ 10MG BASE/12.5ML (EQ 0.8MG BASE/ML)	N022473	001	Nov 18, 2009	Mar CFTG
AP	SILDENAFIL CITRATE					
AP	AUROBINDO PHARMA LTD	EQ 10MG BASE/12.5ML (EQ 0.8MG BASE/ML)	A203988	001	Apr 01, 2015	Mar NEWA

SILODOSIN

CAPSULE; ORAL

RAPAFLO

+	ACTAVIS LABS UT INC	4MG	N022206	001	Oct 08, 2008	Mar CAHN
		8MG	N022206	002	Oct 08, 2008	Mar CAHN

SIMVASTATIN

TABLET; ORAL

SIMVASTATIN

AB	SUN PHARM INDS LTD	5MG	A076285	001	Dec 20, 2006	Apr CAHN
AB		10MG	A076285	002	Dec 20, 2006	Apr CAHN
AB		20MG	A076285	003	Dec 20, 2006	Apr CAHN
AB		40MG	A076285	004	Dec 20, 2006	Apr CAHN
AB		80MG	A076285	005	Jun 23, 2006	Apr CAHN

SODIUM CHLORIDE

INJECTABLE; INJECTION

SODIUM CHLORIDE 0.9%

AP	EUROHLTH INTL SARL	9MG/ML	A201850	001	Jan 20, 2012	Feb CAHN
	SODIUM CHLORIDE 0.9%					
	EUROHLTH INTL SARL	9MG/ML	A201833	001	Sep 24, 2013	Feb CAHN

INJECTABLE;INJECTION

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

+	LIEBEL-FLARSHEIM	45MG/50ML (9MG/ML)	N021569	001	Jul 27, 2006	Feb CAHN
		112.5MG/125ML (9MG/ML)	N021569	002	Jul 27, 2006	Feb CAHN
+		405MG/50ML (9MG/ML)	N021569	001	Jul 27, 2006	Feb CPOT
		1012.5MG/125ML (9MG/ML)	N021569	002	Jul 27, 2006	Feb CPOT

SODIUM FLUORIDE F-18

INJECTABLE;INTRAVENOUS

SODIUM FLUORIDE F-18

AP	PRECISION NUCLEAR	10-200mCi/ML	A204542	001	Feb 27, 2015	Feb NEWA
AP	SPECTRON MRC LLC	10-200mCi/ML	A203912	001	Apr 22, 2015	Apr NEWA
AP	UNIV UTAH CYCLOTRON	10-200mCi/ML	A204497	001	Apr 20, 2015	Apr NEWA

SODIUM IODIDE I-123

CAPSULE;ORAL

SODIUM IODIDE I 123

AA	+	CARDINAL HEALTH 418	100uCi	N018671	001	May 27, 1982	Apr CAHN
AA	+		200uCi	N018671	002	May 27, 1982	Apr CAHN
	@		400uCi	N018671	003	May 27, 1982	Apr CAHN

SODIUM POLYSTYRENE SULFONATE

POWDER;ORAL, RECTAL

KALEXATE

KVK TECH

15GM/BOT

A040905 002 Apr 03, 2015 Mar NEWA

KAYEXALATE

AA	+	CONCORDIA PHARMS INC	453.6GM/BOT	N011287	001		Apr CAHN
----	---	----------------------	-------------	---------	-----	--	----------

SOMATROPIN RECOMBINANT

INJECTABLE;INJECTION

NORDITROPIN FLEXPRO

NOVO NORDISK INC

30MG/3ML

N021148 011 Jan 23, 2015 Jan NEWA

NORDITROPIN NORDIFLEX

NOVO NORDISK INC

30MG/3ML

N021148 007 Mar 10, 2009 Mar CMFD

@

30MG/3ML

N021148 007 Mar 10, 2009 Jan DISC

NUTROPIN

BX	+	GENENTECH	10MG/VIAL	N020168	002	Nov 17, 1993	Mar CTEC
----	---	-----------	-----------	---------	-----	--------------	----------

ZOMACTON

BX	+	FERRING	5MG/VIAL	N019774	002	Jan 04, 2002	Mar CTNA
----	---	---------	----------	---------	-----	--------------	----------

BX			10MG/VIAL	N019774	003	Mar 07, 2012	Apr CRLD
----	--	--	-----------	---------	-----	--------------	----------

BX	+		10MG/VIAL	N019774	003	Mar 07, 2012	Mar NEWA
----	---	--	-----------	---------	-----	--------------	----------

SOTALOL HYDROCHLORIDE

SOLUTION;INTRAVENOUS

SOTALOL HYDROCHLORIDE

+	ALTATHERA PHARMS LLC	150MG/10ML (15MG/ML)	N022306	001	Jul 02, 2009	Apr CAHN
---	----------------------	----------------------	---------	-----	--------------	----------

TABLET;ORAL

BETAPACE

AB1		COVIS PHARMA SARL	80MG	N019865	001	Oct 30, 1992	Mar CAHN
-----	--	-------------------	------	---------	-----	--------------	----------

AB1			120MG	N019865	005	Apr 20, 1994	Mar CAHN
-----	--	--	-------	---------	-----	--------------	----------

AB1	+		160MG	N019865	002	Oct 30, 1992	Mar CAHN
-----	---	--	-------	---------	-----	--------------	----------

AB1			240MG	N019865	003	Oct 30, 1992	Mar CAHN
-----	--	--	-------	---------	-----	--------------	----------

@

320MG

N019865 004 Oct 30, 1992 Mar CAHN

SUCRALFATE

TABLET;ORAL

SUCRALFATE

>A>	AB	MYLAN PHARMS INC	1GM	A074415	001	Jun 08, 1998	May CAHN
-----	----	------------------	-----	---------	-----	--------------	----------

>D>	AB	NOSTRUM LABS	1GM	A074415	001	Jun 08, 1998	May CAHN
-----	----	--------------	-----	---------	-----	--------------	----------

SULFACETAMIDE SODIUM

LOTION;TOPICAL

KLARON

AB	+	VALEANT PHARMS NORTH	10%	N019931	001	Dec 23, 1996	Mar CAHN
----	---	----------------------	-----	---------	-----	--------------	----------

SOLUTION/DROPS;OPHTHALMIC

SULFACETAMIDE SODIUM

AT		AKORN	10%	A040215	001	May 25, 1999	Mar CMFD
----	--	-------	-----	---------	-----	--------------	----------

SULFANILAMIDECREAM;VAGINAL
SULFANILAMIDE

@ G AND W LABS INC

15%

A088718 001 Sep 19, 1985 Apr CAHN

SUMATRIPTAN SUCCINATE

TABLET;ORAL

SUMATRIPTAN SUCCINATE

AB SUN PHARM INDS LTD

EQ 25MG BASE

A076554 001 Aug 10, 2009 Apr CAHN

AB

EQ 50MG BASE

A076554 002 Aug 10, 2009 Apr CAHN

AB

EQ 100MG BASE

A076572 001 Feb 09, 2009 Apr CAHN

TAPENTADOL HYDROCHLORIDE

SOLUTION;ORAL

NUCYNTA

>A> + DEPOMED INC

EQ 20MG BASE/ML

N203794 001 Oct 15, 2012 May CAHN

>D> + JANSSEN PHARMS

EQ 20MG BASE/ML

N203794 001 Oct 15, 2012 May CAHN

TABLET;ORAL

NUCYNTA

>A> DEPOMED INC

EQ 50MG BASE

N022304 001 Nov 20, 2008 May CAHN

>A>

EQ 75MG BASE

N022304 002 Nov 20, 2008 May CAHN

>A> +

EQ 100MG BASE

N022304 003 Nov 20, 2008 May CAHN

>D> JANSSEN PHARMS

EQ 50MG BASE

N022304 001 Nov 20, 2008 May CAHN

>D>

EQ 75MG BASE

N022304 002 Nov 20, 2008 May CAHN

>D> +

EQ 100MG BASE

N022304 003 Nov 20, 2008 May CAHN

TABLET, EXTENDED RELEASE;ORAL

NUCYNTA ER

>A> DEPOMED INC

EQ 50MG BASE

N200533 001 Aug 25, 2011 May CAHN

>A>

EQ 100MG BASE

N200533 002 Aug 25, 2011 May CAHN

>A>

EQ 150MG BASE

N200533 003 Aug 25, 2011 May CAHN

>A>

EQ 200MG BASE

N200533 004 Aug 25, 2011 May CAHN

>A> +

EQ 250MG BASE

N200533 005 Aug 25, 2011 May CAHN

>D> JANSSEN PHARMS

EQ 50MG BASE

N200533 001 Aug 25, 2011 May CAHN

>D>

EQ 100MG BASE

N200533 002 Aug 25, 2011 May CAHN

>D>

EQ 150MG BASE

N200533 003 Aug 25, 2011 May CAHN

>D>

EQ 200MG BASE

N200533 004 Aug 25, 2011 May CAHN

>D> +

EQ 250MG BASE

N200533 005 Aug 25, 2011 May CAHN

TELAPREVIR

TABLET;ORAL

INCIVEK

@ VERTEX PHARMS

375MG

N201917 001 May 23, 2011 Jan DISC

TEMAZEPAM

CAPSULE;ORAL

TEMAZEPAM

>A> AB VINTAGE PHARMS

7.5MG

A201781 001 Jun 04, 2015 May NEWA

>A> AB

15MG

A201781 002 Jun 04, 2015 May NEWA

>A> AB

22.5MG

A201781 003 Jun 04, 2015 May NEWA

>A> AB

30MG

A201781 004 Jun 04, 2015 May NEWA

TEMOZOLOMIDE

CAPSULE;ORAL

TEMOZOLOMIDE

AB AMNEAL PHARMS

5MG

A203691 001 May 08, 2015 Apr NEWA

AB

20MG

A203691 002 May 08, 2015 Apr NEWA

AB

100MG

A203691 003 May 08, 2015 Apr NEWA

AB

140MG

A203691 004 May 08, 2015 Apr NEWA

AB

180MG

A203691 005 May 08, 2015 Apr NEWA

AB

250MG

A203691 006 May 08, 2015 Apr NEWA

TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

TENOFOVIR DISOPROXIL FUMARATE

AB TEVA PHARMS USA

300MG

A091612 001 Mar 18, 2015 Mar NEWA

VIREAD

AB + GILEAD SCIENCES INC

300MG

N021356 001 Oct 26, 2001 Mar CFTG

TERBINAFINE HYDROCHLORIDE

TABLET; ORAL

TERBINAFINE HYDROCHLORIDE

@ WOCKHARDT

EQ 250MG BASE

A078229 001 Jul 02, 2007 Feb DISC

TESTOSTERONE

GEL; TRANSDERMAL

ANDROGEL

AB1 ABBVIE

25MG/2.5GM PACKET

N021015 001 Feb 28, 2000 Jan CTEC

AB1 +

50MG/5GM PACKET

N021015 002 Feb 28, 2000 Jan CTEC

TESTIM

AB2 + AUXILIUM PHARMS

50MG/5GM PACKET

N021454 001 Oct 31, 2002 Jan CTEC

TESTOSTERONE

@ ACTAVIS LABS UT INC

1% (2.5GM/PACKET)

A076737 001 Jan 27, 2006 Mar CAHN

@

1% (5GM/PACKET)

A076737 002 Jan 27, 2006 Mar CAHN

>A> BX ANI PHARMS INC

25MG/2.5GM PACKET

N202763 001 Feb 14, 2012 May CAHN

>A> BX

50MG/5GM PACKET

N202763 002 Feb 14, 2012 May CAHN

AB1 PERRIGO ISRAEL

25MG/2.5GM PACKET

N203098 002 Jan 31, 2013 Jan CTEC

AB1

50MG/5GM PACKET

N203098 003 Jan 31, 2013 Jan CTEC

>D> BX TEVA PHARMS

25MG/2.5GM PACKET

N202763 001 Feb 14, 2012 May CAHN

>D> BX

50MG/5GM PACKET

N202763 002 Feb 14, 2012 May CAHN

VOGELXO

AB2 UPSHER SMITH

50MG/5GM PACKET

N204399 002 Jun 04, 2014 Jan CTEC

TETRABENAZINE

TABLET; ORAL

XENAZINE

VALEANT PHARMS NORTH

12.5MG

N021894 001 Aug 15, 2008 Feb CAHN

+

25MG

N021894 002 Aug 15, 2008 Feb CAHN

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

ACHROMYCIN V

AB + HERITAGE PHARMS INC

500MG

N050278 001

Apr CRLD

TETRACYCLINE HYDROCHLORIDE

@ IVAX SUB TEVA PHARMS

250MG

A060704 001

Apr DISC

@

500MG

A060704 002

Apr DISC

THEOPHYLLINE

TABLET; ORAL

THEOLAIR

@ MEDICIS

125MG

A086399 001

Mar DISC

@

250MG

A086399 002

Mar DISC

TABLET, EXTENDED RELEASE; ORAL

THEOPHYLLINE

>A> AB MYLAN PHARMS INC

400MG

A040595 001 Apr 21, 2006 May CAHN

>A> AB +

600MG

A040560 002 Apr 21, 2006 May CAHN

>D> AB NOSTRUM

400MG

A040595 001 Apr 21, 2006 May CAHN

>D> AB +

600MG

A040560 002 Apr 21, 2006 May CAHN

THIOTEPA

INJECTABLE; INJECTION

THIOTEPA

>D> EUROHLTH INTL SARL

15MG/VIAL

A075547 001 Apr 02, 2001 May CRLD

>A> +

15MG/VIAL

A075547 001 Apr 02, 2001 May CRLD

TIGECYCLINE

INJECTABLE; IV (INFUSION)

TIGECYCLINE

>A> AP SANDOZ INC

50MG/VIAL

A091620 001 May 27, 2015 May NEWA

TYGACIL

>D> + PF PRISM CV

50MG/VIAL

N021821 001 Jun 15, 2005 May CFTG

>A> AP +

50MG/VIAL

N021821 001 Jun 15, 2005 May CFTG

TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

ISTALOL

AT2 + BAUSCH AND LOMB

EQ 0.5% BASE

N021516 001 Jun 04, 2004 Apr CFTG

TIMOLOL MALEATE

AT1 AKORN

EQ 0.5% BASE

A074466 001 Mar 25, 1997 Apr CTEC

AT1

EQ 0.5% BASE

A074516 001 Mar 25, 1997 Apr CTEC

SOLUTION/DROPS;OPHTHALMIC

TIMOLOL MALEATE

AT1	ALCON RES LTD	EQ 0.5% BASE	A074262	001	Apr 28, 1995	Apr CTEC
AT2	APOTEX INC	EQ 0.5% BASE	A204936	001	Apr 17, 2015	Apr NEWA
AT1	BAUSCH AND LOMB	EQ 0.5% BASE	A074776	001	Mar 25, 1997	Apr CTEC
AT1	FDC LTD	EQ 0.5% BASE	A077259	002	Apr 30, 2008	Apr CTEC
AT1	HI TECH PHARMA	EQ 0.5% BASE	A075163	001	Sep 10, 2002	Apr CTEC
AT1	PACIFIC PHARMA	EQ 0.5% BASE	A074747	001	Mar 25, 1997	Apr CTEC
AT1	WOCKHARDT	EQ 0.5% BASE	A078771	002	Sep 28, 2009	Apr CTEC

TIMOPTIC

AT1	+ ATON	EQ 0.5% BASE	N018086	002		Apr CTEC
-----	--------	--------------	---------	-----	--	----------

TOBRAMYCIN

SOLUTION;INHALATION

KITABIS PAK

AN	PULMOFLOW INC	300MG/5ML	N205433	001	Dec 02, 2014	Feb CTEC
----	---------------	-----------	---------	-----	--------------	----------

SOLUTION/DROPS;OPHTHALMIC

TOBREX

AT	+ ALCON LABS INC	0.3%	N050541	001		Mar CAHN
----	------------------	------	---------	-----	--	----------

TOBRAMYCIN SULFATE

INJECTABLE;INJECTION

TOBRAMYCIN SULFATE

	@ IGI LABS INC	EQ 10MG BASE/ML	A063119	001	Oct 31, 1994	Mar CAHN
	@	EQ 40MG BASE/ML	A063120	001	Oct 31, 1994	Mar CAHN
	@	EQ 40MG BASE/ML	A063121	001	Oct 31, 1994	Mar CAHN
	@	EQ 40MG BASE/ML	A063122	001	Oct 31, 1994	Mar CAHN
AP	MYLAN PHARMS INC	EQ 40MG BASE/ML	A065407	001	Mar 11, 2008	Apr CAHN

TOLAZAMIDE

TABLET;ORAL

TOLAZAMIDE

@ G AND W LABS INC

@

@

@

100MG

250MG

500MG

N018894 001 Nov 02, 1984 Apr CAHN

N018894 002 Nov 02, 1984 Apr CAHN

N018894 003 Nov 02, 1984 Apr CAHN

TOLCAPONE

TABLET;ORAL

TASMAR

AB	+ VALEANT PHARMS LLC	100MG	N020697	001	Jan 29, 1998	Mar CFTG
----	----------------------	-------	---------	-----	--------------	----------

TOLCAPONE

AB	PAR PHARM INC	100MG	A204584	001	Mar 26, 2015	Mar NEWA
----	---------------	-------	---------	-----	--------------	----------

TOLMETIN SODIUM

TABLET;ORAL

TOLMETIN SODIUM

>A>	@ G AND W LABS INC	EQ 600MG BASE	A074399	001	Mar 28, 1996	May CAHN
-----	--------------------	---------------	---------	-----	--------------	----------

@

EQ 600MG BASE

A074729 001 Feb 27, 1997 Apr CAHN

>D>	@ IVAX SUB TEVA PHARMS	EQ 600MG BASE	A074399	001	Mar 28, 1996	May CAHN
-----	------------------------	---------------	---------	-----	--------------	----------

TOLTERODINE TARTRATE

TABLET;ORAL

TOLTERODINE TARTRATE

AB	IVAX SUB TEVA PHARMS	1MG	A077006	001	Feb 23, 2015	Feb NEWA
----	----------------------	-----	---------	-----	--------------	----------

AB		2MG	A077006	002	Feb 23, 2015	Feb NEWA
----	--	-----	---------	-----	--------------	----------

TOPIRAMATE

TABLET;ORAL

TOPIRAMATE

AB	SUN PHARM INDS LTD	25MG	A076327	001	Mar 27, 2009	Apr CAHN
----	--------------------	------	---------	-----	--------------	----------

AB		100MG	A076327	002	Mar 27, 2009	Apr CAHN
----	--	-------	---------	-----	--------------	----------

AB		200MG	A076327	003	Mar 27, 2009	Apr CAHN
----	--	-------	---------	-----	--------------	----------

@ WOCKHARDT USA

@

@

@

25MG

50MG

100MG

200MG

A090353 001 Sep 01, 2010 Apr DISC

A090353 002 Sep 01, 2010 Apr DISC

A090353 003 Sep 01, 2010 Apr DISC

A090353 004 Sep 01, 2010 Apr DISC

TOPIRAMATE

>D>	AB	HIKMA PHARMS	25MG	A091185	001	Nov 25, 2013	May DISC
-----	----	--------------	------	---------	-----	--------------	----------

>A>	@	25MG	A091185	001	Nov 25, 2013	May DISC
-----	---	------	---------	-----	--------------	----------

>D>	AB	50MG	A091185	002	Nov 25, 2013	May DISC
-----	----	------	---------	-----	--------------	----------

>A>	@	50MG	A091185	002	Nov 25, 2013	May DISC
-----	---	------	---------	-----	--------------	----------

>D>	AB	100MG	A091185	003	Nov 25, 2013	May DISC
-----	----	-------	---------	-----	--------------	----------

TABLET; ORAL									
TOPIRAMATE									
>A>	@	100MG	A091185	003	Nov 25, 2013	May	DISC		
>D>	AB	200MG	A091185	004	Nov 25, 2013	May	DISC		
>A>	@	200MG	A091185	004	Nov 25, 2013	May	DISC		
<u>TOPOTECAN HYDROCHLORIDE</u>									
CAPSULE; ORAL									
HYCAMTIN									
	NOVARTIS PHARMS CORP	EQ 0.25MG BASE	N020981	001	Oct 11, 2007	Mar	CAHN		
	+	EQ 1MG BASE	N020981	002	Oct 11, 2007	Mar	CAHN		
INJECTABLE; INJECTION									
HYCAMTIN									
AP	+	NOVARTIS PHARMS CORP	EQ 4MG BASE/VIAL	N020671	001	May 28, 1996	Mar	CAHN	
TOPOTECAN HYDROCHLORIDE									
>A>	AP	CHEM WERTH INC	EQ 4MG BASE/VIAL	A201166	001	Aug 08, 2012	May	CAHN	
>D>	AP	INNOPHARMA LICENSING	EQ 4MG BASE/VIAL	A201166	001	Aug 08, 2012	May	CAHN	
<u>TORSEMIDE</u>									
INJECTABLE; INJECTION									
TORSEMIDE									
	@ EUROHLTH INTL SARL	20MG/2ML (10MG/ML)	A078007	001	Jun 11, 2008	Jan	DISC		
	@	50MG/5ML (10MG/ML)	A078007	002	Jun 11, 2008	Jan	DISC		
	@ LUITPOLD	20MG/2ML (10MG/ML)	A090656	001	Apr 21, 2010	Jan	DISC		
	@	50MG/5ML (10MG/ML)	A090656	002	Apr 21, 2010	Jan	DISC		
<u>TRAMETINIB DIMETHYL SULFOXIDE</u>									
TABLET; ORAL									
MEKINIST									
	NOVARTIS PHARMS CORP	EQ 0.5MG NON-SOLVATED PARENT	N204114	001	May 29, 2013	Mar	CAHN		
		EQ 1MG NON-SOLVATED PARENT	N204114	002	May 29, 2013	Mar	CAHN		
	+	EQ 2MG NON-SOLVATED PARENT	N204114	003	May 29, 2013	Mar	CAHN		
<u>TRANEXAMIC ACID</u>									
INJECTABLE; INJECTION									
TRANEXAMIC ACID									
AP	FRESENIUS KABI USA	100MG/ML	A091596	001	Mar 02, 2012	Apr	CMFD		
<u>TRAZODONE HYDROCHLORIDE</u>									
TABLET; ORAL									
DESYREL									
>D>	@ APOTHECON	50MG	N018207	001		May	CAHN		
>D>	@	100MG	N018207	002		May	CAHN		
>D>	@	150MG	N018207	003	Mar 25, 1985	May	CAHN		
>D>	@	300MG	N018207	004	Nov 07, 1988	May	CAHN		
>A>	@ PRAGMA PHARMS LLC	50MG	N018207	001		May	CAHN		
>A>	@	100MG	N018207	002		May	CAHN		
>A>	@	150MG	N018207	003	Mar 25, 1985	May	CAHN		
>A>	@	300MG	N018207	004	Nov 07, 1988	May	CAHN		
TABLET, EXTENDED RELEASE; ORAL									
OLEPTRO									
	@ ANGELINI PHARMA	150MG	N022411	001	Feb 02, 2010	Mar	DISC		
	@	300MG	N022411	002	Feb 02, 2010	Mar	DISC		
<u>TRETINOLIN</u>									
CREAM; TOPICAL									
RENOVA									
	+	VALEANT PHARMS NORTH	0.02%	N021108	001	Aug 31, 2000	Apr	CAHN	
AB2	+		0.05%	N019963	001	Dec 29, 1995	Apr	CAHN	
RETIN-A									
AB	+	VALEANT PHARMS NORTH	0.1%	N017340	001		Apr	CAHN	
<u>TRIAMCINOLONE ACETONIDE</u>									
CREAM; TOPICAL									
TRIAMCINOLONE ACETONIDE									
AT	G AND W LABS	0.025%	A089797	001	May 31, 1991	Apr	CMFD		
AT		0.1%	A089798	001	May 31, 1991	Apr	CMFD		
TRIDERM									
AT	CROWN LABS	0.025%	A088042	002	Mar 25, 2015	Mar	NEWA		
AT		0.5%	A088042	003	Mar 25, 2015	Mar	NEWA		

LOTION;TOPICAL							
TRIAMCINOLONE ACETONIDE							
AT	G AND W LABS INC	0.1%	A089129	001	Aug 14, 1986	Mar	CMFD
OINTMENT;TOPICAL							
KENALOG							
AT	DELCOR ASSET CORP	0.025%	N011600	003		Mar	CMFD
AT		0.1%	N011600	001		Mar	CMFD
SPRAY;TOPICAL							
KENALOG							
AT	+ RANBAXY	0.147MG/GM	N012104	001		Mar	CFTG
TRIAMCINOLONE ACETONIDE							
AT	PERRIGO UK FINCO	0.147MG/GM	A205782	001	Apr 13, 2015	Mar	NEWA

TRIAMTERENECAPSULE;ORAL
DYRENIUM

	CONCORDIA PHARMS INC	50MG	N013174	001		Apr	CAHN
+		100MG	N013174	002		Apr	CAHN

TRIPTORELIN PAMOATEINJECTABLE;INTRAMUSCULAR
TRELSTAR

+	ACTAVIS LABS UT INC	EQ 3.75MG BASE/VIAL	N020715	001	Jun 15, 2000	Jan	CAHN
+		EQ 11.25MG BASE/VIAL	N021288	001	Jun 29, 2001	Jan	CAHN
+		EQ 22.5MG BASE/VIAL	N022437	001	Mar 10, 2010	Jan	CAHN

TROSPIMUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

>D>	SANCTURA XR						
>D> AB	+	ALLERGAN	60MG	N022103	001	Aug 03, 2007	May DISC
>A>	@		60MG	N022103	001	Aug 03, 2007	May DISC
TROSPIMUM CHLORIDE							
>D> AB		ACTAVIS LABS FL INC	60MG	A091289	001	Oct 12, 2012	May CRLD
>A> AB	+		60MG	A091289	001	Oct 12, 2012	May CRLD
AB		SANDOZ INC	60MG	A091635	001	Apr 29, 2015	Apr NEWA
TABLET;ORAL							
>D>	SANCTURA						
>D> AB	+	ALLERGAN	20MG	N021595	001	May 28, 2004	May DISC
>A>	@		20MG	N021595	001	May 28, 2004	May DISC
TROSPIMUM CHLORIDE							
>D> AB		GLENMARK GENERICS	20MG	A091575	001	Aug 13, 2010	May CRLD
>A> AB	+		20MG	A091575	001	Aug 13, 2010	May CRLD

UNOPROSTONE ISOPROPYLSOLUTION/DROPS;OPHTHALMIC
RESCULA

>A>	+	R-TECH UENO LTD	0.15%	N021214	001	Aug 03, 2000	May CAHN
>D>	+	SUCAMPO PHARMA LLC	0.15%	N021214	001	Aug 03, 2000	May CAHN
	+		0.15%	N021214	001	Aug 03, 2000	Jan CAHN

URSODIOLCAPSULE;ORAL
ACTIGALL

	@	ACTAVIS LABS UT INC	150MG	N019594	001	Dec 31, 1987	Mar CAHN
AB	+		300MG	N019594	002	Dec 31, 1987	Mar CAHN

VALACYCLOVIR HYDROCHLORIDE

TABLET;ORAL

VALACYCLOVIR HYDROCHLORIDE							
AB		HETERO LABS LTD V	EQ 1GM BASE	A203047	002	Apr 08, 2015	Mar NEWA
AB			EQ 500MG BASE	A203047	001	Apr 08, 2015	Mar NEWA
AB		SUN PHARM INDS LTD	EQ 1GM BASE	A076588	002	Jan 31, 2007	Apr CAHN
AB			EQ 500MG BASE	A076588	001	Jan 31, 2007	Apr CAHN

VALPROIC ACIDCAPSULE;ORAL
VALPROIC ACID

AB		BANNER LIFE SCIENCES	250MG	A073484	001	Jun 29, 1993	Jan CAHN
CAPSULE, DELAYED RELEASE;ORAL							
STAVZOR							
	@	BANNER LIFE SCIENCES	125MG	N022152	001	Jul 29, 2008	Jan CAHN

CAPSULE, DELAYED RELEASE;ORAL
STAVZOR

@	250MG	N022152	002	Jul 29, 2008	Jan CAHN
@	500MG	N022152	003	Jul 29, 2008	Jan CAHN

VALSARTANTABLET;ORAL
VALSARTAN

>A>	AB	PRINSTON INC	40MG	A204821	001	Jun 09, 2015	May NEWA
>A>	AB		80MG	A204821	002	Jun 09, 2015	May NEWA
>A>	AB		160MG	A204821	003	Jun 09, 2015	May NEWA
>A>	AB		320MG	A204821	004	Jun 09, 2015	May NEWA

VANCOMYCIN HYDROCHLORIDECAPSULE;ORAL
VANCOMYCIN HYDROCHLORIDE

AB	LUPIN LTD	EQ 125MG BASE	A090439	001	Jan 28, 2015	Jan NEWA
AB		EQ 250MG BASE	A090439	002	Jan 28, 2015	Jan NEWA

INJECTABLE;INJECTION
VANCOMYCIN HYDROCHLORIDE

>D>	AP	AGILA SPECLTS	EQ 10GM BASE/VIAL	A091554	001	Sep 19, 2011	May CAHN
	AP	MYLAN PHARMS INC	EQ 1GM BASE/VIAL	A065397	002	Dec 30, 2008	Apr CAHN
>A>	AP		EQ 10GM BASE/VIAL	A091554	001	Sep 19, 2011	May CAHN
	AP		EQ 500MG BASE/VIAL	A065397	001	Dec 30, 2008	Apr CAHN

VARDENAFIL HYDROCHLORIDETABLET, ORALLY DISINTEGRATING;ORAL
STAXYN

AB	+	BAYER HLTHCARE	10MG	N200179	001	Jun 17, 2010	Apr CFTG
		VARDENAFIL HYDROCHLORIDE					
AB		WATSON LABS INC	10MG	A203689	001	Apr 22, 2015	Apr NEWA

VECURONIUM BROMIDEINJECTABLE;INJECTION
VECURONIUM BROMIDE

AP	MYLAN PHARMS INC	10MG/VIAL	A090243	001	May 11, 2010	Apr CAHN
AP		20MG/VIAL	A090243	002	May 11, 2010	Apr CAHN

VENLAFAXINE HYDROCHLORIDECAPSULE, EXTENDED RELEASE;ORAL
VENLAFAXINE HYDROCHLORIDE

AB	VALEANT PHARMS NORTH	EQ 37.5MG BASE	A090071	001	Apr 15, 2011	Feb CAHN
AB		EQ 75MG BASE	A090071	002	Apr 15, 2011	Feb CAHN
AB		EQ 150MG BASE	A090071	003	Apr 15, 2011	Feb CAHN

TABLET;ORAL

VENLAFAXINE HYDROCHLORIDE

>A>	AB	YAOPHARMA CO LTD	EQ 25MG BASE	A202036	001	May 28, 2015	May NEWA
>A>	AB		EQ 37.5MG BASE	A202036	002	May 28, 2015	May NEWA
>A>	AB		EQ 50MG BASE	A202036	003	May 28, 2015	May NEWA
>A>	AB		EQ 75MG BASE	A202036	004	May 28, 2015	May NEWA
>A>	AB		EQ 100MG BASE	A202036	005	May 28, 2015	May NEWA

VERAPAMIL HYDROCHLORIDECAPSULE, EXTENDED RELEASE;ORAL
VERELAN

AB	RECRO GAINESVILLE	120MG	N019614	001	May 29, 1990	Apr CAHN
AB		180MG	N019614	003	Jan 09, 1992	Apr CAHN
AB		240MG	N019614	002	May 29, 1990	Apr CAHN
	+	360MG	N019614	004	May 10, 1996	Apr CAHN

VERELAN PM

AB	RECRO GAINESVILLE	100MG	N020943	001	Nov 25, 1998	Apr CAHN
AB		200MG	N020943	002	Nov 25, 1998	Apr CAHN
AB	+	300MG	N020943	003	Nov 25, 1998	Apr CAHN

INJECTABLE;INJECTION

ISOPTIN

@	MT ADAMS	2.5MG/ML	N018485	001		Apr CAHN
---	----------	----------	---------	-----	--	----------

TABLET;ORAL

ISOPTIN

@	MT ADAMS	40MG	N018593	003	Nov 23, 1987	Apr CAHN
@		80MG	N018593	001	Mar 08, 1982	Apr CAHN
@		120MG	N018593	002	Mar 08, 1982	Apr CAHN

VERTEPORFININJECTABLE;INJECTION
VISUDYNE

+	VALEANT LUXEMBOURG	15MG/VIAL	N021119	001	Apr 12, 2000	Mar CAHN
---	--------------------	-----------	---------	-----	--------------	----------

VILAZODONE HYDROCHLORIDETABLET;ORAL
VIIBRYD

+	FOREST LABS LLC	10MG	N022567	001	Jan 21, 2011	Mar CAHN
		20MG	N022567	002	Jan 21, 2011	Mar CAHN
		40MG	N022567	003	Jan 21, 2011	Mar CAHN

ZAFIRLUKASTTABLET;ORAL
ACCOLATE

AB	PAR PHARM INC	10MG	N020547	003	Sep 17, 1999	Feb CAHN
AB	+	20MG	N020547	001	Sep 26, 1996	Feb CAHN

ZOLEDRONIC ACIDINJECTABLE;IV (INFUSION)
ZOLEDRONIC ACID

AP	FRESENIUS KABI USA	EQ 4MG BASE/5ML	A091516	001	Apr 23, 2015	Apr NEWA
AP	HOSPIRA INC	EQ 4MG BASE/5ML	A090621	001	Mar 19, 2015	Mar NEWA
AP	USV NORTH AMERICA	EQ 4MG BASE/5ML	A202923	001	Sep 04, 2014	Mar CPOT

ZOLPIDEM TARTRATE

TABLET;ORAL

ZOLPIDEM TARTRATE

	@ HIKMA	5MG	A078129	001	Apr 30, 2008	Mar DISC
	@	10MG	A078129	002	Apr 30, 2008	Mar DISC
AB	SUN PHARM INDS LTD	5MG	A078055	001	Apr 23, 2007	Apr CAHN
AB		10MG	A078055	002	Apr 23, 2007	Apr CAHN

TABLET;SUBLINGUAL
INTERMEZZO

>D>	PURDUE PHARMA	1.75MG	N022328	001	Nov 23, 2011	May CFTG
>A> AB		1.75MG	N022328	001	Nov 23, 2011	May CFTG
>D>	+	3.5MG	N022328	002	Nov 23, 2011	May CFTG
>A> AB	+	3.5MG	N022328	002	Nov 23, 2011	May CFTG
>A>	ZOLPIDEM TARTRATE					
>A> AB	NOVEL LABS INC	1.75MG	A204299	001	Jun 03, 2015	May NEWA
>A> AB		3.5MG	A204299	002	Jun 03, 2015	May NEWA

ZONISAMIDECAPSULE;ORAL
ZONISAMIDE

AB	BANNER LIFE SCIENCES	25MG	A077813	001	Aug 16, 2006	Jan CAHN
AB		50MG	A077813	002	Aug 16, 2006	Jan CAHN
AB		100MG	A077813	003	Aug 16, 2006	Jan CAHN

ACETAMINOPHEN

TABLET, EXTENDED RELEASE;ORAL
ACETAMINOPHEN

SUN PHARM INDS LTD 650MG
@ 650MG

A078569 001 Dec 14, 2011 Apr CAHN
A090205 001 Nov 18, 2009 Apr CAHN

AVOBENZONE; OCTINOXATE; OXYBENZONE

LOTION;TOPICAL
SHADE UVAGUARD

+ BAYER HEALTHCARE LLC 3%;7.5%;3%

N020045 001 Dec 07, 1992 Mar CAHN

BUDESONIDE

SPRAY, METERED;NASAL
RHINOCORT ALLERGY

+ ASTRAZENECA PHARMS 0.032MG/SPRAY

N020746 003 Mar 23, 2015 Mar NEWA

BUTENAFINE HYDROCHLORIDE

CREAM;TOPICAL
LOTRIMIN ULTRA

+ BAYER HEALTHCARE LLC 1%

N021307 001 Dec 07, 2001 Mar CAHN

CETIRIZINE HYDROCHLORIDE

CAPSULE;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

BANNER LIFE SCIENCES 5MG

N022429 001 Jul 23, 2009 Jan CAHN

+ 10MG

N022429 004 Jul 23, 2009 Jan CAHN

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

BANNER LIFE SCIENCES 5MG

N022429 003 Jul 23, 2009 Jan CAHN

+ 10MG

N022429 002 Jul 23, 2009 Jan CAHN

TABLET;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

SUN PHARM INDS LTD 5MG

A077498 001 Dec 27, 2007 Apr CAHN

10MG

A077498 002 Dec 27, 2007 Apr CAHN

CETIRIZINE HYDROCHLORIDE HIVES

SUN PHARM INDS LTD 5MG

A077498 003 Dec 27, 2007 Apr CAHN

10MG

A077498 004 Dec 27, 2007 Apr CAHN

TABLET, CHEWABLE;ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

JUBILANT GENERICS 5MG

A091116 001 Feb 19, 2015 Feb NEWA

10MG

A091116 002 Feb 19, 2015 Feb NEWA

SANDOZ 5MG

A078692 001 Feb 14, 2008 Feb CTNA

+ 10MG

A078692 002 Feb 14, 2008 Feb CTNA

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

JUBILANT GENERICS 5MG

A091116 003 Feb 19, 2015 Feb NEWA

10MG

A091116 004 Feb 19, 2015 Feb NEWA

CHLORPHENIRAMINE MALEATE

TABLET, EXTENDED RELEASE;ORAL
CHLOR-TRIMETON

@ BAYER HEALTHCARE LLC 8MG

N007638 001 Mar CAHN

+ 12MG

N007638 002 Mar CAHN

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL
CHLOR-TRIMETON

+ BAYER HEALTHCARE LLC 8MG;120MG

N018397 001 Mar CAHN

CLOTRIMAZOLE

CREAM;VAGINAL
GYNE-LOTRIMIN

+ BAYER HEALTHCARE LLC 1%

N018052 002 Nov 30, 1990 Mar CAHN

GYNE-LOTRIMIN 3

+ BAYER HEALTHCARE LLC 2%

N020574 001 Nov 24, 1998 Mar CAHN

CREAM, TABLET;TOPICAL, VAGINAL

GYNE-LOTRIMIN COMBINATION PACK

+ BAYER HEALTHCARE LLC 1%,100MG

N020289 002 Apr 26, 1993 Mar CAHN

TABLET;VAGINAL

GYNE-LOTRIMIN

+ BAYER HEALTHCARE LLC 100MG

N017717 002 Nov 30, 1990 Mar CAHN

DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN

CAPSULE;ORAL

IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE

BANNER LIFE SCIENCES 25MG;EQ 200MG FREE ACID AND
POTASSIUM SALT

A090397 001 Nov 22, 2010 Jan CAHN

FAMOTIDINE

TABLET;ORAL

FAMOTIDINE

SUN PHARM INDS LTD 10MG
20MG

A090283 001 Nov 17, 2009 Apr CAHN

A090283 002 Nov 17, 2009 Apr CAHN

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

SUN PHARMA GLOBAL 60MG;120MG

A090818 001 Jan 29, 2015 Jan NEWA

GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE

ACTAVIS LABS FL INC 600MG;60MG
1.2GM;120MG

A091071 001 May 27, 2015 May NEWA

A091071 002 May 27, 2015 May NEWA

IBUPROFEN

CAPSULE;ORAL

IBUPROFEN

BANNER LIFE SCIENCES EQ 200MG FREE ACID AND POTASSIUM
SALT

A078682 001 Mar 24, 2009 Jan CAHN

MIDOL LIQUID GELS

+ BANNER LIFE SCIENCES 200MG

N021472 001 Oct 18, 2002 Jan CAHN

KETOTIFEN FUMARATE

SOLUTION/DROPS;OPHTHALMIC

ALAWAY

BAUSCH AND LOMB EQ 0.035% BASE

N021996 002 Feb 11, 2015 Feb NEWA

LEVONORGESTREL

TABLET;ORAL

LEVONORGESTREL

LOTUS PHARM CO LTD 1.5MG
OC PHARMA 1.5MG

A202246 001 Jun 05, 2015 May NEWA

A202380 001 May 29, 2015 May NEWA

LOPERAMIDE HYDROCHLORIDE

CAPSULE;ORAL

LOPERAMIDE HYDROCHLORIDE

BANNER LIFE SCIENCES 1MG
+ 2MG

N021855 001 Aug 04, 2005 Jan CAHN

N021855 002 Aug 04, 2005 Jan CAHN

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET;ORAL

LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE

SUN PHARM INDS LTD 2MG;125MG

A077500 001 Sep 06, 2006 Apr CAHN

LORATADINE

CAPSULE;ORAL

CLARITIN

+ BAYER HEALTHCARE LLC 10MG

N021952 001 Jun 16, 2008 Mar CAHN

SYRUP;ORAL

CLARITIN

+ BAYER HEALTHCARE LLC 1MG/ML

N020641 002 Nov 27, 2002 Mar CAHN

CLARITIN HIVES RELIEF

@ BAYER HEALTHCARE LLC 1MG/ML

N020641 003 Nov 19, 2003 Mar CAHN

TABLET;ORAL

LORATADINE

SUN PHARM INDS LTD 10MG

A076134 001 Aug 18, 2003 Apr CAHN

TABLET, CHEWABLE;ORAL

CHILDREN'S CLARITIN

+ BAYER HEALTHCARE LLC 5MG

N021891 001 Aug 23, 2006 Mar CAHN

TABLET, ORALLY DISINTEGRATING;ORAL									
CLARITIN REDITABS									
+	BAYER HEALTHCARE LLC	5MG			N021993	001	Dec 12, 2006	Mar	CAHN
LORATADINE REDIDOSE									
	SUN PHARM INDS LTD	10MG			A077153	001	Apr 11, 2007	Apr	CAHN
<u>LORATADINE; PSEUDOEPHEDRINE SULFATE</u>									
TABLET, EXTENDED RELEASE;ORAL									
CLARITIN-D									
+	BAYER HEALTHCARE LLC	5MG;120MG			N019670	002	Nov 27, 2002	Mar	CAHN
CLARITIN-D 24 HOUR									
+	BAYER HEALTHCARE LLC	10MG;240MG			N020470	002	Nov 27, 2002	Mar	CAHN
LORATADINE AND PSEUDOEPHEDRINE SULFATE									
	SUN PHARM INDS LTD	10MG;240MG			A076557	001	Sep 22, 2004	Apr	CAHN
<u>NAPROXEN SODIUM</u>									
CAPSULE;ORAL									
NAPROXEN SODIUM									
+	BANNER LIFE SCIENCES	EQ 200MG BASE			N021920	001	Feb 17, 2006	Jan	CAHN
	CATALENT	EQ 200MG BASE			A202807	001	Feb 13, 2015	Feb	NEWA
TABLET;ORAL									
NAPROXEN SODIUM									
	SUN PHARM INDS LTD	EQ 200MG BASE			A091183	001	May 20, 2011	Apr	CAHN
<u>NICOTINE POLACRILEX</u>									
GUM, CHEWING;BUCCAL									
NICOTINE POLACRILEX									
@	IVAX SUB TEVA PHARMS	EQ 2MG BASE			A076880	001	Feb 18, 2009	Mar	DISC
@		EQ 4MG BASE			A077850	001	Feb 18, 2009	Mar	DISC
<u>OMEPRAZOLE; SODIUM BICARBONATE</u>									
CAPSULE;ORAL									
ZEGERID OTC									
+	BAYER HEALTHCARE LLC	20MG;1.1GM			N022281	001	Dec 01, 2009	Mar	CAHN
FOR SUSPENSION;ORAL									
ZEGERID OTC									
+	BAYER HEALTHCARE LLC	20MG/PACKET;1.68GM/PACKET			N022283	001	Jun 17, 2013	Mar	CAHN
<u>OXYMETAZOLINE HYDROCHLORIDE</u>									
SOLUTION/DROPS;OPHTHALMIC									
OCUCLEAR									
	BAYER HEALTHCARE LLC	0.025%			N018471	001	May 30, 1986	Mar	CAHN
<u>POLYETHYLENE GLYCOL 3350</u>									
FOR SOLUTION;ORAL									
MIRALAX									
+	BAYER HEALTHCARE LLC	17GM/SCOOPFUL			N022015	001	Oct 06, 2006	Mar	CAHN
POLYETHYLENE GLYCOL 3350									
	RARITAN PHARMS INC	17GM/SCOOPFUL			A202071	001	Dec 28, 2012	Jan	CAHN
<u>PSEUDOEPHEDRINE HYDROCHLORIDE</u>									
TABLET, EXTENDED RELEASE;ORAL									
PSEUDOEPHEDRINE HYDROCHLORIDE									
	SUN PHARM INDS LTD	120MG			A077442	001	Sep 28, 2005	Apr	CAHN
<u>RANITIDINE HYDROCHLORIDE</u>									
TABLET;ORAL									
RANITIDINE HYDROCHLORIDE									
@	SUN PHARM INDS LTD	EQ 75MG BASE			A075132	001	Jan 14, 2000	Apr	CAHN
@	WOCKHARDT	EQ 75MG BASE			A078884	001	Jul 31, 2008	Jan	DISC

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 5 MAY 2015

NO MAY 2015 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO MAY 2015 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABACAVIR SULFATE - ZIAGEN</u>						
N 020977 001					D-147	Mar 23, 2018
<u>ABACAVIR SULFATE - ZIAGEN</u>						
N 020978 001					D-147	Mar 23, 2018
<u>ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE - TRIUMEQ</u>						
N 205551 001	6417191	Mar 28, 2016	DP U-1572			
	6417191*PED	Sep 28, 2016				
<u>ABACAVIR SULFATE; LAMIVUDINE - EPZICOM</u>						
N 021652 001	6417191	Mar 28, 2016	DP U-257			
	6417191*PED	Sep 28, 2016				
<u>ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE - XARTEMIS XR</u>						
N 204031 001	8980319	Dec 21, 2030	DP			
	8992975	May 16, 2032	DP			
<u>ACYCLOVIR; HYDROCORTISONE - XERESE</u>						
N 022436 001	7223387	Jul 24, 2021	DP U-1006			
	7223387	Jul 24, 2021	DP U-1484			
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO</u>						
N 022320 001	8936800	Dec 23, 2022	DP U-1078			
<u>ALBUTEROL SULFATE - PROAIR RESPICLICK</u>						
N 205636 001	6446627	Dec 18, 2017	DP		NP	Mar 12, 2018
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
<u>ALVIMOPAN - ENTEREG</u>						
N 021775 001	8946262	Feb 12, 2030	U-1655			
<u>APREMILAST - OTEZLA</u>						
N 205437 001	>A> 9018243	Mar 19, 2023	U-1505			
	>A> 9018243	Mar 19, 2023	U-1595			
<u>APREMILAST - OTEZLA</u>						
N 205437 002	>A> 9018243	Mar 19, 2023	U-1505			
	>A> 9018243	Mar 19, 2023	U-1595			
<u>APREMILAST - OTEZLA</u>						
N 205437 003	>A> 9018243	Mar 19, 2023	U-1505			
	>A> 9018243	Mar 19, 2023	U-1595			
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021436 001					ODE	Dec 12, 2021
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021436 002					ODE	Dec 12, 2021
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021436 003					ODE	Dec 12, 2021
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021436 004					ODE	Dec 12, 2021
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021436 005					ODE	Dec 12, 2021
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021436 006					ODE	Dec 12, 2021
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021713 001	5006528	Oct 20, 2014	DS DP U-543		ODE	Dec 12, 2021
	5006528	Oct 20, 2014	DS DP U-761			
	5006528*PED	Apr 20, 2015				
	6977257	Apr 24, 2022	DP			
	6977257*PED	Oct 24, 2022				
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021729 002					ODE	Dec 12, 2021

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPRAZOLE - ABILIFY</u>						
N 021729 003					ODE	Dec 12, 2021
<u>ARIPRAZOLE - ABILIFY</u>						
N 021729 004					ODE	Dec 12, 2021
<u>ARIPRAZOLE - ABILIFY</u>						
N 021729 005					ODE	Dec 12, 2021
<u>ARIPRAZOLE - ABILIFY</u>						
N 021866 001	5006528	Oct 20, 2014	DS DP U-543		ODE	Dec 12, 2021
	5006528	Oct 20, 2014	DS DP U-763			
	5006528*PED	Apr 20, 2015				
<u>ARIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 001	5006528	Oct 20, 2014	DS DP U-543			
	5006528	Oct 20, 2014	DS DP U-1632			
	5006528*PED	Apr 20, 2015				
	8030313	Oct 19, 2024	U-543			
	8030313	Oct 19, 2024	U-1632			
	8338427	Mar 15, 2025	DP U-543			
	8338427	Mar 15, 2025	DP U-1633			
	8338428	Aug 06, 2023	DP U-543			
	8338428	Aug 06, 2023	DP U-1633			
	8399469	Jun 29, 2025	DS			
	8759351	Aug 06, 2023	DP U-1530			
	8759351	Aug 06, 2023	DP U-1633			
	8993761	Sep 25, 2022	DS			
<u>ARIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 002	5006528	Oct 20, 2014	DS DP U-543			
	5006528	Oct 20, 2014	DS DP U-1632			
	5006528*PED	Apr 20, 2015				
	8030313	Oct 19, 2024	U-543			
	8030313	Oct 19, 2024	U-1632			
	8338427	Mar 15, 2025	DP U-543			
	8338427	Mar 15, 2025	DP U-1633			
	8338428	Aug 06, 2023	DP U-543			
	8338428	Aug 06, 2023	DP U-1633			
	8399469	Jun 29, 2025	DS			
	8759351	Aug 06, 2023	DP U-1530			
	8759351	Aug 06, 2023	DP U-1633			
	8993761	Sep 25, 2022	DS			
<u>ARIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 003	5006528	Oct 20, 2014	DS DP U-543			
	5006528	Oct 20, 2014	DS DP U-1632			
	5006528*PED	Apr 20, 2015				
	8030313	Oct 19, 2024	U-543			
	8030313	Oct 19, 2024	U-1632			
	8338427	Mar 15, 2025	DP U-543			
	8338427	Mar 15, 2025	DP U-1633			
	8338428	Aug 06, 2023	DP U-543			
	8338428	Aug 06, 2023	DP U-1633			
	8399469	Jun 29, 2025	DS			
	8759351	Aug 06, 2023	DP U-1530			
	8759351	Aug 06, 2023	DP U-1633			
	8993761	Sep 25, 2022	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 004	5006528	Oct 20, 2014	DS DP U-543			
	5006528	Oct 20, 2014	DS DP U-1632			
	5006528*PED	Apr 20, 2015				
	8030313	Oct 19, 2024	U-543			
	8030313	Oct 19, 2024	U-1632			
	8338427	Mar 15, 2025	DP U-543			
	8338427	Mar 15, 2025	DP U-1633			
	8338428	Aug 06, 2023	DP U-543			
	8338428	Aug 06, 2023	DP U-1633			
	8399469	Jun 29, 2025	DS			
	8759351	Aug 06, 2023	DP U-1530			
	8759351	Aug 06, 2023	DP U-1633			
	8993761	Sep 25, 2022	DS			
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 001	5763476	Jun 09, 2020	DP U-326		M-158	Mar 17, 2018
	5763476*PED	Dec 09, 2020			NPP	Mar 17, 2018
	7741358	Apr 06, 2026	DS DP U-1064		PED	Sep 17, 2018
	7741358*PED	Oct 06, 2026			PED	Sep 17, 2018
	8022228	Apr 06, 2026	DS DP			
	8022228*PED	Oct 06, 2026				
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 002	5763476	Jun 09, 2020	DP U-326		M-158	Mar 17, 2018
	5763476*PED	Dec 09, 2020			NPP	Mar 17, 2018
	7741358	Apr 06, 2026	DS DP U-1064		PED	Sep 17, 2018
	7741358*PED	Oct 06, 2026			PED	Sep 17, 2018
	8022228	Apr 06, 2026	DS DP			
	8022228*PED	Oct 06, 2026				
<u>ATAZANAVIR SULFATE; COBICISTAT - EVOTAZ</u>						
N 206353 001	5849911	Jun 20, 2017	DS DP U-167			
	6087383	Dec 21, 2018	DS DP			
	8148374	Sep 03, 2029	DS DP U-1279			
<u>AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ</u>						
N 206494 001	7112592	Feb 24, 2022	DS DP U-282			
	7612087	Nov 12, 2026	DP			
	8178554	Jul 24, 2021	DS DP U-282			
	8471025	Aug 12, 2031	DS			
	8835455	Oct 08, 2030	DP			
	8969566	Jun 15, 2032	DS			
<u>AZELASTINE HYDROCHLORIDE - ASTEPRO</u>						
N 022203 001					NPP	Feb 20, 2018
					NPP	Feb 20, 2018
<u>AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE - DYMISTA</u>						
N 202236 001	8163723	Aug 29, 2023	U-77		NPP	Feb 20, 2018
	8163723	Aug 29, 2023	U-81			
	8163723	Aug 29, 2023	U-644			
	8163723	Aug 29, 2023	U-707			
	8163723	Aug 29, 2023	U-1667			
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ACANYA</u>						
N 050819 001 >A>	8895070	Jun 03, 2029	U-124			
<u>BESIFLOXACIN HYDROCHLORIDE - BESIVANCE</u>						
N 022308 001	8937062	Nov 13, 2029	U-80			
<u>BIMATOPROST - LUMIGAN</u>						
N 022184 001	8933120	Mar 16, 2025	DP			
	8933127	Mar 16, 2025	DP			
<u>BIMATOPROST - LATISSE</u>						
N 022369 001	7351404	May 25, 2024	U-939	Y		
	7388029	Jan 21, 2022	U-938	Y		
	8541466	Jan 31, 2021	U-1217			
	8986715	Jan 15, 2023	U-1217			
<u>BRIMONIDINE TARTRATE; BRINZOLAMIDE - SIMBRINZA</u>						
N 204251 001 >A>	9044484	Oct 30, 2030	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUDESONIDE - UCERIS</u>						
N 205613 001	5914122	Dec 19, 2015	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 001	8470361	May 22, 2030	DP U-1425			
	8940330	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 002	8470361	May 22, 2030	DP U-1425			
	8940330	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 003	8470361	May 22, 2030	DP U-1425			
	8940330	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 004	8470361	May 22, 2030	DP U-1425			
	8940330	Sep 18, 2032	DP			
<u>BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE - CONTRAVE</u>						
N 200063 001	8916195	Feb 02, 2030	U-1639			
<u>CALCIUM ACETATE - PHOSLO GELCAPS</u>						
N 021160 003	6875445	Jul 30, 2021	DP			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 001	7094427	May 29, 2022	DP U-1645		NDF	Jan 07, 2018
	8377474	Dec 26, 2028	DP U-219			
	8377474	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-219			
	8454998	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-1646			
	8454998	Dec 26, 2028	DP U-1647			
	8454998	Dec 26, 2028	DP U-1649			
	8557283	Dec 26, 2028	DP U-219			
	8557283	Dec 26, 2028	DP U-1645			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 002	7094427	May 29, 2022	DP U-1645		NDF	Jan 07, 2018
	8377474	Dec 26, 2028	DP U-219			
	8377474	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-219			
	8454998	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-1646			
	8454998	Dec 26, 2028	DP U-1647			
	8454998	Dec 26, 2028	DP U-1649			
	8557283	Dec 26, 2028	DP U-219			
	8557283	Dec 26, 2028	DP U-1645			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 003	7094427	May 29, 2022	DP U-1645		NDF	Jan 07, 2018
	8377474	Dec 26, 2028	DP U-219			
	8377474	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-219			
	8454998	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-1646			
	8454998	Dec 26, 2028	DP U-1647			
	8454998	Dec 26, 2028	DP U-1649			
	8557283	Dec 26, 2028	DP U-219			
	8557283	Dec 26, 2028	DP U-1645			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 004	7094427	May 29, 2022	DP U-1645		NDF	Jan 07, 2018
	8377474	Dec 26, 2028	DP U-219			
	8377474	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-219			
	8454998	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-1646			
	8454998	Dec 26, 2028	DP U-1647			
	8454998	Dec 26, 2028	DP U-1649			
	8557283	Dec 26, 2028	DP U-219			
	8557283	Dec 26, 2028	DP U-1645			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CARBIDOPA; LEVODOPA - DUOPA</u>						
N 203952 001					NP ODE	Jan 09, 2018 Jan 09, 2022
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327 001	6417175	Apr 11, 2022	DS DP U-1676			
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327 002	6417175	Apr 11, 2022	DS DP U-1676			
<u>CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA</u>						
N 206829 001	8968753	Mar 14, 2034	U-1672			
	8968753	Mar 14, 2034	U-1673			
<u>CELECOXIB - CELECOXIB</u>						
A 076898 002					PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 076898 003					PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 076898 004					PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 078857 002					PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 078857 003					PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 078857 004					PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 200562 002					PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 200562 003					PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 200562 004					PC	Jun 02, 2015
<u>CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX - TUZISTRA XR</u>						
N 207768 001	8062667	Mar 29, 2029	DP			
	8790700	Mar 15, 2027	DP			
<u>CHOLIC ACID - CHOLBAM</u>						
N 205750 001					ODE	Mar 17, 2022
<u>CHOLIC ACID - CHOLBAM</u>						
N 205750 002					ODE	Mar 17, 2022
<u>CICLESONIDE - ALVESCO</u>						
N 021658 002	8371292	Feb 01, 2028	U-1355			
<u>CICLESONIDE - ALVESCO</u>						
N 021658 003	8371292	Feb 01, 2028	U-1355			
<u>CICLESONIDE - OMNARIS</u>						
N 022004 001	8371292	Feb 01, 2028	U-1356			
<u>CICLESONIDE - ZETONNA</u>						
N 202129 001	8371292	Feb 01, 2028	U-1357			
<u>CLOBETASOL PROPIONATE - CLOBETASOL PROPIONATE</u>						
A 090898 001					PC	Jul 01, 2015
<u>CLOBETASOL PROPIONATE - OLUX E</u>						
N 022013 001	8962000	Aug 31, 2025	DP U-1410			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>COBICISTAT; DARUNAVIR ETHANOLATE - PREZCOBIX</u>						
N 205395 001	5843946	Dec 01, 2015	DP U-1660			
	5843946*PED	Jun 01, 2016				
	7470506	Jun 23, 2019	U-1660			
	7470506*PED	Dec 23, 2019				
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				
	8148374	Sep 03, 2029	DS DP U-1660			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
	8597876	Jun 23, 2019	U-1660			
	8597876*PED	Dec 23, 2019				
	RE42889	Oct 19, 2016	DP			
	RE42889*PED	Apr 19, 2017				
	RE43596	May 09, 2017	DS DP			
	RE43596*PED	Nov 09, 2017				
	RE43802	Oct 19, 2016	U-1660			
	RE43802*PED	Apr 19, 2017				
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD</u>						
N 203100 001	8981103	Oct 26, 2026	DS DP		I-704	Dec 17, 2017
<u>COLCHICINE - MITIGARE</u>						
N 204820 001	8927607	Aug 22, 2033	U-1020			
<u>CRIZOTINIB - XALKORI</u>						
N 202570 001	7230098	Aug 26, 2025	DS			
<u>CRIZOTINIB - XALKORI</u>						
N 202570 002	7230098	Aug 26, 2025	DS			
<u>CROFELEMER - FULYZAQ</u>						
N 202292 001	8962680	Oct 31, 2031	U-1319			
<u>CYANOCOBALAMIN - NASCOBAL</u>						
N 021642 001	7229636	Aug 01, 2024	DP U-817			
	7879349	Aug 01, 2024	DP U-1152			
	8003353	Aug 01, 2024	U-817			
	8940714	Feb 26, 2024	U-1152			
<u>DANTROLENE SODIUM - RYANODEX</u>						
N 205579 001					ODE	Jul 22, 2021
<u>DAPAGLIFLOZIN PROPANEDIOL - FARXIGA</u>						
N 202293 001					M-157	Mar 11, 2018
<u>DAPAGLIFLOZIN PROPANEDIOL - FARXIGA</u>						
N 202293 002					M-157	Mar 11, 2018
<u>DASABUVIR SODIUM ; OMBITASVIR; PARITAPREVR; RITONAVIR - VIEKIRA PAK (COPACKAGED)</u>						
N 206619 001	6037157	Jun 26, 2016	U-1635			
	6703403	Jun 26, 2016	U-1635			
	7148359	Jul 19, 2019	DP			
	7364752	Nov 10, 2020	DP			
	8188104	May 17, 2029	DS DP U-1636			
	8268349	Aug 25, 2024	DP			
	8399015	Aug 25, 2024	DP			
	8420596	Apr 10, 2031	DS DP			
	8466159	Sep 04, 2032	U-1637			
	8492386	Sep 04, 2032	U-1637			
	8501238	Sep 17, 2028	DS DP U-1636			
	8642538	Sep 10, 2029	DS DP U-1638			
	8680106	Sep 04, 2032	U-1637			
	8685984	Sep 04, 2032	U-1637			
	8686026	Jun 09, 2031	DP			
	8691938	Apr 13, 2032	DS DP			
	9006387	Jun 10, 2030	U-1687			
<u>DEFERASIROX - EXJADE</u>						
N 021882 001					ODE	Jan 23, 2020
<u>DEFERASIROX - EXJADE</u>						
N 021882 002					ODE	Jan 23, 2020

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEFERASIROX - EXJADE</u>						
N 021882 003					ODE	Jan 23, 2020
<u>DEFERASIROX - JADENU</u>						
N 206910 001	6465504	Apr 05, 2019	DS DP			
	6596750	Jun 24, 2017	DS	U-735		
<u>DEFERASIROX - JADENU</u>						
N 206910 002	6465504	Apr 05, 2019	DS DP			
	6596750	Jun 24, 2017	DS	U-735		
<u>DEFERASIROX - JADENU</u>						
N 206910 003	6465504	Apr 05, 2019	DS DP			
	6596750	Jun 24, 2017	DS	U-735		
<u>DEOXYCHOLIC ACID - KYBELLA</u>						
N 206333 001	7622130	Dec 10, 2027		U-1690		
	7754230	Dec 10, 2027		U-1690		
	8101593	Mar 02, 2030		DP		
	8242294	May 16, 2028	DS			
	8298556	Aug 03, 2025		U-1690		
	8367649	Mar 02, 2030		DP		
	8461140	Feb 21, 2028		DP		
>A>	8546367	Feb 21, 2028		DP U-1690		
	8653058	Mar 02, 2030		DP		
	8846066	Feb 08, 2025		U-1690		
>A>	8883770	Feb 21, 2028		DP		
<u>DESMOPRESSIN ACETATE - DESMOPRESSIN ACETATE</u>						
A 200653 001					PC	May 16, 2015
<u>DESMOPRESSIN ACETATE - DESMOPRESSIN ACETATE</u>						
A 200653 002					PC	May 16, 2015
<u>DESONIDE - VERDESO</u>						
N 021978 001	8962000	Aug 31, 2025	DP	U-1412		
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N 021992 003	6673838	Mar 01, 2022	DS	U-860		
	6673838	Mar 01, 2022	DS	U-1364		
	8269040	Jul 05, 2027	DS			
<u>DEXAMETHASONE - OZURDEX</u>						
N 022315 001	8043628	Oct 20, 2020		U-1205		
	8088407	Oct 20, 2020		U-1205		
>A>	9012437	Oct 20, 2020		U-1205		
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 001	9011926	Feb 24, 2026		DP		
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 002	>A> 8784885	Oct 15, 2023		DP U-1552		
	>A> 8784885	Oct 15, 2023		DP U-1553		
	>A> 8784885	Oct 15, 2023		DP U-1554		
	>A> 8784885*PED	Apr 15, 2024				
	9011926	Feb 24, 2026		DP		
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 004	6716867	Mar 31, 2019		U-1472		
	6716867*PED	Oct 01, 2019				
	8242158	Jan 04, 2032		DP		
	8242158*PED	Jul 04, 2032				
	8338470	Jan 04, 2032		DP		
	8338470*PED	Jul 04, 2032				
	8455527	Jan 04, 2032		U-421		
	8455527*PED	Jul 04, 2032				
	8648106	Jan 04, 2032		DP		
	8648106*PED	Jul 04, 2032				
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - DEXMETHYLPHENIDATE HYDROCHLORIDE</u>						
A 078908 002					PC	Aug 01, 2015
<u>DICLOFENAC - ZORVOLEX</u>						
N 204592 001	8999387	Apr 23, 2030		U-55		
	9017721	Apr 23, 2030		DP		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DICLOFENAC - ZORVOLEX</u>						
N 204592 002	8999387	Apr 23, 2030	U-55			
	9017721	Apr 23, 2030	DP			
<u>DICLOFENAC POTASSIUM - CAMBIA</u>						
N 022165 001	8927604	Jun 16, 2026	U-436			
<u>DICLOFENAC SODIUM - DYLOJECT</u>						
N 022396 001	6407079	Jun 18, 2019	DP			
	8946292	Mar 22, 2027	U-1659			
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 001	5061703	Apr 11, 2015	U-1641			
	5061703*PED	Oct 11, 2015				
	8058291	Dec 05, 2029	U-1641			
	8168209	Nov 22, 2025	DP			
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-1641			
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-1641			
	8283379*PED	May 22, 2026				
	8293794	Nov 22, 2025	DP			
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 002	5061703	Apr 11, 2015	U-1641			
	5061703*PED	Oct 11, 2015				
	8039009	Mar 24, 2029	U-1641			
	8039009*PED	Sep 24, 2029				
	8058291	Dec 05, 2029	U-1641			
	8168209	Nov 22, 2025	DP			
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-1641			
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-1641			
	8283379*PED	May 22, 2026				
	8293794	Nov 22, 2025	DP			
	8329752	Nov 22, 2025	DP			
	8329752*PED	May 22, 2026				
	8338485	Nov 22, 2025	DP			
	8338486	Nov 22, 2025	U-1641			
	8362085	Nov 22, 2025	U-1641			
	8362085*PED	May 22, 2026				
	8580858	Nov 22, 2025	U-1641			
	8598233	Nov 22, 2025	DP			
	8598233*PED	May 22, 2026				
<u>DOXYCYCLINE HYCLATE - DOXTERIC</u>						
N 050795 006	6958161	Dec 15, 2022	DP U-918			
	8715724	Feb 03, 2028	DP			
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 001	7365205	Jun 12, 2023	DS		NCE	Jan 08, 2020
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 002	7365205	Jun 12, 2023	DS		NCE	Jan 08, 2020
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 003	7365205	Jun 12, 2023	DS		NCE	Jan 08, 2020
<u>EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA</u>						
N 021937 001	>A> 9018192	Jun 13, 2026	U-750			
	>A> 9018192	Jun 13, 2026	U-1170			
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 001					>A> NCE	May 27, 2020
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 002					>A> NCE	May 27, 2020
<u>ELVITEGRAVIR - VITEKTA</u>						
N 203093 001	8981103	Oct 26, 2026	DS DP			
<u>ELVITEGRAVIR - VITEKTA</u>						
N 203093 002	8981103	Oct 26, 2026	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 001	6303661	Apr 24, 2017	U-1651		NC	Jan 30, 2018
	6890898	Feb 02, 2019	U-1652		NCE	May 02, 2016
	7078381	Feb 02, 2019	U-1651		NCE	Aug 01, 2019
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019	U-1651			
	7579449	Nov 05, 2025	DS			
	7713938	Apr 15, 2027	DS DP			
	8119648	Aug 12, 2023	U-1651			
	8178541	Aug 12, 2023	DP U-1653			
	8178541	Aug 12, 2023	DP U-1654			
	8551957	Oct 19, 2029	DP U-1651			
	8673927	May 04, 2027	DP U-1652			
	8846695	Jun 04, 2030	U-1652			
	8883805	Nov 26, 2025	DP			
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 002	6303661	Apr 24, 2017	U-1651		NC	Jan 30, 2018
	6890898	Feb 02, 2019	U-1652		NCE	May 02, 2016
	7078381	Feb 02, 2019	U-1651		NCE	Aug 01, 2019
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019	U-1651			
	7579449	Nov 05, 2025	DS			
	7713938	Apr 15, 2027	DS DP			
	8119648	Aug 12, 2023	U-1651			
	8178541	Aug 12, 2023	DP U-1653			
	8178541	Aug 12, 2023	DP U-1654			
	8551957	Oct 19, 2029	DP U-1651			
	8673927	May 04, 2024	DP U-1652			
	8846695	Jun 04, 2030	U-1652			
	8883805	Nov 26, 2025	DP			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 001	8920377	Nov 23, 2024	DP			
	8926594	Mar 31, 2026	DP			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 002	8920377	Nov 23, 2024	DP			
	8926594	Mar 31, 2026	DP			
<u>ERIBULIN MESYLATE - HALAVEN</u>						
N 201532 001	6214865	Jul 20, 2023	DS			
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 001	5747498	Nov 08, 2018	DS DP U-659		I-671	May 14, 2016
	5747498*PED	May 08, 2019			PED	Nov 14, 2016
	6900221	Nov 09, 2020	DS DP U-659			
	6900221	Nov 09, 2020	DS DP U-875			
	6900221	Nov 09, 2020	DS DP U-1046			
	6900221	Nov 09, 2020	DS DP U-1403			
	6900221*PED	May 09, 2021				
	7087613	Nov 09, 2020	U-659			
	7087613	Nov 09, 2020	U-1045			
	7087613	Nov 09, 2020	U-1403			
	7087613*PED	May 09, 2021				
	RE41065	Nov 08, 2018	DS DP			
	RE41065*PED	May 08, 2019				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 002	5747498	Nov 08, 2018	DS DP U-659		I-671	May 14, 2016
	5747498*PED	May 08, 2019			PED	Nov 14, 2016
	6900221	Nov 09, 2020	DS DP U-659			
	6900221	Nov 09, 2020	DS DP U-875			
	6900221	Nov 09, 2020	DS DP U-1046			
	6900221	Nov 09, 2020	DS DP U-1403			
	6900221*PED	May 09, 2021				
	7087613	Nov 09, 2020	U-659			
	7087613	Nov 09, 2020	U-1045			
	7087613	Nov 09, 2020	U-1403			
	7087613*PED	May 09, 2021				
	RE41065	Nov 08, 2018	DS DP			
	RE41065*PED	May 08, 2019				
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 003	5747498	Nov 08, 2018	DS DP U-659		I-671	May 14, 2016
	5747498*PED	May 08, 2019			PED	Nov 14, 2016
	6900221	Nov 09, 2020	DS DP U-659			
	6900221	Nov 09, 2020	DS DP U-875			
	6900221	Nov 09, 2020	DS DP U-1046			
	6900221	Nov 09, 2020	DS DP U-1403			
	6900221*PED	May 09, 2021				
	7087613	Nov 09, 2020	U-659			
	7087613	Nov 09, 2020	U-1045			
	7087613	Nov 09, 2020	U-1403			
	7087613*PED	May 09, 2021				
	RE41065	Nov 08, 2018	DS DP			
	RE41065*PED	May 08, 2019				
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM 24HR</u>						
N 204655 001	5690960	Nov 25, 2014	DP U-1509			
	5690960*PED	May 25, 2015				
	5714504	Feb 03, 2015	DP U-1509			
	5714504*PED	Aug 03, 2015				
	5877192*PED	Nov 27, 2014				
	5900424	May 04, 2016	DS U-1509			
	5900424*PED	Nov 04, 2016				
	6369085	May 25, 2018	DS DP U-1509			
	6369085*PED	Nov 25, 2018				
	6428810	Nov 03, 2019	DP U-1509			
	6428810*PED	May 03, 2020				
	6875872*PED	Nov 27, 2014				
	7411070	May 25, 2018	DS			
	7411070*PED	Nov 25, 2018				
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511 001	8945621	Oct 17, 2031	U-1661			
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511 002	8945621	Oct 17, 2031	U-1661			
<u>ESTRADIOL - MINIVELLE</u>						
N 203752 005	6841716	Apr 27, 2020	DP			
	8231906	Jul 04, 2030	DS DP			
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 001	9006224	Jul 01, 2028	U-1681			
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 002	9006224	Jul 01, 2028	U-1681			
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 003	9006224	Jul 01, 2028	U-1681			
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 004	9006224	Jul 01, 2028	U-1681			
<u>FERRIC CITRATE - AURYXIA</u>						
N 205874 001	8901349	Feb 18, 2024	U-1577			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FERRIC PYROPHOSPHATE CITRATE - TRIFERIC</u>						
N 206317 001	6689275	Dec 31, 2016	U-1656			
	6779468	Dec 31, 2016	U-1656			
	7816404	Apr 17, 2029	DP U-1656			
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY</u>						
N 201373 001	8933097	Aug 16, 2032	DP			
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA HIVES</u>						
N 201373 002	8933097	Aug 16, 2032	DP			
<u>FINAFLOXACIN - XTORO</u>						
N 206307 001	6133260	Apr 12, 2017	DS DP			
	6432948	Apr 12, 2017	DS DP			
	8536167	Aug 08, 2031	U-1679			
<u>FLUTEMETAMOL F-18 - VIZAMYL</u>						
N 203137 001	8916131	Sep 16, 2028	DP			
<u>FLUTEMETAMOL F-18 - VIZAMYL</u>						
N 203137 002	8916131	Sep 16, 2028	DP			
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 001	6537983	Aug 03, 2021	DP U-1401		I-708	Apr 30, 2018
	6537983	Aug 03, 2021	DP U-1691			
	6759398	Aug 03, 2021	DP U-1401			
	6759398	Aug 03, 2021	DP U-1691			
	7101866	Aug 03, 2021	DS DP U-1401			
	7101866	Aug 03, 2021	DS DP U-1691			
	7439393	Sep 11, 2022	DS DP U-1401			
	7439393	Sep 11, 2022	DS DP U-1691			
	>A> 8511304	Jun 14, 2027	DP U-1424			
	>A> 8511304	Jun 14, 2027	DP U-1691			
	RE44874	Mar 23, 2023	DS DP U-1548			
	RE44874	Mar 23, 2023	DS DP U-1691			
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 002	5873360	Feb 23, 2016	DP		NP	Apr 30, 2018
	6537983	Aug 03, 2021	DP U-1691			
	6759398	Aug 03, 2021	DP U-1691			
	7101866	Aug 03, 2021	DS DP U-1691			
	7439393	Sep 11, 2022	DS DP U-1691			
	7629335	Aug 03, 2021	DP			
	7776895	Sep 11, 2022	DP			
	8113199	Oct 23, 2027	DP			
	8161968	Feb 05, 2028	DP			
	>A> 8511304	Jun 14, 2027	DP U-1691			
	8534281	Aug 10, 2029	DP			
	8746242	Oct 11, 2030	DP			
	RE44874	Mar 23, 2023	DS DP U-1691			
<u>FLUTICASONE PROPIONATE - CUTIVATE</u>						
N 021152 001					NPP	Jan 16, 2018
<u>GADOXETATE DISODIUM - EOVIIST</u>						
N 022090 001					M-155	Mar 27, 2018
<u>GADOXETATE DISODIUM - EOVIIST</u>						
N 022090 002					M-155	Mar 27, 2018
<u>GLATIRAMER ACETATE - COPAXONE</u>						
N 020622 003	8969302	Aug 19, 2030	U-441			
<u>GUANFACINE HYDROCHLORIDE - GUANFACINE HYDROCHLORIDE</u>						
A 200881 001					PC	May 30, 2015
<u>GUANFACINE HYDROCHLORIDE - GUANFACINE HYDROCHLORIDE</u>						
A 200881 002					PC	May 30, 2015
<u>GUANFACINE HYDROCHLORIDE - GUANFACINE HYDROCHLORIDE</u>						
A 200881 003					PC	May 30, 2015
<u>GUANFACINE HYDROCHLORIDE - GUANFACINE HYDROCHLORIDE</u>						
A 200881 004					PC	May 30, 2015
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037 001					M-154	Mar 18, 2018

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037 002					M-154	Mar 18, 2018
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037 003					M-154	Mar 18, 2018
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037 004					M-154	Mar 18, 2018
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 001 >A>	9023401	Oct 30, 2021	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 002 >A>	9023401	Oct 30, 2021	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 003 >A>	9023401	Oct 30, 2021	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 004 >A>	9023401	Oct 30, 2021	DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	8497277	Dec 28, 2026		U-1456	I-702	Jan 29, 2018
	8497277	Dec 28, 2026		U-1491	ODE	Jan 29, 2022
	8497277	Dec 28, 2026		U-1650		
	8957079	Dec 28, 2026	DS DP			
	8999999	Jun 03, 2031		U-1683		
	8999999	Jun 03, 2031		U-1684		
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 002	8871810	Sep 30, 2029		U-1599		
	9012508	Sep 14, 2030		U-981		
<u>IDELALISIB - ZYDELIG</u>						
N 205858 001	8980901	May 12, 2025		U-1678		
<u>IDELALISIB - ZYDELIG</u>						
N 205858 002	8980901	May 12, 2025		U-1678		
<u>ILOPERIDONE - FANAPT</u>						
N 022192 001	8652776	Aug 31, 2030		U-1685		
	8999638	Oct 28, 2030		U-1674		
<u>ILOPERIDONE - FANAPT</u>						
N 022192 002	8652776	Aug 31, 2030		U-1685		
	8999638	Oct 28, 2030		U-1674		
<u>ILOPERIDONE - FANAPT</u>						
N 022192 003	8652776	Aug 31, 2030		U-1685		
	8999638	Oct 28, 2030		U-1674		
<u>ILOPERIDONE - FANAPT</u>						
N 022192 004	8652776	Aug 31, 2030		U-1685		
	8999638	Oct 28, 2030		U-1674		
<u>ILOPERIDONE - FANAPT</u>						
N 022192 005	8652776	Aug 31, 2030		U-1685		
	8999638	Oct 28, 2030		U-1674		
<u>ILOPERIDONE - FANAPT</u>						
N 022192 006	8652776	Aug 31, 2030		U-1685		
	8999638	Oct 28, 2030		U-1674		
<u>ILOPERIDONE - FANAPT</u>						
N 022192 007	8652776	Aug 31, 2030		U-1685		
	8999638	Oct 28, 2030		U-1674		
<u>INDOMETHACIN - TIVORBEX</u>						
N 204768 001	8992982	Apr 23, 2030	DP			
<u>INDOMETHACIN - TIVORBEX</u>						
N 204768 002	8992982	Apr 23, 2030	DP			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG FLEXTOUCH</u>						
N 020986 005	8920383	Jul 17, 2026	DP			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXTOUCH</u>						
N 021536 005	8920383	Jul 17, 2026	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN GLARGINE RECOMBINANT - LANTUS SOLOSTAR</u>						
N 021081 002	8992486	Jun 05, 2024	DP			
	9011391	Mar 26, 2024	DP			
<u>INSULIN GLARGINE RECOMBINANT - TOUJEO SOLOSTAR</u>						
N 206538 001	7918833	Sep 23, 2027	DP		NP	Feb 25, 2018
	7918833*PED	Mar 23, 2028				
	8512297	Sep 15, 2024	DP			
	8556864	Mar 03, 2024	DP			
	8603044	Mar 02, 2024	DP			
	8679069	Apr 12, 2025	DP			
	8992486	Jun 05, 2024	DP			
	9011391	Mar 26, 2024	DP			
<u>INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR</u>						
N 021629 003	8992486	Jun 05, 2024	DP			
	9011391	Mar 26, 2024	DP			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 003	>A> 6444226	Jun 29, 2020	DP U-1534		>A> NP	Jun 27, 2017
	>A> 6652885	Jun 29, 2020	U-1535			
	>A> 7305986	Jan 16, 2023	DP			
	>A> 7464706	Mar 02, 2023	DP			
	>A> 7648960	Jun 29, 2020	U-1535			
	>A> 7943178	Jun 29, 2020	DP U-1535			
	>A> 7943572	Aug 10, 2026	U-1539			
	>A> 8119593	Aug 11, 2029	U-1537			
	>A> 8146588	Apr 24, 2023	DP			
	>A> 8156936	Jan 16, 2023	DP			
	>A> 8215300	Nov 24, 2022	DP			
	>A> 8258095	Aug 11, 2029	U-1537			
	>A> 8389470	Jun 29, 2020	DP U-1697			
	>A> 8394414	May 15, 2015	DP U-1533			
	>A> 8424518	Oct 17, 2031	DP			
	>A> 8485180	Mar 25, 2030	DP			
	>A> 8499757	Feb 19, 2032	DP			
	>A> 8551528	Jun 11, 2030	DP			
	>A> 8623817	Sep 18, 2029	U-1537			
	>A> 8636001	Jul 12, 2032	DP			
	>A> 8729019	Jun 06, 2028	DP			
	>A> 8734845	Jun 11, 2030	DP			
	>A> 8778403	Jun 11, 2030	DP U-1538			
	>A> 8889099	Jun 29, 2020	DP U-1621			
<u>IOFLUPANE I-123 - DATSCAN</u>						
N 022454 001	5310912	Feb 25, 2016	DS			
<u>IPRATROPIUM BROMIDE - ATROVENT HFA</u>						
N 021527 001	>A> 8474447	Jan 17, 2030	DP			
<u>ISAVUCONAZONIUM SULFATE - CRESEMBA</u>						
N 207500 001	6812238	Oct 31, 2020	DS		NCE	Mar 06, 2020
	7459561	Oct 31, 2020	DS		>A> ODE	Mar 06, 2022
					GAIN	Mar 06, 2025
<u>ISAVUCONAZONIUM SULFATE - CRESEMBA</u>						
N 207501 001	6812238	Oct 31, 2020	DS		NCE	Mar 06, 2020
	7459561	Oct 31, 2020	DS		>A> ODE	Mar 06, 2022
					GAIN	Mar 06, 2025
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 001	8952064	Sep 21, 2021	DP			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 002	8952064	Sep 21, 2021	DP			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 003	8952064	Sep 21, 2021	DP			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 004	8952064	Sep 21, 2021	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 005	7435427	Sep 21, 2021	DP			
	8367102	Sep 21, 2021	U-1347			
	8952064	Sep 21, 2021	DP			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 006	7435427	Sep 21, 2021	DP			
	8367102	Sep 21, 2021	U-1347			
	8952064	Sep 21, 2021	DP			
<u>IVABRADINE HYDROCHLORIDE - CORLANOR</u>						
N 206143 001	7361649	Apr 17, 2026	DS DP U-1694		NCE	Apr 15, 2020
	7361650	Apr 14, 2026	DS DP U-1694			
	7867996	Feb 22, 2026	DS DP U-1694			
	7879842	Feb 22, 2026	DS DP U-1694			
<u>IVABRADINE HYDROCHLORIDE - CORLANOR</u>						
N 206143 002	7361649	Apr 17, 2026	DS DP U-1694		NCE	Apr 15, 2020
	7361650	Apr 14, 2026	DS DP U-1694			
	7867996	Feb 22, 2026	DS DP U-1694			
	7879842	Feb 22, 2026	DS DP U-1694			
<u>IVACAFTOR - KALYDECO</u>						
N 203188 001	8354427	Jul 06, 2026	U-1311		I-705	Dec 30, 2017
<u>IVACAFTOR - KALYDECO</u>						
N 207925 001	7495103	May 20, 2027	DS DP			
	8324242	Apr 18, 2027	U-1311			
	8354427	Jul 06, 2026	U-1311			
	8410274	Dec 28, 2026	DP			
	8754224	Dec 28, 2026	DS DP			
	8883206	Feb 27, 2033	DP			
<u>IVACAFTOR - KALYDECO</u>						
N 207925 002	7495103	May 20, 2027	DS DP			
	8324242	Apr 18, 2027	U-1311			
	8354427	Jul 06, 2026	U-1311			
	8410274	Dec 28, 2026	DP			
	8754224	Dec 28, 2026	DS DP			
	8883206	Feb 27, 2033	DP			
<u>IVERMECTIN - SOOLANTRA</u>						
N 206255 001	5952372	Sep 18, 2018	U-1631			
	6133310	Apr 26, 2019	U-1631			
	7550440	Apr 22, 2024	DP U-1631			
	8080530	Apr 22, 2024	DP U-1631			
	8093219	Apr 22, 2024	DP U-1631			
	8415311	Apr 22, 2024	DP U-1631			
	8470788	Apr 22, 2024	DP U-1631			
	8815816	Apr 22, 2024	DP U-1631			
<u>KETOROLAC TROMETHAMINE - ACULAR LS</u>						
N 021528 001	8946281	May 28, 2024	U-1662			
<u>KETOROLAC TROMETHAMINE - ACUVAIL</u>						
N 022427 001	8992952	Aug 05, 2024	DP			
<u>LAMIVUDINE - LAMIVUDINE</u>						
A 203564 001					PC	Sep 01, 2015
<u>LAMIVUDINE - EPIVIR</u>						
N 020564 001	5905082	May 18, 2016	DS DP		D-147	Mar 23, 2018
	5905082*PED	Nov 18, 2016				
<u>LAMIVUDINE - EPIVIR</u>						
N 020564 003	5905082	May 18, 2016	DS DP		D-147	Mar 23, 2018
	5905082*PED	Nov 18, 2016				
<u>LAMIVUDINE - EPIVIR</u>						
N 020596 001	5905082	May 18, 2016	DS DP		D-147	Mar 23, 2018
	6004968	Mar 20, 2018	DP U-248			
	6004968*PED	Sep 20, 2018				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LAMIVUDINE; RALTEGRAVIR POTASSIUM - DUTREBIS</u>						
N 206510 001	7169780	Oct 03, 2023	DS DP			
	7217713	Oct 21, 2022		U-1663		
	7435734	Oct 21, 2022		U-1663		
	7754731	Mar 11, 2029	DS DP	U-1663		
	7820660	Apr 25, 2023	DS			
<u>LAMOTRIGINE - LAMOTRIGINE</u>						
A 200828 001					PC	Sep 28, 2015
<u>LAMOTRIGINE - LAMOTRIGINE</u>						
A 200828 002					PC	Sep 28, 2015
<u>LAMOTRIGINE - LAMOTRIGINE</u>						
A 200828 003					PC	Sep 28, 2015
<u>LAMOTRIGINE - LAMOTRIGINE</u>						
A 200828 004					PC	Sep 28, 2015
<u>LAMOTRIGINE - LAMICTAL</u>						
N 020241 001					>A> M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL</u>						
N 020241 002					>A> M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL</u>						
N 020241 003					>A> M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL</u>						
N 020241 004					>A> M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL</u>						
N 020241 005					>A> M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL</u>						
N 020241 006					>A> M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL CD</u>						
N 020764 001					>A> M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL CD</u>						
N 020764 002					>A> M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL CD</u>						
N 020764 003					>A> M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL CD</u>						
N 020764 004					>A> M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 001					>A> M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 002					>A> M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 003					>A> M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 004					>A> M-159	May 18, 2018
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N 204734 001	8980327	Dec 01, 2030	DP			
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N 204734 002	8980327	Dec 01, 2030	DP			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 001					I-706 ODE	Feb 17, 2018 Feb 17, 2022
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 002					I-706 ODE	Feb 17, 2018 Feb 17, 2022
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 003					I-706 ODE	Feb 17, 2018 Feb 17, 2022
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 004					I-706 ODE	Feb 17, 2018 Feb 17, 2022

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 005					I-706 ODE	Feb 17, 2018 Feb 17, 2022
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 006	5635517	Oct 04, 2019	DS U-1211		I-706 ODE	Feb 17, 2018 Feb 17, 2022
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 001	7253286	Oct 19, 2021	DS DP		NCE	Feb 13, 2020
	7612208	Sep 19, 2026	DS DP		ODE	Feb 13, 2022
	9006256	Jul 27, 2027	U-1695			
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 002	7253286	Oct 19, 2021	DS DP		NCE	Feb 13, 2020
	7612208	Sep 19, 2026	DS DP		ODE	Feb 13, 2022
	9006256	Jul 27, 2027	U-1695			
<u>LEUPROLIDE ACETATE - LUPRON DEPOT</u>						
N 020517 003	7429559	Jan 13, 2019	DP			
	8815801	Jun 28, 2022	DP			
	8921326	Feb 05, 2031	DP U-1666			
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N 020837 001					M-151	Jan 22, 2018
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N 020837 002					M-151	Jan 22, 2018
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N 020837 003					M-151	Jan 22, 2018
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N 020837 004					M-151	Jan 22, 2018
<u>LEVALBUTEROL TARTRATE - XOPENEX HFA</u>						
N 021730 001					M-156	Mar 12, 2018
<u>LEVETIRACETAM - ELEPSIA XR</u>						
N 204417 001	8163306	Sep 03, 2027	DP			
	8425938	Feb 22, 2026	DP			
	8431156	Oct 31, 2027	DP			
	8470367	Jun 30, 2024	DP			
	8535717	Feb 22, 2026	DP			
<u>LEVETIRACETAM - ELEPSIA XR</u>						
N 204417 002	8163306	Sep 03, 2027	DP			
	8425938	Feb 22, 2026	DP			
	8431156	Oct 31, 2027	DP			
	8470367	Jun 30, 2024	DP			
	8535717	Feb 22, 2026	DP			
<u>LEVOLEUCOVORIN CALCIUM - LEVOLEUCOVORIN CALCIUM</u>						
A 203563 001					PC	Oct 20, 2015
<u>LEVOLEUCOVORIN CALCIUM - LEVOLEUCOVORIN CALCIUM</u>						
A 203563 002					PC	Oct 20, 2015
<u>LEVONORGESTREL - LILETTA</u>						
N 206229 001					NP	Feb 26, 2018
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 202231 001	9006289	Oct 03, 2032	DP			
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 202231 002	9006289	Oct 03, 2032	DP			
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 202231 003	9006289	Oct 03, 2032	DP			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 001	8933030	Feb 17, 2031	DP			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 002	8933030	Feb 17, 2031	DP			
<u>LINAGLIPTIN - TRADJENTA</u>						
N 201280 001	8673927	May 04, 2027	U-1503			
	8853156	Mar 05, 2031	U-1642			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 001	8673927	May 04, 2027	U-1503			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 002	8673927	May 04, 2027	U-1503			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 003	8673927	May 04, 2027	U-1503			
<u>LINEZOLID - LINEZOLID</u>						
A 200222 001					>A> PC	Jul 04, 2015
<u>LIRAGLUTIDE RECOMBINANT - VICTOZA</u>						
N 022341 001	8846618	Jun 27, 2022	DP			
<u>LIRAGLUTIDE RECOMBINANT - SAXENDA</u>						
N 206321 001	6268343	Aug 22, 2022	DS DP U-1255			
	6458924	Aug 22, 2017	DS DP U-1255			
	6899699	Jan 01, 2022	DP			
	7235627	Aug 22, 2017	DS DP			
	7686786	Aug 03, 2026	DP			
	8114833	Aug 13, 2025	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8846618	Jun 27, 2022	DP			
	8920383	Jul 17, 2026	DP			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 001					I-703	Jan 30, 2018
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 002					I-703	Jan 30, 2018
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 003					I-703	Jan 30, 2018
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 004					I-703	Jan 30, 2018
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 005					I-703	Jan 30, 2018
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 006					I-703	Jan 30, 2018
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 007					I-703	Jan 30, 2018
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 001	5712279	Feb 21, 2016	DS U-1317			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 002	5712279	Feb 21, 2016	DS U-1317			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 003	5712279	Feb 21, 2016	DS U-1317			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 004	>A> 5712279	Feb 21, 2016	DS U-1317		>A> NCE	Dec 21, 2017
	>A> 6492365	Dec 10, 2019	U-1318		>A> ODE	Dec 21, 2019
	>A> 7932268	Aug 19, 2027	U-1316			
	>A> 8618135	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 005	>A> 5712279	Feb 21, 2016	DS U-1317		>A> NCE	Dec 21, 2017
	>A> 6492365	Dec 10, 2019	U-1318		>A> ODE	Dec 21, 2019
	>A> 7932268	Aug 19, 2027	U-1316			
	>A> 8618135	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 006	>A> 5712279	Feb 21, 2016	DS U-1317		>A> NCE	Dec 21, 2017
	>A> 6492365	Dec 10, 2019	U-1318		>A> ODE	Dec 21, 2019
	>A> 7932268	Aug 19, 2027	U-1316			
	>A> 8618135	Mar 07, 2025	U-1316			
<u>LORATADINE - CLARITIN</u>						
N 020641 002	>A> 6132758	Jun 01, 2018	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LORCASERIN HYDROCHLORIDE - BELVIO</u>						
N 022529 001	8946207	Jun 16, 2024	DP			
	8980881	Dec 20, 2025	U-1252			
	8980881	Dec 20, 2025	U-1253			
	8980881	Dec 20, 2025	U-1254			
	8980881	Dec 20, 2025	U-1255			
	8999970	Feb 07, 2033	U-1688			
	8999970	Feb 07, 2033	U-1689			
	8999970	Feb 07, 2033	U-1692			
<u>LOXAPINE - ADASUVE</u>						
N 022549 001	8955512	Oct 26, 2021	DP			
	8991387	May 21, 2024	DP			
<u>LULICONAZOLE - LUZU</u>						
N 204153 001	8980931	Apr 28, 2034	DP			
	9012484	Sep 06, 2033	DS DP U-540			
<u>MESALAMINE - APRISO</u>						
N 022301 001	8940328	Apr 20, 2018	DP			
	8956647	Apr 20, 2018	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 001	8945063	Mar 19, 2030	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 002	8945063	Mar 19, 2030	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 003	8945063	Mar 19, 2030	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 004	8945063	Mar 19, 2030	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 005	8945063	Mar 19, 2030	DP U-1442			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 001 >A>	9034370	Oct 07, 2025	DP			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 002 >A>	9034370	Oct 07, 2025	DP			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 003 >A>	9034370	Oct 07, 2025	DP			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 004 >A>	9034370	Oct 07, 2025	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 001	9000038	Jul 31, 2017	U-666			
	9000038	Jul 31, 2017	U-1693			
	9000038*PED	Jan 31, 2018				
>A>	9029416	Jul 31, 2017	DP U-666			
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 002	9000038	Jul 31, 2017	U-666			
	9000038	Jul 31, 2017	U-1693			
	9000038*PED	Jan 31, 2018				
>A>	9029416	Jul 31, 2017	DP U-666			
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 003	9000038	Jul 31, 2017	U-666			
	9000038	Jul 31, 2017	U-1693			
	9000038*PED	Jan 31, 2018				
>A>	9029416	Jul 31, 2017	DP U-666			
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 004	9000038	Jul 31, 2017	U-666			
	9000038	Jul 31, 2017	U-1693			
	9000038*PED	Jan 31, 2018				
>A>	9029416	Jul 31, 2017	DP U-666			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLIVANT XR</u>						
N 202100 001	8956649	Feb 15, 2031	DP U-1665			
>A>	9040083	Feb 15, 2031	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 001	>A> 6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	>A> 7083808	Dec 16, 2019	DP			
	>A> 7247318	Dec 16, 2019	DP			
	>A> 7438930	Dec 16, 2019	DP			
	>A> 8580310	Apr 12, 2022	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 002	>A> 6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	>A> 7083808	Dec 16, 2019	DP			
	>A> 7247318	Dec 16, 2019	DP			
	>A> 7438930	Dec 16, 2019	DP			
	>A> 8580310	Apr 12, 2022	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 003	>A> 6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	>A> 7083808	Dec 16, 2019	DP			
	>A> 7247318	Dec 16, 2019	DP			
	>A> 7438930	Dec 16, 2019	DP			
	>A> 8580310	Apr 12, 2022	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 004	>A> 6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	>A> 7083808	Dec 16, 2019	DP			
	>A> 7247318	Dec 16, 2019	DP			
	>A> 7438930	Dec 16, 2019	DP			
	>A> 8580310	Apr 12, 2022	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 005	>A> 6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	>A> 7083808	Dec 16, 2019	DP			
	>A> 7247318	Dec 16, 2019	DP			
	>A> 7438930	Dec 16, 2019	DP			
	>A> 8580310	Apr 12, 2022	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 006	>A> 6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	>A> 7083808	Dec 16, 2019	DP			
	>A> 7247318	Dec 16, 2019	DP			
	>A> 7438930	Dec 16, 2019	DP			
	>A> 8580310	Apr 12, 2022	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 007	>A> 6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	>A> 7083808	Dec 16, 2019	DP			
	>A> 7247318	Dec 16, 2019	DP			
	>A> 7438930	Dec 16, 2019	DP			
	>A> 8580310	Apr 12, 2022	DP			
<u>METRONIDAZOLE - NUVESSA</u>						
N 205223 001	7893097	Feb 19, 2028	DP			
	8658678	Jun 27, 2028		U-1682		
	8877792	Feb 02, 2028	DP			
	8946276	Jun 28, 2032		U-1664		
<u>MIFEPRISTONE - KORLYM</u>						
N 202107 001	8921348	Aug 27, 2028		U-1643		
<u>MINOCYCLINE HYDROCHLORIDE - ARESTIN</u>						
N 050781 001	7699609	Mar 29, 2022	DP			
<u>MINOXIDIL - WOMEN'S ROGAINE</u>						
N 021812 002	6946120	Apr 20, 2019	DP	U-702		
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 001	8623418	Nov 07, 2029		U-1640		
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 002	8623418	Nov 07, 2029		U-1640		
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 003	8623418	Nov 07, 2029		U-1640		
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 004	8623418	Nov 07, 2029		U-1640		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 005	8623418	Nov 07, 2029	U-1640			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 006	8623418	Nov 07, 2029	U-1640			
<u>NALOXEGOL OXALATE - MOVANTIK</u>						
N 204760 001	>A> 7056500	Jun 29, 2024	DP U-1185			
	>A> 9012469	Apr 02, 2032	DS DP			
<u>NALOXEGOL OXALATE - MOVANTIK</u>						
N 204760 002	>A> 7056500	Jun 29, 2024	DP U-1185			
	>A> 9012469	Apr 02, 2032	DS DP			
<u>NALOXONE HYDROCHLORIDE - EVZIO</u>						
N 205787 001	8926594	Mar 31, 2026	DP			
	8939943	Feb 28, 2031	DP			
	>A> 9022022	Feb 28, 2031	DP			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIO</u>						
N 205777 001	8969369	May 10, 2022	DP U-1556			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIO</u>						
N 205777 002	8969369	May 10, 2022	DP U-1556			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIO</u>						
N 205777 003	8969369	May 10, 2022	DP U-1556			
<u>NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE - TREXIMET</u>						
N 021926 001	6060499	Aug 14, 2017	DP U-867			
	6060499*PED	Feb 14, 2018				
	6586458	Aug 14, 2017	DP U-867			
	6586458*PED	Feb 14, 2018				
	7332183	Oct 02, 2025	DP U-867			
	7332183*PED	Apr 02, 2026				
	8022095	Aug 14, 2017	DP U-867			
	8022095*PED	Feb 14, 2018				
<u>NEPAFENAC - ILEVRO</u>						
N 203491 001	>A> 8921337	Mar 31, 2032	DP			
<u>NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 205718 001	8951969	Nov 18, 2030	DP			
<u>NICOTINE - NICODERM CO</u>						
N 020165 004	8999379	Feb 13, 2020	U-1686			
<u>NICOTINE - NICODERM CO</u>						
N 020165 005	8999379	Feb 13, 2020	U-1686			
<u>NICOTINE - NICODERM CO</u>						
N 020165 006	8999379	Feb 13, 2020	U-1686			
<u>NICOTINE POLACRILEX - NICORETTE</u>						
N 022360 001	8940772	Apr 30, 2029	DP			
<u>NICOTINE POLACRILEX - NICORETTE</u>						
N 022360 002	8940772	Apr 30, 2029	DP			
<u>NINTEDANIB ESYLATE - OFEV</u>						
N 205832 001	7989474	Apr 06, 2024	U-1677			
<u>NINTEDANIB ESYLATE - OFEV</u>						
N 205832 002	7989474	Apr 06, 2024	U-1677			
<u>OLAPARIB - LYNPARZA</u>						
N 206162 001	7151102	Apr 29, 2022	DS DP		ODE	Dec 19, 2021
	7449464	Oct 11, 2024	DS DP			
	7981889	Oct 11, 2024	DS DP			
	8143241	Aug 12, 2027	U-1634			
	8247416	Sep 24, 2028	DS			
	8859562	Aug 04, 2031	U-1634			
	8912187	Mar 12, 2024	U-1634			
<u>OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - STIOLTO RESPIMAT</u>						
N 206756 001				>A> NC		May 21, 2018
				>A> NCE		Jul 31, 2019

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OLOPATADINE HYDROCHLORIDE - PAZEO</u>						
N 206276 001	8791154	May 19, 2032	DP U-1680		NP PED	Jan 30, 2018 Jul 30, 2018
<u>OMEGA-3-CARBOXYLIC ACIDS - EPANOVA</u>						
N 205060 001 >A>	9012501	Feb 07, 2025	DP U-1511			
<u>OMEPRAZOLE - OMEPRAZOLE</u>						
N 022032 001 >A>	9023391	Aug 16, 2025	DP			
<u>OSPEMIFENE - OSPHENA</u>						
N 203505 001	8642079	Jul 09, 2028	DP			
<u>OXYBUTYNIN CHLORIDE - GELNIQUE</u>						
N 022204 001	8920392	Mar 26, 2031	U-1644			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 001					M-153	Apr 16, 2016
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 002					M-153	Apr 16, 2016
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 003					M-153	Apr 16, 2016
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 004					M-153	Apr 16, 2016
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 005					M-153	Apr 16, 2016
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 006					M-153	Apr 16, 2016
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 007					M-153	Apr 16, 2016
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 001	6936612	Jan 22, 2023	DS DP		NCE	Feb 03, 2020
	7208489	Jan 16, 2023	DS DP			
	7456168	Jan 16, 2023	U-1658			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 002	6936612	Jan 22, 2023	DS DP		NCE	Feb 03, 2020
	7208489	Jan 16, 2023	DS DP			
	7456168	Jan 16, 2023	U-1658			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 003	6936612	Jan 22, 2023	DS DP		NCE	Feb 03, 2020
	7208489	Jan 16, 2023	DS DP			
	7456168	Jan 16, 2023	U-1658			
<u>PALIPERIDONE PALMITATE - INVEGA TRINZA</u>						
N 207946 001 >A>	6077843	May 12, 2017	DP U-543		>A> NP	May 18, 2018
	>A> 6077843*PED	Nov 12, 2017				
<u>PALIPERIDONE PALMITATE - INVEGA TRINZA</u>						
N 207946 002 >A>	6077843	May 12, 2017	DP U-543		>A> NP	May 18, 2018
	>A> 6077843*PED	Nov 12, 2017				
<u>PALIPERIDONE PALMITATE - INVEGA TRINZA</u>						
N 207946 003 >A>	6077843	May 12, 2017	DP U-543		>A> NP	May 18, 2018
	>A> 6077843*PED	Nov 12, 2017				
<u>PALIPERIDONE PALMITATE - INVEGA TRINZA</u>						
N 207946 004 >A>	6077843	May 12, 2017	DP U-543		>A> NP	May 18, 2018
	>A> 6077843*PED	Nov 12, 2017				
<u>PANOBINOSTAT LACTATE - FARYDAK</u>						
N 205353 001	6552065	Aug 31, 2021	DS DP		NCE	Feb 23, 2020
	6833384	Sep 30, 2021	DS DP		ODE	Feb 23, 2022
	7067551	Aug 31, 2021	U-1669			
	7989494	Jan 17, 2028	DS DP			
	8883842	Jun 13, 2028	U-1669			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PANOBINOSTAT LACTATE - FARYDAK</u>						
N 205353 002	6552065	Aug 31, 2021	DS DP		NCE	Feb 23, 2020
	6833384	Sep 30, 2021	DS DP U-1669		ODE	Feb 23, 2022
	7067551	Aug 31, 2021	U-1669			
	7989494	Jan 17, 2028	DS DP			
	8883842	Jun 13, 2028	U-1669			
<u>PANOBINOSTAT LACTATE - FARYDAK</u>						
N 205353 003	6552065	Aug 31, 2021	DS DP		NCE	Feb 23, 2020
	6833384	Sep 30, 2021	DS DP U-1669		ODE	Feb 23, 2022
	7067551	Aug 31, 2021	U-1669			
	7989494	Jan 17, 2028	DS DP			
	8883842	Jun 13, 2028	U-1669			
<u>PAROXETINE MESYLATE - BRISDELLE</u>						
N 204516 001	8946251	Aug 04, 2026	DS DP U-904			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N 022580 001	9011905	Jun 09, 2028	DP			
	9011906	Jun 09, 2028	U-1262			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N 022580 002	9011905	Jun 09, 2028	DP			
	9011906	Jun 09, 2028	U-1262			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N 022580 003	9011905	Jun 09, 2028	DP			
	9011906	Jun 09, 2028	U-1262			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N 022580 004	9011905	Jun 09, 2028	DP			
	9011906	Jun 09, 2028	U-1262			
<u>PIRFENIDONE - ESBRIET</u>						
N 022535 001	7696236	Dec 18, 2027	U-1601			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 001 >A>	5653517	Jul 24, 2016	U-1359		I-707	Apr 23, 2018
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 002 >A>	5653517	Jul 24, 2016	U-1359		I-707	Apr 23, 2018
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 003 >A>	5653517	Jul 24, 2016	U-1359		I-707	Apr 23, 2018
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 004 >A>	5653517	Jul 24, 2016	U-1359		I-707	Apr 23, 2018
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 001 >A>	9029533	Dec 22, 2026	U-836			
	>A> 9029533	Dec 22, 2026	U-1283			
	>A> 9029533	Dec 22, 2026	U-1699			
	>A> 9029533	Dec 22, 2026	U-1700			
	>A> 9029533	Dec 22, 2026	U-1701			
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 002 >A>	9029533	Dec 22, 2026	U-836			
	>A> 9029533	Dec 22, 2026	U-1283			
	>A> 9029533	Dec 22, 2026	U-1699			
	>A> 9029533	Dec 22, 2026	U-1700			
	>A> 9029533	Dec 22, 2026	U-1701			
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 003 >A>	9029533	Dec 22, 2026	U-836			
	>A> 9029533	Dec 22, 2026	U-1283			
	>A> 9029533	Dec 22, 2026	U-1699			
	>A> 9029533	Dec 22, 2026	U-1700			
	>A> 9029533	Dec 22, 2026	U-1701			
<u>POSACONAZOLE - NOXAFIL</u>						
N 205596 001 >A>	9023790	Jul 04, 2031	DP U-1698			
<u>RIFAXIMIN - XIFAXAN</u>						
N 022554 001	8946252	Jul 24, 2029	U-1481		>A> I-709	May 27, 2018
	8969398	Oct 02, 2029	U-1481			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RISEDRONATE SODIUM - RISEDRONATE SODIUM</u>						
A 077132 001					>A> PC	Nov 28, 2015
<u>RISEDRONATE SODIUM - RISEDRONATE SODIUM</u>						
A 077132 002					>A> PC	Nov 28, 2015
<u>RISEDRONATE SODIUM - RISEDRONATE SODIUM</u>						
A 077132 003					>A> PC	Nov 28, 2015
<u>ROFLUMILAST - DALIRESP</u>						
N 022522 001	5712298	Jan 27, 2016	DS DP U-1115			
<u>SODIUM OXYBATE - XYREM</u>						
N 021196 001	8952062	Dec 22, 2019	U-1101			
	8952062	Dec 22, 2019	U-1102			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 008	8920383	Jul 17, 2026	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 009	8920383	Jul 17, 2026	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 010	8920383	Jul 17, 2026	DP			
<u>SORAFENIB TOSYLATE - NEXAVAR</u>						
N 021923 001	>A> 8841330	Jan 12, 2020	U-1696			
<u>SPINOSAD - NATROBA</u>						
N 022408 001	6063771	Jul 25, 2023	DP U-1670		M-152	Nov 30, 2017
<u>SUMATRIPTAN SUCCINATE - ZECUITY</u>						
N 022278 001	8983594	Nov 19, 2030	DP U-1328			
<u>TEDUGLUTIDE RECOMBINANT - GATTEX KIT</u>						
N 023441 001	5789379	Apr 14, 2016	DS DP U-1320			
<u>TESTOSTERONE - AXIRON</u>						
N 022504 001	8435944	Sep 27, 2027	U-1390			
	8993520	Jun 02, 2026	U-1390			
<u>TIGECYCLINE - TYGACIL</u>						
N 021821 001	8975242	Oct 24, 2028	DP			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 001	8992989	Nov 16, 2027	DP U-1675			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 002	8992989	Nov 16, 2027	DP U-1675			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 003	8992989	Nov 16, 2027	DP U-1675			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 004	8992989	Nov 16, 2027	DP U-1675			
<u>TRANEXAMIC ACID - LYSTEDA</u>						
N 022430 001	8957113	Mar 04, 2025	DP U-1182			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 001	7417070	Jul 30, 2026	DS			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 002	7417070	Jul 30, 2026	DS			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 003	7417070	Jul 30, 2026	DS			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 004	7417070	Jul 30, 2026	DS			
<u>TRETINOIN - RETIN-A-MICRO</u>						
N 020475 003	5955109	Sep 21, 2016	DP U-134			
<u>ULIPRISTAL ACETATE - ELLA</u>						
N 022474 001	8962603	Jun 12, 2030	U-1657			
<u>UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - ANORO ELLIPTA</u>						
N 203975 001	>A> 8511304	Jun 14, 2027	DP U-1476			
<u>VALGANCICLOVIR HYDROCHLORIDE - VALCYTE</u>						
N 021304 001					D-148 NPP	Apr 23, 2018 Apr 23, 2018

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VALGANCICLOVIR HYDROCHLORIDE - VALCYTE</u>						
N 02257 001					D-148 NPP	Apr 23, 2018 Apr 23, 2018
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 02257 001					D-146	Mar 16, 2018
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 02257 002					D-146	Mar 16, 2018
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 02257 003					D-146	Mar 16, 2018
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 024447 001	>A> 8722684 8969355	Jun 30, 2031 Jun 15, 2027	DS DP U-1668			
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 024447 002	>A> 8722684 8969355	Jun 30, 2031 Jun 15, 2027	DS DP U-1668			
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 024447 003	>A> 8722684 8969355	Jun 30, 2031 Jun 15, 2027	DS DP U-1668			
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 024447 004	>A> 8722684 8969355	Jun 30, 2031 Jun 15, 2027	DS DP U-1668			

Footnote:

1. Patents are published upon receipt by the Orange book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).

2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 35th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at
<http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm>

The current complete list of exclusivity terms is available at
<http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm>